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The finely tuned regulation of haematopoiesis is crucial in order to maintain life-long 
haematopoiesis. The disruption of the balance among cell fates, can lead to 
malignant transformation. It has become increasingly evident that the metabolic 
regulation haematopoietic stem cells is critical for stem cell fate decisions.  
Haematopoietic stem cells reside in a hypoxic microenvironment within the bone 
marrow and are thought to mainly utilize glycolysis rather than oxidative 
phosphorylation in order to maintain their pool. However recent evidence suggests 
that oxidative phosphorylation is critical for quiescent HSCs and in several cases, for 
leukaemic stem cells (LSCs). 
One of the key parts of mitochondrial respiration is the tricarboxylic cycle (TCA), 
providing co-factors for its efficient activity. The TCA functions by catalysing the 
oxidation of pyruvate via key enzymatic activities.  
A key component of the TCA cycle is fumarate hydratase (Fh1) which catalyses the 
hydration of fumarate into malate within the mitochondria, but also catalyses the 
same reaction in the cytoplasm. FH is a tumour suppressor in human lyomeioma and 
renal kidney cancer (HLRCC). Previous work conducted by our team has shown that 
Fh1 is essential for foetal and adult haematopoiesis, as Fh1 deletion within the 
haematopoietic system is embryonic lethal. Furthermore, conditional deletion of Fh1 
in donor cells of the Mx1-Cre system that were injected in lethally irradiated 
recipients, resulted in the complete reduction of their chimerism in the peripheral 
blood of recipient mice. Mechanistically, these phenotypes were mostly associated 
with supra-physiological levels of fumarate as a result of Fh1 deletion. Interestingly, 
by employing mice that ubiquitously express the human cytosolic isoform of FH 
(FHCyt, which lacks the mitochondrial targeting sequence and therefore is excluded 
from the mitochondria), we rescued the embryonic lethality that Fh1 causes, and 
reduced the levels of fumarate. Importantly, although FHCyt expression restored 
fumarate-associated lethality, it did not restore the mitochondrial defects, allowing us 
to study the importance of genetically intact TCA in the context of haematopoiesis. 
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Here I investigated the impact that a genetic truncation of the TCA cycle (as a result 
of the lack of the mitochondrial isoform of Fh1) has on leukaemic transformation 
and on aged haematopoiesis. Fh1fl/fl; FHCyt; Vav-iCre mice of approximately 60 
weeks old displayed and expansion in the pool of early stem and progenitor 
compartment (Lin- Sca-1+ c-Kit+), as well as in the early progenitors HPC-1 (LSK 
CD48+ CD150-) and HPC-2 (LSK CD48+ CD150+). Furthermore, the mice exhibited 
a drastic depletion of B cells (CD19+ B220+) and an expansion in the frequency of 
the myeloid compartment (Mac-1+ Gr1+).  
In order to assess the importance of the TCA cycle in malignant transformation, I 
isolated stem and progenitor cells from Fh1fl/fl; FHCyt; Vav-iCre (and control (Fh1fl/fl; 
FHCyt Vav-iCre negative or Fh1fl/fl Vav-iCre negative)) E 14.5 day old embryos and 
infected them with retroviruses expressing Meis1 and Hoxa9, and generated pre-
leukaemic cells (pre-LCs). Genetically intact TCA was required for the efficient 
generation of leukaemia-initiating cells (LICs), as injection of pre-LCs lacking 
mitochondrial Fh1 into sub-lethally irradiated recipient mice, resulted in 76 % of 
leukaemia-free mice while injection of control pre-LCs resulted in 25 % of 
leukaemia-free mice. However, the genetic perturbation of the TCA did not exert and 
effect on the long-term self-renewal capacity of LICs.  Inducible deletion of 
mitochondrial Fh1 in established LICs of the Mx1-Cre background using poly (I:C) 
did not affect their ability to generate AML in primary and secondary recipient mice. 
These data indicate that genetically intact TCA is required for the efficient 
generation of LICs in vivo but is dispensable for their long-term self-renewal 
capacity, highlighting the metabolic rewiring that occurs at different stages of 
leukaemic transformation. 
In an effort to understand whether, similarly to HLRCC, Fh1 plays a tumour-
suppressive role in malignant haematopoiesis, I isolated LSK cells from the foetal 
liver of E 14.5 old embryos lacking both isoforms of Fh1. Fh1fl/fl; Vav-iCre cells 
transduced with Meis1/Hoxa9 or MLL-AF9, MLL-ENL, AML-ETO (chromosomal 
translocations involved in AML development) -expressing retroviruses, failed to 
generate colonies in methylcellulose, indicating that stem and progenitor cells require 
Fh1 to undergo in vitro transformation by these oncogenes. Furthermore, acute 
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deletion of Fh1 (via the use of lentivirally-expressed Cre) in pre-LCs generated using 
the Meis1/Hoxa9 retroviruses, rendered them unable to generate colonies in 
methylcellulose, indicating that Fh1 is required for the self-renewal capacity of pre-
LCs in vitro. Similarly, when LICs (Fh1fl/fl; Vav-iCre negative) isolated from primary 
recipient mice were infected with Cre to induce deletion of Fh1, they were unable to 
generate colonies indicating that Fh1 is required for the self-renewal capacity of 
LICs in vitro. Finally, in order to identify whether Fh1 is important for LIC self-
renewal in vivo I generated Fh1fl/fl; Mx1-Cre pre-LCs by infecting stem and 
progenitor cells of E 14.5 embryos with Meis1/Hoxa9 retroviruses, and injected them 
into sub-lethally irradiated mice. After the mice developed AML, I induced the 
deletion of Fh1, by injecting the mice with poly (I:C). Interestingly, the percentage 
of LICs in the peripheral blood of recipient mice was drastically decreased, leaving 
recipient mice leukaemia-free for the remaining time they were monitored. 
Surprisingly however, approximately 50 % of the recipient mice exhibited a drastic 
increase in LIC chimerism after two weeks post poly (I:C). Assessment of LICs 
isolated from recipient mice indicated that Fh1 was fully deleted. These data indicate 
that while in some cases Fh1 is required for LIC self-renewal in vivo, in other cases it 
is dispensable. Therefore, the tumour-suppressive roles of Fh1 are likely tissue-
specific and do not extend to haematopoietic cells.  
Overall, this study agrees with published work supporting the notion that intact 
mitochondrial respiration is important (in varying degrees), in both the contexts of 





It has become increasingly evident that the metabolic regulation of haematopoietic 
stem cells (HSCs) is critical for stem cell fate decision. HSCs reside in a low oxygen 
environment within the bone marrow and are thought to utilise glycolysis rather than 
mitochondrial respiration in order to maintain their pool. However recent evidence 
suggests that mitochondrial respiration is critical for quiescent HSCs and in several 
cases, for leukaemia initiating cells (LICs). One of the key components of 
mitochondrial respiration is the tricarboxylic cycle (TCA) that provides essential co-
factors for its efficient activity. A key component of the TCA is the enzyme fumarate 
hydratase (Fh1 in mouse and FH in humans), that also functions in the cytoplasm. 
Fh1 converts the metabolite fumarate into malate. Furthermore, FH is a tumour 
suppressor in human lyomeioma and renal kidney cancer (HLRCC) but its role in 
haematopoiesis is unknown. 
Here I investigated the role of Fh1 in aged haematopoiesis and in leukaemic 
transformation. Haematopoiesis-specific deletion of the mitochondrial isoform of 
Fh1 in mice aged for approximately 60 weeks, resulted in an expansion of the early 
stem and progenitor cell populations. Furthermore the aged mice exhibited a 
depletion of the B cell compartment with the myeloid and T cell compartments 
remaining relatively unaffected. These results indicate that efficient fumarate 
metabolism is important for B cell development or survival.  
Deletion of the mitochondrial isoform of Fh1 did not impact the generation of pre-
leukaemic cells as indicated by in vitro experiments. However, the mitochondrial 
isoform of Fh1 was required for the efficient generation of LICs, as injection of pre-
leukaemic cells lacking mitochondrial Fh1 into sub-lethally irradiated recipient mice, 
resulted in 76 % of leukaemia-free mice while injection of control pre-LCs resulted 
in 25 % of leukaemia-free mice. The genetic deletion of the mitochondrial isoform of 
Fh1 did not exert an impact on the long-term self-renewal capacity of LICs as 
indicated by in vivo experiments using an inducible system. Finally, in an effort to 
understand whether, similarly to HLRCC, Fh1 plays a tumour-suppressive role in 
malignant haematopoiesis, both lentivirally inducible and non-inducible in vitro 
methods were utilised. In vitro leukaemia initiation and propagation were not 
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possible in the absence of Fh1, indicating that Fh1 does not act as a tumour 
suppressor in the haemaopoieic system.    
 
Overall, this study agrees with published work supporting the notion that intact 
mitochondrial respiration is important (in varying degrees), in both the contexts of 
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1.1 The haematopoietic hierarchy  
The blood system serves as a paradigm for understanding tissue stem cells. 
Differentiated blood cells are short lived, and therefore, a constant replenishment 
throughout life is provided by haematopoietic stem cells (HSCs) and multilineage 
progenitors.  HSCs are defined as cells with self-renewal and differentiation potential 
(Till et al., 1964). Accumulating evidence demonstrates that HSCs are a 
heterogeneous population in varying aspects, including their self-renewal potential 
(Guenechea et al., 2001; Ema et al., 2005), differentiation pattern (Muller-Sieburg et 
al., 2012; Compley et al., 2012) and lifespan (Osawa et al., 1996; Morrison et al., 
1997; Yang et al., 2005). Retroviral-based studies indicate that HSCs clonally give 
rise to all cells of the haematopoietic system and also self-renew, unequivocally 
proving the existence of HSCs in the bone marrow (Dick et al., 1985; Keller et al., 
1985; Lemischka et al., 1986). In the traditional view of the haematopoietic 
hierarchy, long-term haematopoietic stem cells (LT-HSC) provide life-long 
haematopoiesis, while short-term HSCs (ST-HSC) support haematopoiesis for 
approximately four months (Morrison and Weissman, 1994). It has become 
increasingly evident that LT-HSCs are functionally heterogeneous. Muller-Sieburg et 
al identified the presence of myeloid-biased HSCs (My-bi HSCs), lymphoid-biased 
HSCs (Ly-bi HSCs), and balanced HSCs (Bala HSCs) (Challen et al., 2010; Muller-
Sieburg et al, 2004; Muller-Sieburg et al., 2012). On the other hand Eaves et al have 
identified these HSCs as α, β, γ, and δ (Benz et al., 2012; Dykstra et al., 2007). Both 
types of classification are defined based on myeloid and lymphoid reconstitution 
ratios, but the criteria used to make these classifications are different. α HSCs are 
thought to correspond to My-bi HSCs, β to Bala HSCs, and γ/δ to Ly-bi HSCs. 
In the traditional view, LT-HSCs give rise to multipotent progenitor cells (MPP) that 
exhibit a lower self-renewal capacity and can give rise to all subsequent lineages 
(Morrison et al., 1997; Adolfson et al., 2001). MPPs in turn give rise to common 
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lymphoid (CLP) and common myeloid progenitors (CMP), segregating myeloid and 
lymphoid lineages early in haematopoiesis, thus constituting the initial step of 
lineage commitment.  CMPs give rise to granulocyte-monocyte progenitors (GMP), 
which become committed to the granulocyte-monocyte fate, and MEPs, which only 
produce erythroid and megakaryocyte cells. On the lymphoid side, CLPs give rise to 
B cell precursors and early progenitors for T and natural killer (NK) lineages (Akashi 
et al., 2000; Kondo et al., 1997). However recent evidence suggests that lymphoid 
progenitors (LMPP-like population) are mostly T cell restricted, potentially 
suggesting that CLPs are not common progenitor for both B and T cells (Luis et al., 
2016). Although the standard model is still extensively used as an operational 
paradigm, further purification and functional assays have led to key revisions to the 
model (Figure 1-1). The identification of lymphoid-primed multipotent progenitors 
(LMPPs) argued that megakaryocyte-erythrocyte potential is the first branch lost in 
lympho-myeloid specification, as LMPPs give rise to macrophage-granulocyte and 
T-B lineages but not megakaryocyte-erythrocyte lineages (Adolfson et al., 2005; 
Mansson et al., 2007). However, lineage tracing studies have shown that LMPPs can 
in fact differentiate into megakaryocyte-erythrocyte progenitors (Forsberg et al., 
2006; Boyer et al., 2011). Furthermore, paired-daughter HSC cell divisions have 
demonstrated that megakaryocyte-erythrocyte progenitors can be derived from HSCs 
directly, without the conventional progression through MPPs and CMPs (Yamamoto 
et al., 2013). Furthermore, Sten Eric Jacobsen’s group provided evidence for a 
megakaryocyte-biased HSC population by using a transgenic mouse model with a 
GFP reporter driven by the megakaryocyte-associated gene, VWF (Sanjuan-Pla et 
al., 2013). The authors specifically showed that the VWF-positive HSCs exhibited a 
strong platelet bias and contribution to the myeloid lineage, but with very limited 
(short-term) lymphoid potential. Evidence for megakaryocyte-biased HSCs has also 
been provided by the Waskow and Park groups (Grinenko et al., 2014; Shin et al., 
2014).  Finally, a recent study separated cells of the haematopoietic system based on 
their Gata1 expression, highlighting the heterogeneity within already 
immunophenotypically defined cell populations (Drissen et al., 2016). More 
specifically, Gata1-expressing pre granulocyte-monocyte progenitors (pre-GMs) and 
granulocyte-monocyte progenitors (GMPs) gave rise to mast cells and eosinophils, 
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but lacked monocyte-macrophage and had little or no neutrophil potential. 
Conversely, Gata1-non expressing pre-GMs and GMPs (as well as LMPPs) 
generated monocytes and neutrophils, but no mast cells and few eosinophils. 
Notably, monocyte-neutrophil and mast cell-eosinophil potentials segregated prior to 
separation from other blood lineages, as Gata1-expressing pre-GMs generated 
megakaryocytes and erythroid cells, whereas LMPPs contained robust B- and T-
lineage potential. The authors termed the Gata-1-expressing pre-GMs and GMPs 
erythroid-megakaryocyte-primed multi-potent progenitors (EMkMPP) and 
eosinophil-mast cell progenitors (EoMPs) respectively, and the Gata1-non 
expressing pre-GMs and GMPs pre-neutrohil monocyte-progenitors (pre-NM) and 
neutrophil-monocyte progenitors (NMPs) (Figure 1-1). Their findings therefore 
identified an early blood lineage fate decision segregating lymphoid-macrophage-
neutrophil potential from mast cell-eosinophil-megakaryocytic-erythroid potential, 
establishing separate myeloid-erythroid and myelo-lymphoid differentiation 
pathways, and generating two distinct myeloid-restricted progenitor subsets, instead 
of a common GMP harboring all monocyte-macrophage and granulocyte potentials 
(Drissen et al., 2016). 
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Figure 1-1. Recently proposed model of haematopoiesis. Immunophenotypically 
defined heterogeneous HSC populations with respect to lineage potential give rise to 
the immediate progeny of multipotent progenitors (MPP) that then give rise to 
lymphoid-primed progenitors (LMPP), common myeloid progenitors (CMP) and pre 
neutrophil-macrophage progenitors (pre NM). LMPPs give rise to common lymphoid 
progenitors (CLP) and pre NMs that give rise to neutrophil-macrophage progenitors 
(NMP). NMPs and CLPs then give rise to differentiated cells. CMPs also give rise to 
erythroid-megakaryocyte primed multi-potent progenitors (EMkMPP) which in turn 
give rise to eosinophil-mast cell (and likely basophil) fate (EoMP) or to 
megakaryocyte-erythrocyte progenitors (MegE) that then give rise to oligopotent 
megakaryocyte (MkP) and erythrocyte (PreE) progenitors giving, rise to erythrocytes 
and platelets respectively. (Adapted from Drissen et al., 2016).  
 
1.1.1 Reconceiving the haematopoietic hierarchy  
The majority of the work that has been conducted so far has been based on 
transplantation assays. However, although the transplantation assay is considered as 
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the “golden standard” for the analysis of the haematopoietic system, it comes with 
considerable caveats. To begin with, it detects only the cells that are able to home to 
the bone marrow and proliferate rapidly. Furthermore, given the immense stress that 
transplanted cells endure during isolation, engraftment and transplantation, it is 
questionable whether these cells share the same characteristics as cells present in 
physiological, non-transplant haematopoiesis.  As a result, more recent studies that 
utilise novel tracking techniques were able to challenge the long-standing view of the 
haematopoietic hierarchy (Sun et al., 2014; Notta et al., 2016; Drissen et al., 2016; 
Biasco et al; 2016).  
In their study, Sun et al utilised in situ labelling and clonal tracking of murine 
haematopoietic cells. Based on their study, the authors propose that in an 
unperturbed system, LT-HSCs have limited contribution to blood production during 
adulthood, while MPPs provide constant replenishment of the blood lineages (Sun et 
al., 2014). In a study published earlier this year, the authors studied the myeloid-
erythroid-megakaryocyte differentiation process, using human cord blood, foetal 
liver tissue and adult bone marrow (Notta et al., 2016). Intriguingly, in their model 
they challenge the existence of oligopotent progenitors such as CMPs and GMPs, 
inferring that multipotent cells differentiate into unipotent cells directly. More 
specifically, they suggested that in cord blood and the bone marrow, most 
megakaryocytes emerged as part of mixed clones from HSC/MPPs, indicating that 
megakaryocytes branch directly from multipotent progenitors (Notta et al., 2016). 
This study therefore provided major insight into the myeloid-erythroid-
megakaryocyte lineage, suggesting that these cells can differentiate directly from 
primitive cells.  
In another study, Biasco and colleagues utilised an in vivo tracking system in order to 
study the clonal expansion of human haematopoietic cells in early and late stages of 
autologous transplantation (Biasco et al., 2016). Based on their data, they were able 
to conclude that the initial, short-term haematopoiesis was maintained by lineage-
committed progenitor cells. However, after approximately 6 months post 
transplantation, they observed a switch in haematopoiesis where the first wave of 
cells was exhausted, and LT-HSCs progressively took over, generating a stable 
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output up to 3 years post-transplantation (Biasco et al., 2016). This study provided 
invaluable insight of what occurs after human transplantations and parallels well with 
animal studies, thereby validating some long-standing models regarding 
haematopoiesis but also shedding new light on the clonal dynamic of blood cells. 
Overall, these studies indicate that haematopoietic cells exhibit immense plasticity 
and that perhaps one firm model of the haematopoietic hierarchy is not sufficient to 
describe the true complexity of haematopoietic differentiation.   
1.2 Immunophenotypic characterisation of HSCs and 
progenitor cells 
Prospective isolation of cellular subsets based on expression of cell-surface markers 
and functional characterisation using in vivo and in vitro assays has provided key 
insights into the haematopoietic development (Weissman, 2000). HSCs have been 
highly enriched as Thy-1lo Sca-1+ Lineage- c-Kit+ or as CD34- Sca-1+ Lineage- c-Kit+ 
(Spangrude et al., 1988; Morrison and Weissman, 1994; Osawa et al., 1996). 
Furthermore, early progenitors of the haematopoietic system also reside within the 
Lineage- Sca-1 + c-Kit+ (LSK) compartment (Ikuta and Weissman, 1992; Li and 
Johnson, 1995; Spangrude et al., 1988; Weissman et al., 2001). More recently, LT-
HSCs and early progeny have been classified based on the SLAM family of surface 
markers (Kiel et al., 2005). These markers include CD48, CD150 and CD244 and 
have been extensively used over the past decade to isolate LT-HSCs (LSK CD48- 
CD150+ CD244-), multipotent primitive progenitors (LSK CD48- CD150- CD244+) 
and committed progenitor cells (HPC-1: LSK CD48+ CD150- CD244+; HPC-2: LSK 
CD48+ CD150+ CD244+) (Kiel et al., 2005). Furthermore, LT-HSCs and early 
progenitor cells can also be isolated based on CD34 and Flt3 expression (Adolfson et 
al., 2001; 2005). LT-HSCs lack the expression of CD34 and Flt3, whereas short-term 
HSCs (ST-HSCs) are CD34+ and Flt3- (Adolfson et al., 2001; 2005; Osawa et al., 
1996). Additionally, CD34 and Flt3 expression has allowed the prospective isolation 
of a population of early progenitors that possess B-cell, T-cell and granulocytic 
monocytic (GM) potential but lack significant megakaryocyte erythrocyte (MegE) 
potential can be isolated. 
 This population is double positive for CD34 and Flt3 (LSK CD34+ Flt3+) and is 
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referred to as lymphoid-primed multipotent progenitors (LMPP) (Adolfsson et al., 
2005). Committed progenitor cells that arise from the Lineage – c-Kit+ Sca-1- (LK) 
population, can be discriminated based on their expression of CD34 and CD16/32 
(receptor-II/III (FcgR)) (Akashi et al., 2000). CD16/32 is an important marker for 
myelomonocytic cells and CD34 marks the fraction of haematopoietic stem and 
progenitor cells (Osawa et al., 1996; Lacaud et al., 1998). The resultant populations 
are the common myeloid progenitors (CMP, CD16/32- CD34+), granulocyte-
monocyte progenitors (GMP, CD16/32+ CD34+) and megakaryocyte-erythrocyte 
progenitors (MkEP, CD16/32- CD34-). Finally, Drissen et al. made use of 
Gata1expression in order to segregate EMkMPPs, EoMPs, pre-NMs and NMPs. 
EMkMPPs, EoMPs are Gata1+ while pre-NMs and NMPs are Gata1- (Drissen et al., 
2016). The surface makers used to immunophenotypically mouse haematopoietic 
stem and progenitor cells are summarized in Figure 1-2. 
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Figure 1-2. Surface marker expression on stem and progenitor cell 
compartments of mouse haematopoiesis. EMkMPPs and pre-NMs are defined as 
Lin−Sca-1−c-Kit+ CD41− CD16/32+ CD150- CD105- whereas EoMPs and NMPs are 
defined as Lin−Sca-1−c-Kit+ CD41− CD16/32+ CD150-. Finally, EMkMPPs, EoMPs, 
pre-NMs and NMPs are segregated based on their Gata1 expression. EMkMPPs, 
EoMPs are Gata1+ while pre-NMs and NMPs are Gata1-. (Adapted from Doulatov et 
al., 2012; Drissen et al., 2016). 
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1.3 HSC ageing 
Ageing of HSCs is associated with reduction in function. Aged HSCs exhibit 
increased number/frequency (Rossi et al., 2005; Harrison et al.,1989) and reduced 
self-renewal capacity, determined by serial transplantation assays (Jansen et al., 
2006; Kamminga et al., 2005). Furthermore, when aged HSCs are transplanted with 
young HSCs into lethally irradiated recipient mice, aged HSCs contribute to 
multilineage haematopoiesis less efficiently (Morrison et al., 1996; Chen et al., 
2000), and exhibit a two-fold reduced ability to home to the bone marrow (Liang et 
al., 2005). In terms of differentiation potential, aged HSCs are deficient in their 
ability to support erythropoiesis, they generate B and T cells less efficiently and 
exhibit a bias towards the myeloid lineage (Dykstra et al., 2007; 2011; Benz et al., 
2012; Cho et al., 2008). With respect to lineage skewing, it is proposed that myeloid-
biased HSCs increase in the expense of lymphoid-bias or balanced HSC clones upon 
ageing (Beerman et al., 2010; Challn et al., 2010; Sienburgh et al., 2004; Morita et 
al., 2010).  
 
1.4 Early haematopoiesis 
In mammals, haematopoiesis occurs in multiple waves in distinct anatomical sites 
during embryonic development (Johnson and Moore, 1975; Medvinsky and 
Dzierzak, 1996; Metcalf & Moore, 1972) (Figure 1-3). The initial wave of blood 
production occurs in the mammalian yolk sac, at day 7.5 of embryonic development 
(E 7.5), and is termed as “primitive” haematopoiesis (Russell and Bernstein, 1966).  
Primitive haematopoiesis involves the production of red blood cells that facilitate 
oxygenation of the tissue as the embryo rapidly grows (Russell and Bernstein, 1966). 
Furthermore, during primitive haematopoiesis, megakaryocytes and macrophages are 
generated presumably to scavenge apoptotic cells and debris during development. 
The second or “definitive” wave also occurs in the yolk sac and is characterised by 
the presence of myeloid lineages, at E8.25. The next site of definitive haematopoiesis 
is the aorta-gonad-mesonephros (AGM) region of the embryo, where definitive 
HSCs arise, at E10.5 of embryonic development (Medvinski and Dzierzak, 1996; 
Muller et al, 1995). The definitive HSCs then migrate to the foetal liver and by E12.5 
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of embryonic development, the foetal liver is the major site of haematopoiesis 
(Kumaravelu et al, 2002; Morrison et al., 1995). Subsequent definitive 
haematopoiesis takes place in the spleen, the thymus and ultimately the bone marrow 
at E16-E17. Thereafter, the bone marrow is the main site of haematopoiesis soon 
after birth and throughout adult life (Clapp et al., 1995 Zanjani et al., 1993).  
1.4.1 Foetal liver haematopoiesis 
Although foetal liver HSCs are considered as the “definitive” HSCs that colonise the 
bone marrow, they nevertheless exhibit differences when compared to adult bone 
marrow HSCs. For instance, foetal liver HSCs display faster expansion kinetics when 
grafted in adult bone marrow, compared to long term-HSCs isolated from the bone 
marrow of adult mice (8 weeks old; Morrison et al., 1995). Furthermore, foetal liver 
HSCs undergo more symmetrical self-renewing cell divisions compared to adult (8 
weeks old) long-term HSCs (Harrison et al, 1997; Dykstra et al, 2007), and foetal 
liver progenitors, appear to follow the same differentiation hierarchy as bone marrow 
progenitors (Traver et al., 2001). More recently, it was demonstrated that foetal liver 
HSCs rely more on oxidative phosphorylation whereas adult bone marrow HSCs rely 
on glycolysis in order to self-renew (Manesia et al, 2015; Suda et al, 2011). It is also 
interesting that the spectrum of clonal differentiation is different for foetal and adult 
sources (Benz et al., 2012). In the developing foetal liver, the lymphoid-deficient α-
HSCs constitute less than 5 % of all HSCs and less than 10 % of the HSCs with 
durable self-renewal activity. However, they are much more prevalent in the initial 
HSC population that can be detected in the bone marrow just before birth (Benz et 
al., 2012). Finally, foetal liver HSCs and adult bone marrow HSCs also differ 
immunophenotypically. For instance, while Mac-1 marks foetal liver HSCs, in the 
adult bone marrow it is a marker of myeloid cells (Morrison et al., 1995; Jordan ET 
AL., 1990; Kim et al, 2006). Haematopoietic cells of the foetal liver exist in a 
specific microenvironment that controls their proliferation and differentiation. This 
microenvironment is created by different cell populations including epithelial cells, 
macrophages, cells that undergo epithelial-to mesenchymal transition, and various 
stromal cells such as fibroblasts, mesenchymal stromal cells, hepatic cells and 
vascular smooth muscle cells (Paiushina et al., 2012).  
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Figure 1-3.  Sites of haematopoiesis during murine development. The mesoderm 
forms during gastrulation at day E6.5; development of the yolk sac blood islands 
occurs at day E7.5; emergence of HSCs in the aorta-gonad-mesonephros (AGM) 
region occurs at day E10.5; active haematopoiesis occurs at the foetal liver at day 
E14.5; haematopoiesis in the bone marrow of the late gestation embryo occurs at day 
E18.5 and throughout adulthood (Adapted from Baron et al., 2012). 
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1.5 Regulation of HSCs 
1.5.1 Transcription factors regulating HSC emergence and 
lineage specification 
A complex network of various transcription factors (TFs) regulate the early 
development of HSCs and the self-renewal of adult HSCs. Generally, TFs are 
classified as basic helix-loop-helix TFs, homeobox TFs, Ets TFs and zinc finger TFs. 
Some critical factors include stem cell leukaemia (Slc), runt-related transcription 
factor 1 (Runx1), mixed lineage leukaemia (Mll), globin transcription factor 2 
(Gata2), myeloid ecotropic viral integration site 1 (Meis1) and homeobox A9 
(Hoxa9) (described in section 4.1), Lim only domain 2 (Lmo2), Ets-related gene 
(Erg), c-Myb, and are described below.  
Scl encodes a basic helix-loop-helix transcription factor required for haematopoietic 
development, as mutation of Scl results in severe defects in blood formation and lack 
of all haematopoietic lineages in mice (Porcher et al., 1996). Runx1 is a core-binding 
factor and is shown to be required for definitive haematopoiesis, and its transient 
expression is correlated with the emergence of HSCs in the AGM (North et al., 
1999). Runx1 continues to be expressed in HSCs during subsequent development 
and in adult life (North et al., 1999; Teitell et al., 2006; North et al., 2004). Runx1-
null embryos lack foetal liver haematopoietic progenitor cells, indicating that it is 
important in definitive haematopoiesis (North et al., 1999; Teitell et al., 2006; North 
et al., 2004). Similarly to Runx1, Mll that encodes for a SET-domain containing 
histone methyltransferase, is essential for the development of HSCs in the AGM 
(McMahon et al., 2007).  Lmo2 is a protein required for erythropoiesis in the yolk 
sac, as ex vivo differentiation of erythroid development was impaired in yolk sac 
tissue. Furthermore, Lmo2 plays a critical role in definitive haematopoiesis as Lmo2-
null cells do not contribute to any of the haematopoietic lineages (Yamada et al., 
1998).  Erg is a member of the ETS family and has been shown to play a significant 
role in the endothelial and haematopoietic development (McLaughlin et al., 2001; 
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Murakami et al., 1993). Erg was shown to be a positive regulator of Gata2 and 
Runx1 gene expression once haematopoiesis progressed to the foetal liver, and to be 
involved in HSC self-renewal (Taoudi et al., 2011). Furthermore, Erg is required to 
maintain the adult HSC pool and reconstitution ability, and differentiation to 
committed progenitors (Loughran et al., 2008; Ng et al., 2011). C-Myb plays an 
important role in adult HSC self-renewal. Its conditional deletion causes a defect in 
HSC proliferation and loss of reconstitution ability (Lieu et al., 2009). Gfi1 is a 
transcriptional repressor that promoters HSC quiescence, and maintains HSC self-
renewal and reconstitution potential (Zeng et al., 2004; Hock et al., 2004).    
HSC lineage-priming transcription factors promote their own lineage differentiation 
while simultaneously suppressing other factors. For instance, Gata1 and Pu1 promote 
erythroid-megakaryocyte-eosinophil and myeloid differentiation, respectively. The 
proteins physically interact and antagonize each other’s actions. The complementary 
roles of these two transcription factors have been exhibited in zebrafish. Inhibition of 
GATA1 expression in morpholinos shifted the haematopoietic progenitors towards a 
myeloid differentiation, whereas the opposite occurred upon inhibition of PU1 
expression (Galloway et al., 2005; Rhodes et al., 2005). In a similar fashion, C/EBP 
and friend of Gata1 (Fog1) control eosinophil and multipotential cell fates (Querfurth 
et al., 2000). Erythroid kruppel-like factor (Eklf) and Fli1 are critical for erythroid 
and megakaryocyte choice (Starck et al., 2003), GATA3 and T-bet for T helper 1 and 
2 cells (Usui et al., 2006), and growth factor independent-1 (Gfi1) and PU1 for 
neutrophil versus monocyte outcomes (Dahl et al., 2007).  
Lineage commitment in B-cell development is orchestrated in a regulatory network 
of key transcription factors. Pu1 and E2A are critical for lymphoid cell fate 
determination and induce specific B-lineage commitment factors like early B-cell 
factor 1 (Ebf1) and Pax5. Ebf1 is a primary determinant of B-cell fate and its 
expression is controlled by high expression of Ikaros (regulator of lymphoid lineage 
priming in HSCs) and E2A in conjunction with Pu1 and by extrinsic signals provided 
by the IL-7 receptor (Seet et al., 2004; Kwon et al., 2008) 
T-lymphoid development depends upon Notch signalling and principally acts by 
repressing factors such as Pu1. Notch signalling turns LMPPs into early T-cell 
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progenitors by inducing a pro-T-cell developmental program with the activation of 
Gata3, Tcf7 and other T-cell restricting genes. Furthermore, although Gata3 has been 
viewed as a T-cell specific transcription factor, recent evidence indicates that it 
functions only within the context of Notch (Rothernberg, 2007).  
1.5.2 Regulation of HSC functions by the bone marrow niche 
The bone marrow microenvironment is uniquely adapted to support the properties of 
HSCs. The idea of a stem cell niche was initially proposed by Scofield and 
colleagues in 1978. In this model, a niche comprised of specialised cells of the bone 
marrow, physically interact with HSCs and provide signals that support their 
function (Schofield, 1978). These cells include mesenchymal stem cells (MSCs), 
endothelial cells and osteoblasts. Furthermore, other cells of the bone marrow such 
as glial cells, adipocytes and neuronal cells are thought to also regulate 
haematopoiesis (Figure 1-4).  
The location of HSCs within the bone marrow remains controversial. Initial studies 
utilising labelled HSCs for transplantation assays suggested that HSCs mostly reside 
in the endosteal location of the bone marrow (Nilsson et al., 2001; Xie et al., 2009). 
In contrast, by immunophenotypically defining HSCs (CD150+ CD48- CD41- lineage 
-), Kiel et al demonstrated that HSCs are in contact with cells of the endothelium 
(Kiel et al., 2005). Consistent with this report, a recent study suggested that HSCs 
and early progenitor cells are localised near the sinusoidal endothelium, with a 
preference for the endosteal region (Nombela-Arrieta et al., 2013). Collectively, 
these studies suggest that the majority of HSCs reside in the perivascular region and 
are enriched in the highly vascular endosteal region. The niche cells that support 
HSC function are outlined below. 
The endosteal niche contains osteoblasts as the main supportive cell type for HSC 
maintenance. Osteoblasts secrete cytokines implicated in HSC regulation including 
thrombopoietin (Qian et al., 2007; Yoshihara et al., 2007) and C-X-C motif 
chemokine 12 (CXCL12) (Jung et al., 2006). The role of osteoblastic cells in the 
maintenance of HSCs is controversial. Conditional ablation of osteoblastic cells has 
been associated with loss of HSCs in the bone marrow and extramedullary 
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haematopoiesis (Visnjic et al., 2004). Furthermore, expansion of osteoblastic cells 
through expression of the parathyroid hormone receptor 1 or through conditional 
deletion of bone morphogenic protein receptor 1 (Calvi et al., 2003), is associated 
with an expansion of HSCs (Zhang et al., 2003). In contrast, treatment of mice with 
the bone stimulating agent, strontium, leads to expansion of mature osteoblasts but 
does not affect the numbers of HSCs (Lymperi et al, 2008). Finally, deletion of SCF 
or CXCL12 from mature osteoblasts had no effect on HSCs (Ding et al., 2013; 
Greenbaum et al., 2013; Ding et al., 2012). The apparent discrepancy between 
studies can be partially attributed to the fact that osteoblasts are a heterogeneous 
population comprising of both mature and immature cells. In particular, it was 
recently demonstrated that immature osteoblastic cells express higher levels of SCF 
and CXCL12 than more differentiated osteoblasts (Nakamura et al., 2010), 
suggesting that mature osteoblasts do not regulate HSCs but immature osteoblasts 
do.  
The perivascular location of most HSCs has focused recent attention to the stromal 
cells that reside in the perivascular niche. Apart from endothelial cells, the 
perivascular niche contains mesenchymal stem cells (MSCs) and a heterogeneous 
population of stromal cells that express high levels of CXCL12. This population is 
defined by transgene expression using stromal-specific promoters. These stromal 
populations include the CXCL12-abundant reticular (CAR) cells, leptin+ receptor 
stromal cells and nestin-GFP+ stromal cells and are referred to as CXCL12-
expressing mesenchymal progenitors (CEMP) cells.  
CAR cells are mesenchymal progenitors that exhibit adipogenic and osteogenic 
potential in vitro (Omatsu et al., 2010). CAR cells are the major source of SCF and 
CXCL12 in the bone marrow, and ablation of these cells is associated with a 
significant loss of SCF and CXCL12. Conditional ablation of CAR cells using 
transgenic mice expressing the diphtheria toxin receptor under the control of Cxcl12 
regulatory elements resulted in a reduction of HSC numbers and long-term 
reconstitution capacity of HSCs (Omatsu et al., 2010). 
Lineage mapping using Cre recombinase under the expression of the leptin receptor 
identified another perivascular stromal population in the bone marrow (Ding et al., 
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2013). Similarly to CAR cells, leptin+ stromal cells express high levels of SCF and 
CXCL12. Deletion of SCF from the leptin+ stromal cells resulted in loss of HSCs, 
indicating that these cells are important for the regulation of HSCs (Ding et al., 
2012). 
Nestin-GFP+ cells are perivascular stromal cells that express high levels of GFP 
under the nestin promoter (Mendez-Ferrer et al., 2010). Nestin-GFP+ cells are 
enriched for MSCs and express several genes implicated in HSC maintenance such 
as CXCL12, SCF and angiopoietin. Conditional deletion of nestin-expressing cells 
results in loss of HSCs (Mendez-Ferrer et al., 2010). 
Bone marrow endothelial cells express several genes implicated in HSC maintenance 
including CXCL12, SCF and angiopoietin (Chute et al., 2006). Deletion of the 
endothelial-specific adhesion molecule E-selectin, results in increased HSC 
quiescence, suggesting that endothelial cells regulate HSC proliferation (Winkler et 
al., 2012). Furthermore, SCF deletion in endothelial cells results in loss of HSCs, 
indicating that endothelial cells are key components of the HSC niche (Ding et al., 
2012).  
Adipocytes are also part of the bone marrow niche and are thought to exert an 
inhibitory effect on HSCs, as adipose-rich bone marrows have decreased HSC 
numbers compared to adipose-poor bone marrows (Naveiras et al., 2009).  
Recent studies have shown that the sympathetic nervous system contributes to HSC 
trafficking from the bone marrow by regulating local production of CXCL12 
(Katayama et al., 2006). Another recent study has also implicated glial cells, 
specifically non-myelinating Schwann cells, in the regulation of HSCs (Yamazaki et 
al., 2011). More specifically, glial cells are thought to be a major source of the 
transforming growth factor beta (TGF-beta). TGF-beta is an important regulator of 
HSC function as it induces quiescence in vitro. Furthermore, loss of TGF-beta 
signalling in HSCs results in impaired long-term repopulation capacity (Yamazaki et 
al., 2011). Finally, surgical disruption of the sympathetic nervous system, resulting in 
loss of Schwann cells, is associated with a decreased expression of TGF-beta and 
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consequent loss of HSCs (Yamazaki et al., 2011).  A summary of the bone marrow 




Figure 1-4. Stromal cell populations in the bone marrow contributing to HSC 
maintenance. Endothelial cells, mesenchymal stem cells (MSCs), and CXCL12-
expressing mesenchymal progenitor (CEMP) cells have been identified as CAR cells, 
leptin receptor+ cells (Leptr+), and nestin-GFP+ cells. Osteoblasts produce several 
factors that support HSC function such as thrombopoietin (TPO) and CXCL12. 
Synpathetic neurons indirectly regulate HSCs by targeting CXCL12 expression. 
Glial cells regulate HSCs through production of active TGF-beta, and adipocytes are 
likely to exert inhibitory effects on HSCs (Adapted from Anthony and Link, 2014). 
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1.6 Hypoxia and the stem cell niche 
The bone marrow is considered to be a tissue with limited oxygen supply and as a 
result the prevailing view is that HSCs are maintained in a hypoxic environment 
(Nombela-Arrieta et al., 2013; Spencer et al., 2014; Kiel et al., 2003). The proposed 
view is that the endosteal niche might provide a hypoxic environment for 
maintaining HSCs in a quiescent state whereas the perivascular niche allows HSCs to 
proliferate and differentiate in an environment where more oxygen is available 
(Wilson et al., 2008; Suda et al., 2011). However, in a recent study, live in vivo 
imaging of oxygen concentration provided evidence that the most hypoxic region is 
actually located 40 µm from the bone in the perisinusoidal region, and there is a 
modest increase in oxygen concentration within 20 µm of the bone in the endosteal 
region (Spencer et al., 2014). Furthermore, higher oxygen tension is found near 
nestin-GFP+ vessels, which harbor quiescent HSCs (Kunisaki et al., 2013). 
Interestingly, haematopoietic stem and progenitor cells display a hypoxic profile (as 
evidenced by pimonidazole retention and expression of HIF-1α) regardless of their 
location in the bone marrow, suggesting that hypoxia might be HSC autonomous 
(Nombela-Arrieta et al., 2013). In fact, SCF (Pedersen et al., 2008) and 
thrombopoietin (Kirito et al., 2005) are known to increase HIF-1α levels, which 
could alter the distribution of hypoxic HSCs. Therefore, intrinsic metabolic 
properties rather than localisation in a hypoxic microenvironment may define the 
hypoxic prolife of HSCs. 
1.7 HIF-1α  as a regulator of HSCs 
Oxygen homeostasis is key for the normal development and physiology of the vast 
majority of multicellular organisms. As mentioned in the previous section, HSCs 
reside in a hypoxic niche within the bone marrow (Nombela-Arrieta et al., 2013; 
Spencer et al., 2014; Kiel et al., 2003). The understanding of how oxygen is sensed at 
the cellular level has recently been intensely investigated. Oxygen sensing primarily 
occurs through the hypoxia inducible factors (HIF), a family of transcription factors 
that act as key regulators of a hypoxic response (Parmar et al., 2007; Semenza et al., 
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2000; Simsek et al., 2010; Smith et al., 2008; Spencer et al., 2014; Takubo et al., 
2010). Under normoxic conditions, HIF is mainly regulated by propyl hydroxylase 
domain enzymes (PHDs) that mark HIFs for proteosomal degradation via the von 
Hippel-Lindau tumour (VHL) suppressor protein (Epstein et al., 2001; Jaakkola et 
al., 2001; Masson et al., 2001). Furthermore, HIF action is also regulated by the 
factor inhibiting HIF-1 (FIH-1), via asparagine residue hydroxylation (Elvidge et al., 
2006; Schodel et al., 2011). 
Several studies have investigated the role of HIF in HSC fate decisions (Takubo et 
al., 2010; Simsek et al., 2010; Guitart et al., 2013; Speth et al., 2014; Vukovic et al., 
2016). Our lab has for many years investigated the role of HIF in both normal and 
malignant haematopoiesis (Guitart et al., 2013; Vukovic et al., 2015; Vukovic et al., 
2016). In contrast with other reports (Takubo et al., 2010; Speth et al., 2014; Forristal 
et al., 2015), our work has conclusively demonstrated that HIF is dispensable for 
HSC maintenance, as deletion of Hif-1a, Hif-2a or both had no impact on the 
survival or maintenance of HSCs in both steady-state haematopoiesis or under stress 
conditions (Guitart et al., 2013; Vukovic et al., 2016).  
1.8 Metabolic regulation of HSCs 
In mammalian cells, ATP is mainly produced by the mitochondrial respiratory chain 
oxidative phosphorylation (OXPHOS). The remaining ATP is provided by anaerobic 
cytosolic degradation of nutrients, mainly by glycolysis (Papa et al., 2012). In order 
for OXPHOS to take place, necessary co-factors such as NADH and FADH2 need to 
be generated that will act as electron carriers during OXPHOS and will generate 
ATP. NADH and FADH2 are mainly generated by the tricarboxylic acid (TCA) 
cycle, a key part of mitochondrial respiration. The TCA cycle is essentially the 
carboxylation of carbon-based entities which occurs through a combination of 
multiple steps, catalysed by several enzymes. An outline of the TCA cycle and 
glycolysis are presented in Figure 1-5. 
Emerging evidence has linked metabolic activity of HSCs with their functional 
behaviour (Folmes et al, 2012). Previous studies have shown that quiescent HSCs 
reside in a hypoxic microenvironment and rely on glycolysis in order to meet their 
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energy demands (Simsek et al, 2010; Suda et al., 2011). More recently, studies have 
shed light on the metabolic regulation of HSCs, providing a better understanding of 
how metabolic regulators dictate HSC fate and function. Below, I describe some of 
the most recent advances regarding our understanding about the metabolic regulation 
of haematopoietic cells. 
In a recent study, genetic deletion of pyruvate dehydrogenase (Pdk), one of the key 
enzymes of the glycolytic pathway, drove murine HSCs out of quiescence. 
Furthermore, HSCs lacking Pdk were unable to reconstitute the haematopoiesis of 
recipient mice (Takubo et al., 2013). The results of this study highlight a key feature 
of HSCs, which is their need to maintain glycolysis in order to remain at a quiescent 
state. However, in another recent study, genetic deletion of pyruvate kinase isoform 2 
(Pkm2), a key enzyme of the glycolytic pathway that catalyses the conversion of 
phosphoenol pyruvate to pyruvate, did not affect the function or survival of HSCs 
(Wang et al., 2014).  
Considering that glycolysis is an inefficient way for ATP production, how can HSCs 
undergo differentiation? In another seminal study, conditional deletion of Ptpmt1, a 
PTEN-like mitochondrial phosphatase, using the Mx1-Cre model that allows 
conditional deletion of Ptpmt1 in haematopoietic cells, resulted in disruption of 
mitochondrial respiration and a complete block in HSC differentiation, and 
ultimately HSC failure (Yu et al., 2013). Surprisingly, this was not due to the loss of 
the HSC compartment, but rather to the complete inability of HSCs to undergo 
differentiation. This study highlights another essential feature of self-renewing 
HSCs, which is that they cannot undergo efficient differentiation when mitochondrial 
respiration is impaired. This statement has been supported by other studies 
(Maryanovich et al., 2015). Loss of the mitochondrial carrier homologue 2 (MTCH2) 
which acts as a negative regulator of OXPHOS, using the haematopoiesis-specific 
deleter Vav, resulted in cell cycle entry of HSCs and progenitor cells, and HSC 
exhaustion (Maryanovich et al., 2015). This study supports the view that metabolism 
plays a key role in co-ordinating HSC fates such as self-renewal and differentiation. 
Recently, the importance of liver kinase B1(LKB-1), an important promoter of 
Chapter 1 – Introduction 
Doctor of Philosophy           University of Edinburgh 2017 22 
mitochondrial biogenesis, for HSC functions was highlighted by three independent 
laboratories (Gurumurthy et al., 2010; Gan et al., 2010; Nakada et al., 2010).  
Targeted conditional deletion of Lbk1 in mice of either Mx1-Cre background or 
Rosa26-ERT, severely compromised HSC functions. Loss of Lkb1 resulted in bone 
marrow failure, preceded by an increase in proliferation and subsequent loss of HSC 
quiescence (Gurumurthy et al., 2010; Gan et al., 2010; Nakada et al., 2010). 
Importantly, the authors demonstrated that HSCs exhibited defective mitochondrial 
bioenergetics, indicating that Lkb1 acts as a metabolic checkpoint, balancing HSC 
proliferation and quiescence. In another study, the authors looked at the importance 
of fatty acid oxidation (FAO) in HSC functions. FAO takes place within the 
mitochondria and is effectively the breakdown of fatty acids in order to generate 
NADH and FADH2, which are necessary for ATP synthesis. Inhibition of the 
peroxisome-proliferator activated receptor (PPARδ)-FAO pathway using the FAO 
inhibitor etimoxir, profoundly reduced the absolute numbers of HSCs in vivo. 
Mechanistically, depletion of Pparδ resulted in the symmetric division of HSCs 
while Pparδ activation increased asymmetric division (Ito et al., 2012), highlighting 
the importance of FAO for the regulation of HSC self-renewal and differentiation.  
Cell differentiation is associated with proliferation and an increase in energy 
demands. As a result, quiescent HSCs need to switch from glycolysis to OXPHOS in 
order to support the energetically-expensive differentiation process. Furthermore, 
progenitors and more differentiated cells exhibit a different metabolic profile from 
HSCs (Piccoli et al., 2013). Therefore, studies have focused on understanding the 
precise metabolic profiles of HSCs and progenitor cells. For instance, genetic 
deletion of the M2 pyruvate kinase isoform (Pkm2) in mice, which favours glycolysis 
and synthesis of macromolecules, impaired progenitor function without perturbing 
HSCs. In contrast, deletion of lactate dehydrogenase A (Ldha), a key enzyme directly 
driving glycolysis, affected the function of both HSCs and progenitor cells (Wang et 
al., 2014). Furthermore, recent studies have shown that different metabolic pathways 
are key for specific lineages of the haematopoietic system. Oburoglu et al 
demonstrated that human HSCs and progenitor cells that are committed to the 
erythroid lineage, are strictly dependent on glutamine metabolism (Oburoglu et al., 
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2014). Furthermore, inhibition of glutamine uptake by blocking the glutamine 
transporter ASCT2, drove human HSCs towards myeloid differentiation, 
highlighting the importance of metabolic processes in lineage specification. 
 
 
Figure 1-5. Illustration of the TCA cycle and glycolysis. (A) The TCA cycle 
begins with the reaction between acetyl-coA and the four carbon oxaloacetate that 
form six carbon citrate. In the second step, citrate is converted to its isomer, isocitrate 
through a two-step process by a loss and then addition of a water molecule. In the 
first step, citrate is converted to cis-aconitase which is then converted to isocitrate. In 
the third step, isocitrate is oxidised, producing a five carbon molecule, a-
ketoglutarate (a-KG), together with a molecule of carbon dioxide (CO2), two 
electrons, which reduce NAD+ to NADH + H+. a-KG is then converted to succinyl 
group which binds to a molecule of CoA to form succinyl-CoA, while carboxylation 
of a-KG results in the release of another CO2 molecule and the reduction of NAD+ to 
NADH + H+. Step five involves the removal of CoA from succinyl CoA and is 
replaced by a phosphate group. The phosphate group is then removed and attached to 
guanosine diphosphate (GDP), thereby forming guanosine triphosphate (GTP). The 
final product from the removal of CoA from succinyl CoA is succinate. The sixth 
step involves the oxidation of succinate to fumarate, while Flavin adenine 
dinucleotide (FAD) is reduced and forms FADH2 in the process. The seventh step 
involves the hydration of fumarate into malate and during the eighth step malate is 
oxidized, forming oxaloacetate, the initial substrate of the cycle, while NAD+ is 
reduced to NADH+ H+ in the process. (Image taken from Munnich, 2008). (B) 
Glycolysis. Glucose enters the cell and is phosphorylated to glucose-6-phosphate 
(G6P) by hexokinase (1). G6P either proceeds through glycolysis to produce ATP, 
NADH and pyruvate (2), or through the PPP, producing ribose-5-phosphate and 
NADPH. G6P dehydrogenase (G6PD) dictates entry of G6P into the pentose 
phosphate pathway (PPP), and G6P oxidation produces NADPH. NADPH is an 
important cellular antioxidant and is a cofactor in the reductive biosynthesis of fatty 
acids, nucleotides and amino acids. Pyruvate produced by glycolysis is converted to 
acetyl-CoA, which enters the TCA cycle and produces two ATP molecules and six 
NADH molecules per glucose. (Image taken from Buchakjian and Kornbluth, 2010).   
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1.8.1 Oxidative stress and redox regulation in HSCs 
Reactive oxygen species (ROS) are highly reactive free radicals that act as key 
regulators of the oxidoreductive state, and are generated as by-products of normal 
physiological processes (Chance et al., 1979). They are short-lived oxygen-derived 
molecules mainly represented superoxide anions (O2-), hydrogen peroxide (H2O2), 
and hydroxyl radicals (OH). Hydrogen peroxide is the most important ROS, involved 
in signalling and acting as a second messenger in cells, and is mostly generated by 
the dismutation of O2- to H2O2. (Loschen et al., 1974). Superoxide anions can be 
produced by NADPH oxidases (NOXs, NOX1-NOX5), by the mitochondrial 
complexes I and III of the electron transport chain, or by physical stimuli such as 
ultraviolet radiation. NOXs were first identified in 1999 and constitutively generate 
low levels of ROS through electron transfer from NADPH to molecular oxygen (Suh 
et al., 1999). However, upon specific stimuli or growth factors, NOX enzymes can 
increase ROS production.  
ROS are functionally involved in the control of the biological activity of HSCs. 
Murine HSCs with low ROS production are quiescent and exhibit an increased self-
renewal capacity, while HSCs with higher ROS production have a reduced self-
renewal capacity (Jang and Shakris, 2007; Ludin et al., 2014). Recent studies have 
provided strong evidence that low levels of ROS are strictly required in order to 
maintain HSC quiescence and stemness, while increased ROS levels favour HSC 
differentiation. The molecular mechanism underlying the implication of ROS in self-
renewal of HSCs has been recently elucidated, revealing the involvement of the p38 
MAPK and mammalian target of rapamycin (mTOR) pathways. Activation of p38 
MAPK in response to elevated ROS, limited the life-span of murine HSCs in vivo 
and drove HSCs out of quiescence (Ito et al., 2006). Inhibition of either of those 
pathways rescued the ROS-induced effects in the repopulating capacity of HSCs (Ito 
et al., 2006). Furthermore, prolonged treatment with an antioxidant extended the 
lifespan of HSCs from wild-type mice in transplantation experiments. Conversely, 
stimulation of ROS triggered HSC differentiation in murine models (Jang et al., 
2007; Ito et al., 2006). In addition, a study exploring the ROS production in different 
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progenitor cells found that while production of ROS remained low in HSCs. CMPs 
were classified according to their ROS expression, to high ROS and low ROS CMPs. 
High ROS CMPs differentiated into GMPs whereas low ROS differentiated into 
MEPs. (Shinohara et al., 2014). Additionally, after culturing low ROS CMPs with 
H2O2 in semi-solid media, the authors observed a decrease in MEP colony 
production. In contrast, when they cultured high ROS CMPs with catalase, a ROS 
scavenger, they observed an increased generation of GMP colonies, at the expense of 
MEP colonies (Shinohara et al., 2014). Further studies have shown the importance of 
ROS in granulopoiesis (Segal et al., 2005), platelet production and megakaryopoiesis 
(McCrann et al., 2009; Motohashi et al., 2010). 
 
1.9 AML 
Leukaemias are a heterogeneous group of diseases characterised by the infiltration of 
immature blood cells into the blood, bone marrow, spleen and other tissues such as 
the liver, lungs and lymph nodes. These clonal haematopoietic malignancies arise 
from stem and progenitor cells of the haematopoietic system and are characterised by 
impaired differentiation and enhanced proliferation of immature cells. Leukaemias 
are classified based on the speed of the disease and the particular blood lineage cell 
of origin. As a result, leukaemias are classified as chronic myeloid leukaemia 
(CML), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (AML) 
and acute lymphoblastic leukaemia (ALL). AML represents the largest group of 
haematopoietic malignancies, accounting for 80 % of all acute leukaemias in adults. 
As such, our lab is interested in understanding how AML develops and whether it 
can be eradicated using novel strategies.  
AML is an aggressive type of leukaemia that is characterised by the rapid expansion 
of immature myeloid cells that accumulate in the bone marrow and infiltrate 
secondary organs such as the spleen and the lymph nodes (Wang and Dick, 2005; 
Andersson et al., 2015; Khwaja, 2016; Metzeler et al., 2016). The incidence of AML 
increases with age, with people over 60 years of age being most affected. Although 
AML is mostly prevalent in adults, AML accounts for approximately 20 % of all 
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leukaemia cases in children (De Kouchkovsky & Abdul-Hay, 2016; Kelly & 
Gilliland, 2002). 
1.9.1 Pathophysiology of AML 
Expansion of the immature blast cells cause the initial clinical symptoms of the 
disease, including haemorrhage, fatigue and recurrent infections as a result of 
decreased numbers of platelets, red blood cells and neutrophils. Infiltration of 
leukaemic cells in secondary organs such as the lungs, liver, spleen, lymph nodes and 
the central nervous system, results in a variation of other symptoms including 
shortness of breath, excessive sweating and weight loss (Lowenberg et al., Downing, 
1999). In the clinic, patients are diagnosed with AML when there are at least 20 % of 
blast cells present in the bone marrow (Estey and Döhner, 2006). 
1.9.2 The cell of origin of AML 
Leukaemias and solid tumours are known to exhibit tumour heterogeneity and the 
mechanism by which malignancies are maintained has been the focus of intense 
investigation. More than 50 years ago the idea of a ‘cancer stem cell’ model arose, 
describing the notion that cancers arise from one cell that exhibits self-renewal 
capacity. Seminal studies using 3H-thymidine showed that only a small fraction of 
cells in AML patients proliferate (AML-CFU), and were enriched exclusively in the 
CD34+ CD38- fraction (Bhatia et al., 1997; McCulloch, 1983; Griffin, 1986). As the 
normal HSCs are found within the same compartment, it was proposed that 
leukaemic stem cells (LSCs) arise exclusively from HSCs (Bhatia, 1997; Hope and 
Dick, 2004).  
However, the idea that LSCs can only arise from HSCs was challenged by a series of 
studies, some of which are described below. A series of recent reports it has been 
demonstrated that progenitor cells retrovirally transduced with oncogenic fusion 
proteins (such as MLL-AF9, MLL-ENL, MOZ-TIF2 fusions), are capable of 
propagating AML (Huntly et al, 2004; Cozzio et al, 2003; Somervaille and Cleary 
2006; Krivstov et al, 2006). The MOZ-TIF2 chromosomal translocation has been 
identified in subsets of AML and is a fusion between the histone acetyltransferase 
MOZ and the nuclear receptor transcriptional intermediary factor 2 (TIF) (Carapeti et 
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al., 1998). Transformation of murine CMP cells with the human MOZ-TIF2 
conferred a proliferative advantage of CMPs in vitro in serial-replating assays. 
Furthermore, transplantation of the cells generated AML in primary recipient mice 
(Huntly et al, 2004). In a similar study, Cozzio et al isolated murine HSCs, GMPs, 
CMPs and MEPs and transformed them in vitro with the human MLL (mixed lineage 
leukaemia) fusion protein MLL-ENL (eleven nineteen leukaemia), the third most 
common MLL translocation in AML (Tkachuk et al., 1992; Cozzio et al., 2003). 
MLL-ENL- transduced stem and progenitor cells generated colonies in vitro and 
exhibited granulocyte/monocyte potential. Upon transplantation of these populations 
in recipient mice, apart from MEPs, they all generated AML with a similar latency of 
average of 90 days (Cozzio et al., 2003). More recently, by utilising a transgenic 
MLL-ENL mouse model, Ugale et al demonstrated that AML developed from 
multiple progenitor cells, but not HSCs (Ugale et al., 2014). In another study, by 
utilising a transgenic mouse model of human MLL-AF9, a frequently occurring MLL 
fusion oncogene (Swansbury et al., 1998), it was demonstrated that LSCs from the 
MLL-AF9 mouse model were neither rare nor resembled HSCs (Somervaille and 
Cleary 2006). Specifically, the authors showed that the LSCs were not derived from 
the HSC compartment as none of the cells displayed an LSK immunophenotype.  By 
using a similar model, Krivstov et al., isolated GMPs from wild-type mice and 
transduced them with retroviruses expressing the human MLL-AF9 fusion protein 
(Krivstov et al, 2006). Injection of the MLL-AF9-transduced cells generated AML in 
primary and secondary recipient mice and shared a common genetic signature with 
normal GMPs. However, a subset of genes normally expressed in HSCs was re-
activated in the GMP-derived LSCs, indicating that a self-renewal-associated 
signature, similar to that of normal HSCs, can be activated. Amongst others, HoxA5, 
HoxA9, HoxA10, Runx2 and Meis1 exhibited increased expression in the GMP-
derived LSCs. In a more recent study carried out by the same group, the authors 
utilised the human MLL-AF9 knock-in mouse model that has a defined cell of origin 
(Krivstov et al., 2013). Their findings showed that MLL-AF9-mediated 
transformation differed when HSCs were the cells of origin as compared with GMPs. 
Specifically, although they were immunophenotypically similar, the LSCs arising 
from these two populations exhibited differences in gene expression and DNA 
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methylation status. More specifically HSC-derived LSCs were expressing “stemness-
associated” genes such as Evi1, c-Jun, Fos1, Bcl6 while the GMP-derived LSCs were 
not. Additionally, HSC-derived LSCs exhibited an elevated global 5-hydroxy-
methylcytosine (5-hmC) profile when compared to GMP-derived LSCs. 
Furthermore, LSCs derived from HSCs, were less responsive to the chemotherapy 
drug cytarabicine when treated in vitro (Krivstov et al., 2013). These data 
demonstrate that the cell of origin can influence the gene expression profile, 
epigenetic profile and response to chemotherapy, highlighting the true heterogeneity 
of AML as well as the clinical relevance of identifying the cell of origin of different 
AML subtypes.  
Overall, it is evident that AML does not exclusively originate from a single cell 
population such as the HSC but rather, frequently arises from committed progenitor 
cells such as GMPs.  
1.9.3 Mutations and chromosomal translocations in AML 
1.9.3.1 FAB and WHO classifications of AML 
A classification for AML, originally proposed in 1976, provided a consistent 
morphological and cytogenetic framework in which the significance of the genetic 
abnormalities could be appreciated (Bennet et la., 1976). The classification was 
referred to as French- American- British (FAB) classification and is outlined in Table 
1. However genetic and morphological correlations are not always perfect and in 
many cases, cannot be identified. Furthermore, the underlining genetic and molecular 
defects cannot be identified. For that reason, a new way of classifying AML was 
developed by the world health organization (WHO), that was later updated (Hossfeld 
et al., 2002; Swerdlow et al., 2008). The WHO classification is outlined in Table 2. 
Pioneering work led by Janet Rowley established that AML is a genetic disease, with 
the discovery of somatic chromosomal abnormalities, including balanced 
translocations in patient samples (Rowley et al., 1973; 1977). These studies set the 
stage for the identification of the genes involved at the chromosomal breakpoints, 
providing major insight into the cytogenetic abnormalities found in AML. However, 
approximately 40 % of AML patients present a normal karyotype, suggesting that 
there are molecular changes that cannot be identified using cytogenetics (Grimwade 
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et al., 2010). However, over the course of the past 20 years, major technological 
advances have been made such as whole exome sequencing, thus allowing us to 
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1.9.3.2 Genetic mutations in AML 
Next-generation sequencing and whole-exome sequencing have led to the discovery 
of numerous recurrent mutated genes in AML (Ley et al., 2008). Furthermore, the 
Cancer Genome Atlas consortium studied the mutational status of 200 AML patient 
samples and found a large proportion to be “significantly mutated”, at a higher than 
expected frequency (The Cancer Genome Atlas (TCGA), 2013). Although the 
functional significance of many of these mutations is not fully understood yet, these 
mutations can become clinically useful, as they could be used as biomarkers. Below, 
I outline the classes of the most common mutations that have been implicated in 
AML development in Figure 1-6. Broadly speaking, the identified mutations fall 
under the following categories: mutations involving components of signalling 
pathways, mutations in epigenetic modifiers, splicing factor gene mutations and 
CEBPA, NPM1 and RUNX1 mutations.  
1.9.3.3 Mutations in signalling pathway components 
A major step forward was the discovery that the receptor tyrosine kinase fms-like 
tyrosine kinase 3 (FLT3) is mutated in a third of all AML cases (Grimwade et al., 
2016). These mutations involve in-frame duplications within the juxtamembrane 
region (FLT3-ITD), and point mutations in the tyrosine kinase domain (FLT3-TKD) 
in 25 % and 7 % of AML, respectively. Both classes of mutation lead to constitutive 
activation of the receptor, yet surprisingly carry different prognostic implications. 
FLT3-ITD mutations are associated with a poorer prognosis while FLT3-TKD are 
associated with a more favorable prognosis (Mead et al., 2007). Following studies 
established that a number of other genes encoding signalling pathway components 
such as RAS and cKIT, are recurrent mutations in AML (Grimwade et al., 2016).  
1.9.3.4 Epigenetic modifier mutations 
Recent studies have identified a number of epigenetic modulators to be mutated in 
AML. Alterations include a number of genes such as DNMT3A, TET2, WT1 and 
IDH1/2 mutations (Grimwade et al., 2016). DNMT3A, is a methyltransferase 
generating de novo DNA methylation, mutated in approximately 30 % of all AML 
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cases (Ley et al., 2010) and often appears in conjunction with NPM1 (Slush et al., 
2014) and FLT3 mutations (Thiede et al., 2006). Most DNMT3A mutations are 
heterozygous and alter the R882 catalytic domain, suggesting the possibility of 
dominant-negative consequences (Russler-Germain et al., 2014). 
Recently, mutations in other epigenetic modifiers such as TET2, WT1 and IDH1/2 
have been identified as well. Mutations in these genes were found to be mutually 
exclusive but shared similar signatures in terms of DNA methylation profiling 
(Figuoeroa et al., 2010; Wang et al., 2015; Rampal et al., 2014). The key downstream 
target is TET2, which is mutated in 8 % of all AML cases. IDH1 mutations affecting 
R132 are found in 7 % of all AML cases while IDH2 mutations are found in 9 % of 
all AML cases (TCGA, 2013).  
IDH enzymes catalyze the conversion of isocitrate to alpha-ketoglutarate. However, 
IDH mutations not only reduce the formation of alpha-ketoglutarate but also exhibit 
a neomorphic activity, altering the enzyme’s function to produce the 
“oncometabolite” 2-hydroxyglutarate, which inhibits the function of TET2 (Xiao et 
al., 2011). WT1 mutations are found in 9 % of all AML cases and has been recently 
identified as a binding partner of TET2 (TCGA, 2013; Wang et al., 2015; Rampal et 
al., 2014). These studies collectively demonstrate that the IDH/WT1/TET2 axis plays 
an important role in AML pathogenesis. 
1.9.3.5 CEBPA, NPM1, and RUNX1 mutations 
Major insight into the molecular pathogenesis of AML was provided by the 
discovery of mutations in genes encoding CCAAT/enhancer binding protein alpha 
(CEBPA) and nucleophosmin (NPM1). These mutations were recognised by the 
WHO in 2008 classification and define prognostically relevant subsets in AML 
(Swerdlow et al., 2008). CEBPA encodes a myeloid transcription factor and 
mutations of CEBPA are found in approximately 10 % of all AML cases (TCGA, 
2013). CEBPA mutations result in the expression of a truncated version, potentially 
acting in a dominant-negative manner (Pabst et al., 2001).  
NPM1 is the single most commonly mutated gene in AML, found in approximately 
35 % of all AML (Falini et al., 2005; Thiede et al., 2006). The NPM1 gene encodes a 
nucleoplasmic shuttling protein with prominent localisation in the nucleus. However, 
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mutation in NPM1 result in an aberrant cytoplasmic localisation (Fallini et al., 2005). 
Although NPM1 mutations are very frequent in AML, the exact molecular 
mechanisms by which they contribute to AML is not fully understood yet. Finally, 
NPM1 mutations are frequently associated with alterations in FLT3, DNMT3A and 
IDH1/2 genes (Dohter et al., 2005; Schnittger et al., 2005). 
RUNX1 is a relatively common mutation target in cytogenetically abnormal AML. 
Germ-line mutations of RUNX1 lead to familial platelet disorder and predispose to 
AML (Lam et al., 2012). In adult AML, RUNX1 mutations tend to be mutually 
exclusive with balanced chromosomal translocations and mutations involving 
NPMT1, IDH2 and CEBPA mutations (Lam et al., 2012).  
1.9.3.6 Splicing factor gene mutations 
Recently, mutations in genes encoding members of the pre- messenger RNA splicing 
machinery were identified in myelodysplastic syndromes (MDS) (Yoshida et al., 
2011; Papaemmanuil et al., 2011). MDS are a heterogeneous group of myeloid 
neoplasms characterised by deregulated blood cell production with evidence of 
myeloid dysplasia and a predisposition to AML (Yoshida et al., 2011). The most 
common mutations of splicing factors involve SF3B1, SRSF2, ZRSR2, SF3B1 and 
U2AF1 (TCGA, 2013; Yoshida et al., 2011; Lindsley et al., 2015). A recent study 
focusing on SRSF2 showed that the mutation impaired normal differentiation in vivo. 
Specifically, the mutation resulted in missplicing of targets such as EZH2 (Kim et al., 
2015). Further insights into the functional consequences of splice factor mutations 
came from in vivo studies involving U2AF1 (Shirai et al., 2015). Shirai et al found 
that U2AF1 mutations altered haematopoiesis by missplicing genes involved in AML 
and MDS, such as MLL and BCOR (Shirai et al., 2015). Splice factor mutations are 
the most frequent mutations in MDS, where they are considered to be an initiating 
event (Papaemmanuil et al., 2013), but are much less common in AML (found in 5-
10 % of all AML cases) (TCGA, 2013; Yoshida et al., 2011).  
1.9.3.7 Mutations in cohesin complex members 
By the use of whole exome sequencing, genes encoding components of the cohesin 
complex were identified as recurrent mutations in AML (TCGA, 2013; Tho et al., 
2014; Kon et al., 2014). The cohesin complex is a ring-like structure composed of 
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SMC1A, SMC3, RAD21 and one of either STAG1 or STAG2 (Nasmyth et al., 
2009). The cohesin complex is involved in sister chromatid exchange during 
anaphase, regulation of DNA repair, and transcriptional control by coordinating 
interaction between promoters, via DNA looping (Kagey et al., 2010; Degner et al., 
2011; Schaaf et al., 2013). Interestingly, cohesin mutations are associated with 
altered transcriptional regulation in the development of AML and are detected in 20 
% of AML patients. Cohesin complex mutations are often associated with mutations 
involving RUNX1and ASXL1 (Thota et al., 2014). For an overview of the most 
common mutations in AML, please refer to Figure 1-6. 
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Figure 1-6. Overview of the most common 
mutations identified in AML patients (Adapted from 
Metzeler et al., 2016). 
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1.9.3.8 Cytogenetic characterisation of AML 
1.9.3.8.1 Chromosomal rearrangements and translocations 
Balanced chromosomal rearrangements are detected in approximately 25-30 % of all 
adult AML and give rise to in-frame chimeric fusion genes. Frequently targeted 
genes encode haematopoietic transcription factors such as RARA, RUNX1 or the 
CBFb subunit of the core binding factor complex, components of the nuclear pore 
complex (NUP98, NUP214) and epigenetic regulators such as MLL (Grimwade et 
al., 2016; Mrozek et al., 2008). The most common balanced chromosomal 
rearrangements in AML are: (1) the t (8;21) translocation resulting in RUNX1-ETO 
fusion protein, (2) inv(16)/ t(16;16) resulting to the core binding factor beta (CBFB) 
fusion with the muscle myosin heavy chain (MYH11) gene (Liu et al., 1993; 
Shurtleff et al., 1995), (3) the t (15;17) translocation creating the PML-RARA gene 
fusion (de The et al., 1990).  
1.9.3.8.2 t (8;21)/ RUNX1-ETO 
Approximately 10 % of AML cases carry the t(8;21) translocation, which involves 
the RUNX1 and ETO genes, and express the DNA- binding transcription factor, 
crucial for normal haematopoietic differentiation (Erickson et al., 1992; Mrozek et 
al., 2008; Cameron et al., 2004), while ETO is a protein acting as a transcriptional 
repressor (Davis et al., 2003). The fusion protein is suggested to function as a 
transcriptional repressor that blocks RUNX1-dependent transactivation of various 
promoters, suggesting that the fusion protein might act as a dominant negative 
regulator of wild-type RUNX1 (Meyers et al., 1995; Bulchi et al., 2014).  
1.9.3.8.3 Inv (16)/ CBFB-MYH11 
Inv (16) is found in 8 % of AML cases and fuses the first 165 amino acids of CBFB 
to the C-terminal coiled-coil region of MYH11 (Liu et al., 1993; Shurtleff et al., 
1995). CBFB-MYH11 fusion protein is suggested to co-operate with RUNX1 to 
repress transcription (Lutterbach et al., 1999; 2000). 
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1.9.3.8.4 t (15;17)/ PML-RARA 
The PML-RARA oncogenic fusion protein is found in approximately 95 % of all 
M3FAB (APL) subtypes of AML, and acts as a transcriptional repressor that 
interferes with gene expression programs involved in normal differentiation, self-
renewal and apoptosis (Jing et al., 2004; Licht, 2006). 
1.9.3.8.5 MLL rearranged leukaemias 
The MLL gene is located on chromosome 11 and is a frequent target for 
chromosomal rearrangements and translocations (Ziesmin-van der Poel et al., 1991; 
de Boer et al. 2013; Martin et al., 2003; Rao &Dou, 2015). MLL is a trithorax-related 
histone methyltransferase (H3K4), homologous to yeast Set1, the first H3K4 
methylase that was identified (Djabali et al., 1992; Miller et al., 2001). 
MLL has been found in 73 different translocations and 54 partner genes have been 
cloned (TCGA, 2013). MLL rearrangements are found in approximately 80 % of all 
infant ALL cases and in 10 % of all adult leukaemia cases (Mohan et al., 2010). 
MLL fusion proteins underline some of the most aggressive human leukaemias and 
represent the most frequent translocations found in both myeloid and lymphoid 
leukaemias (Garcia-Cuellar et al., 2016; Cano et al., 2007; Cozzio et al., 2003). As a 
result, most of the leukaemias harboring MLL rearrangements are associated with 
poor prognosis (Mohan et al., 2010; Anderson et al., 2015). Over 90 % of all MLL 
cases are accounted for by gene fusion with AF4 (42 %), AF9 (16 %), ENL (11 %), 
AF10 (7 %) and ELL (4 %) (Mayer et al., 2009).  
Expression of the MLL promoter after translocation produces an MLL fusion protein 
consisting of the N-terminus of MLL and the C-terminus of the fusion protein, which 
does not contain H3K4 methyltransferase activity (Marschalek, 2010). MLL fusion 
proteins appear to interfere with normal transcriptional regulators and mediate 
leukaemogenesis. Four of the most common fusion partners of MLL, namely AF4, 
AF9, ENL and ELL participate in a common biological reaction known as the 
positive transcription elongation factor b (P-TEF-b)- dependent transcriptional 
activation cycle of RNA polymerase II, converting a “promoter-arrested RNA 
polymerase II”, into “elongating RNA polymerase II” (Peterlin and Price, 2006). 
These factors along with the polymerase associated factor 1 complex, the H3K79 
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methyltransferase DOTL1, and the BET family protein BRD4, are thought to form a 
large complex and transcriptionally alter target genes (Yokomama et al., 2010; 
Biswas et al., 2011; Milne et al., 2010; Jang et al., 2005). MLL fusion proteins 
appear to promote leukaemogenesis through a common molecular mechanism that 
involves aberrant transcriptional elongation of target genes involved in proliferation, 
differentiation and survival (Wang et al., 2011). Furthermore, MLL fusion proteins 
target transcriptional regulators of HSC self-renewal, in particular MEIS1 and 
HOXA9 (described in more detail in section 4.1) (Kawagoe et al., 1999; Imamura et 
al., 2002; Ayton and Cleary, 2003).  
Finally, although MLL fusions may contribute to leukaemogenesis via a common 
molecular mechanism to dysregulate transcription of target genes, many of these 
target genes are likely to be unique to the particular MLL fusion partner, and may 
depend on the cell of origin and additional mutations that may be present, thus 
explaining the heterogeneity in the pathology of the different MLL leukaemias.   
1.9.3.9 Mutational evolution of AML 
Next generation sequencing studies have documented the stepwise acquisition of 
mutations by identifying differences in the relative proportion of co-occurring 
mutations in the bulk AML cells at the time of diagnosis (Mardis et al., 2009; Walter 
et al., 2012). Longitudinal sequencing studies using samples at the time of diagnosis 
as well as relapse of the same patient, have shown that the patterns of relapse are 
heterogeneous.  Relapse was shown to occur from the expansion of both major and 
minor clones that were present in diagnosis, or from new clones that did not share 
ancestry with the diagnostic clone (Ding et al., 2012; Wong et al., 2015).  
Recent studies have identified several mutations that arise as initiating or secondary 
events (Jan et al., 2012; Corces-Zimmerman et al., 2014; Slush et al., 2014). For 
instance, mutations in DNMT3A, TET2, IDH1/2 and ASXL1 are thought to occur in 
progenitor and haematopoietic stem cells without affecting the normal characteristics 
of the cells. However, upon the acquisition of secondary mutations such as a 
mutation of the NPM1 gene, lead to the generation of AML (Slush et al., 2014). Pre-
leukaemic mutations such as DNMT3A, TET2 and ASXL1 are associated with poorer 
prognosis (Slush et al., 2014).  
Chapter 1 – Introduction 
Doctor of Philosophy           University of Edinburgh 2017 38 
Taken together, recent studies have identified early mutations and mutations that 
persist after treatment failure, therefore pointing towards the critical molecular 
drivers that need to be therapeutically targeted.  
1.9.4 Two hit model 
AML is considered to develop in a “two hit” fashion. This view suggests that the 
development of AML is a multistep process, where initial and secondary mutations 
are required (Papaemmanuil et al., 2016; Kelly and Gilliland, 2002). More 
specifically, initial mutations occurring in stem or progenitor cells lead to the 
generation of pre-leukaemic stem cells (pre-LSCs). In murine models, pre-LSCs are 
characterised by their ability to generate disease in primary recipient mice with 
varying latency. Secondary mutations then lead to the generation of leukaemic stem 
cells (LSCs), and the founding clone(s) of AML. LSCs are defined by their self-
renewal capacity and their ability to propagate disease with very short latency. The 
mutations are broadly classified in type I and type II mutations, with type I 
conferring a survival and proliferative advantage, and type II mutations impairing 
normal haematopoietic differentiation (Kelly and Gilliland, 2002). However, more 
recent studies have identified epigenetic mutations that do not necessarily fall under 
either of those categories, challenging the simplicity of the “two hit” model (TCGA 
2013; Metzeler et al., 2016). While the mutational status and cytogenetic 
abnormalities involved in AML are well described, the metabolic properties of AML 
cells are only recently better understood. Below I describe the most recent studies 
that aim to uncover the metabolic properties of AML cells. 
1.9.5 Current treatments for AML 
Standard therapy for AML patients is delivered in two phases. The first phase is the 
“induction” phase, and the second phase is the “consolidation” phase that eradicates 
any residual disease in order to achieve lasting remission. The induction phase 
consists of a standard “7+3” treatment that consists of a 7-day continuous infusion 
with cytarabicine (interfering with DNA synthesis), followed by 3 days of treatment 
with anthracycline (inhibiting RNA and DNA synthesis, as well as topoisomerase II, 
ultimately blocking DNA replication and transcription). The “7+3” regimen is 
generally offered to patients with a favorable or intermediate prognosis. The 
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“consolidation” phase normally involves a sequence of higher doses of cytarabicine, 
with 40 % of young patients remaining in complete remission for approximately 5 
years (Burnett et al., 2011). This treatment is repeated approximately every 4 weeks, 
of a total of 3 to 4 cycles. Young patients can also undergo allogeneic stem cell 
transplant (ASCT) after “induction” therapy. ASCT has been found to reduce the risk 
of patient relapse but comes with serious complications, including the risk of 
treatment-associated death. Older patients are often not able to tolerate such intensive 
“consolidation” treatment and as a result are treated with fewer cycles (1 or 2) of 
cytarabicine. Some of the novel agents currently used as first-line AML treatment 
and those currently being developed for the clinic include: FLT3-ITD inhibitors 
(such as Sorafenib, Midostaurin and Quizartinib), STAT inhibitors (such as C188-9), 
and IDH1/IDH2 small molecule inhibitors (such as Clofarabine) (Dombret and 
Gardin, 2016; Kouchkovsky and Abdul-hay, 2016). Emerging therapies for AML 
currently include inhibitors for histone deacetylase (HDAC), DOTL1, BCL-2 and 
BET bromodomain inhibitors. Finally, antibody-drug conjugates (ADCs) are also in 
early-phase clinical trials (Sten and Tallman, 2016).  
1.10 Abnormalities in the metabolism of LSCs 
1.10.1 OXPHOS in LSCs 
Elevated ROS production has been associated with various myeloid malignancies, 
including CML and AML (Hole et al., 2011). The use of experimental mouse models 
has provided evidence that ROS production contributes to leukaemogenesis. For 
example, in murine breakpoint cluster region-abelson (BCR-ABL) models, 
expression of BCR-ABL induced the production of ROS, which contributed to 
malignant transformation (Sattler et al., 2000; Kim et al., 2005). Transformation of 
the haematopoietic cell lines, Ba/F3, 32Dcl3 and MO7e with retrovirally expressed 
BCR-ABL, resulted in an increase of ROS (Sattler et al., 2000). The authors showed 
that the increase in ROS was a direct consequence of BCR-ABL expression, since 
treatment of the cell lines with an ABL-specific tyrosine kinase inhibitor, decreased 
ROS levels. Finally, stimulation of untransformed MO7e cells with H2O2 (to mimic 
increase of ROS), increased the phosphorylation of components of the BCR-ABL 
pathway, including c-ABL, SHC and SHP-2 (Sattler et al., 2000). A more recent 
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study suggested that elevated ROS is dependent on BCR-ABL-dependent increase in 
glucose metabolism, as treatment of BCR-ABL-transformed Ba/F3 and MO7e cells 
with the glycolysis inhibitor 2-deoxy-glucose, reduced ROS levels (Kim et al., 2005). 
 
Similarly, human AML cell lines MOLM13 and MV4-11 that express FLT3-ITD, 
exhibited increased levels of ROS that was attributed to high transcript expression of 
NOX4. Knock-down of NOX4 in these cell lines resulted in diminished colony 
forming potential in vitro. Furthermore, the essential role of ROS in FLT3-ITD-
mediated leukaemia was supported by the fact that in a murine model of FLT3-ITD, 
NOX4-targeting compounds had an inhibitory effect on the development of AML in 
vivo (Jayavelu et al., 2016). Interestingly, in another study, Lagadinou et al 
demonstrated that ROS production is heterogeneous in primary human AML cells. In 
particular, the authors isolated LSCs based on their ROS expression via flow 
cytometry. While ROS-low cells were quiescent and exhibited functional LSC 
properties, ROS-high cells proliferated more and did not possess LSC properties 
(Lagadinou et al., 2013). Ectopic expression of the Ras oncogene via retroviral 
vectors in CD34+ cells isolated from healthy donors, promoted ROS production as 
indicated by a superoxide-sensitive chemiluminescent probe (Hole et al., 2010). 
Furthermore, ROS production was attributed to the activation of NOX enzymes. 
More importantly, the authors showed that Ras-expressing CD34+cells exhibited 
augmented proliferation that was specifically attributed to ROS production, as 
treatment with the antioxidants DPI and NAC, supressed the proliferation of the cells 
(Hole et al., 2010).  
 
In another study primary cells isolated from the peripheral blood or bone marrow of 
AML patients, exhibited a strong elevation of ROS (specifically superoxide), when 
compared to cord blood CD34+ cells of healthy donors (Hole et al., 2013). 
Furthermore, the elevated ROS production was attributed to increased expression of 
NOX2/4 enzymes and inhibitors of such, decreased the concentration of superoxide. 
Finally, treatment of the human AML cell lines MV4-11 and KG1 (that normally 
exhibit low levels of ROS) with H2O2, in order to mimic elevated ROS increased the 
proliferation of the cells in a dose-dependent manner (Hole et al., 2013). Overall, this 
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study demonstrated that primary AML cells exhibit a strong ROS signature and that 
NOX-derived ROS production promotes the proliferation of AML cells (Hole et al., 
2013). 
 
Skrtic et al. also analysed mitochondrial function in primary AML cells and found 
that these cells exhibited greater mitochondrial mass when compared to normal 
progenitor cells (Skrtic et al., 2011). Interestingly, the AML cells with the greater 
mitochondrial mass selectively underwent apoptosis when treated with tigecycline, 
an antimicrobial agent that blocks mitochondrial respiration (Skrtic et al., 2011). The 
same authors extended their study and found that the increased mitochondrial mass 
was not concomitant with the increase of respiratory chain activity. Furthermore, the 
cells exhibited low spare respiratory capacity and were thus more sensitive to 
oxidative stress (Sriskanthadevan et al., 2015). The authors took advantage of this 
sensitivity and selectively killed the AML cells by treating them with the fatty acid 
palmitate, which increases the flux of electrons through the electron transport chain, 
eliciting oxidative stress (Sriskanthadevan et al., 2015).  
 
1.10.2 Mitochondrial metabolism alterations in AML cells 
Recent efforts have been made in order to understand the biochemical mechanisms 
responsible for the apparent increased dependence of cancer cells on aerobic 
glycolysis (i.e. reliance on glycolysis even in the presence of oxygen). An interesting 
hypothesis that has emerged from recent studies, indicate that mitochondrial 
uncoupling (the uncoupling of ATP synthesis from mitochondrial membrane 
potential), could promote the shift to aerobic glycolysis. When culturing AML cell 
lines on a layer of feeder MSC cells, Samudio et al demonstrated OCI-AML3 and 
MOLM13 cells were more resistant to chemotherapy and decreased the entry of 
pyruvate into the TCA cycle, without compromising oxidative phosphorylation 
(Samudio et al, 2008; 2009). This observation suggested that the shift to oxidation of 
non-glucose nutrients could be mainly sustained by fatty acids. Consistent with this 
notion, pharmacological inhibition of fatty acid oxidation (FAO) sensitised human 
primary AML cells to apoptosis, by induction of the molecule ABT-737, a molecule 
that releases pro-apoptotic Bcl-2 proteins (Samudio et al., 2010). The rate-limiting 
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step of FAO, is carried out by the enzyme carnitine palmitoytransferase 1 (CPT1). 
Inhibition of FAO, using a CPT1 inhibitor, resulted in mitochondrial damage, growth 
arrest and apoptosis of primary AML cells derived from bone marrow aspirates and 
cell lines (Ricciardi et al., 2014). More recently, avocatin B, a lipid derived from the 
avocado fruit, was shown to exert cytotoxic effects in vitro on the AML cell lines 
TEX and OCI-AML2, as well as on primary AML cells. Interestingly, avocatin B 
exerted its cytotoxic effects via inhibition of FAO, highlighting the fact that AML 
cells rely on FAO in order to sustain their energy demands (Lee et al., 2015).   
 
Apart from lipids, glutamine also represents an important source of carbon molecules 
in order to sustain oxidative phosphorylation. Recently, the importance of glutamine 
metabolism for AML cells was highlighted by the observation that knock-down of 
the glutamine transporter SLC1A5 induced apoptosis in the AML cell lines MV4-11 
and OCI-AML13 and inhibited AML development in a xenotransplantation mouse 
model, without affecting normal CD34+ cells (Willems et al., 2013; Jacque et al., 
2015). Interestingly, glutamine deprivation in the AML cell lines HL-60, THP-1 and 
K-562, induced upregulation of enzymes involved in serine metabolism, namely 
phosphoglycerate dehydrogenase and phosphoserine aminotransferase (Polet et al., 
2016). This observation potentially highlights new therapeutic windows via the 
inhibition of glutamine and serine metabolism. 
 
Finally, in an effort to identify members of the mitochondrial proteome for which 
inhibition may reduce the viability of AML cells, Cole et al identified the 
caseinolytic mitochondrial matrix protease CIcp, a mitochondrial protease, being 
overexpressed in approximately half the AML samples (Cole et al., 2015). Down-
regulation of CIcp in primary AML samples, selectively induced apoptosis while 
sparing normal haematopoietic cells (Cole et al., 2015).   
 
1.10.3 Abnormalities of the glycolytic pathways in AML 
cells 
Similarly to other cancers, the level of glycolytic metabolism is high in AML patient 
samples (Herst et al., 2011). Interestingly, the level of the glycolytic pathway was 
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variable between patients, separating patients into two groups. One group exhibited 
high glycolytic activity and the other group exhibited moderate levels of glycolytic 
activity as measured by a dye-reduction assay in vitro (Herst et al., 2011). These 
findings were corroborated by another study that measured the concentration of 
different metabolites from the sera of AML patients (Chen et al., 2014). Based on 
their metabolomics study, Chen et al identified a total of 6 metabolites representing a 
glucose metabolism signature. Based on these metabolites, the authors were able to 
separate patients into a high- and low- prognostic risk score (PRS). Low-PRS 
patients had a poor prognosis and were characterised by an increase in the levels of 
lactate, pyruvate, 2-oxoglutarate, 2-hydroxyglutarate and glycerol-3-phosphate and 
decreased levels of citrate, thereby suggesting a truncation of the TCA cycle and an 
augmentation of glycolysis (Chen et al., 2014). Inhibition of glycolysis using 2-
deoxyglucose decreased survival of AML cells and increased their sensitivity to the 
anti-leukaemic agent arabinofuranosyl cytidine (Chen et al., 2014). 
Given these observations, efforts have been made to evaluate whether blocking 
enzymes of the glycolytic pathway, would exert an inhibitory effect on leukaemic 
cells in terms of their survival. Pyruvate dehydrogenase kinase-1 (PDK1), is a key 
enzyme of the glycolytic pathway, regulating the flux of pyruvate into the TCA 
cycle. PDK1 is often over-expressed in cancer cells. Recently, it was shown that the 
use of a PDK1 inhibitor, dichloroacetophenone, induced apoptosis of the AML cell 
line U937, and inhibited their growth when transplanted in nude mice (Qin et al., 
2016). 
PKM2, is another key enzyme of the glycolytic pathway most predominantly 
expressed in cancer cells. Genetic deletion of Pkm2 in mice decreased survival of 
LSCs but had no effect on normal haematopoietic cells (Wang et al., 2014). Lactate 
dehydrogenase A (LDHA) catalyzes the final step in the glycolysis pathway 
(oxidation of pyruvate to lactate). The authors furthered their study by genetically 
deleting Ldha in mice using the transgenic Mx1-Cre mouse model, which affected 
the survival of both leukaemic and normal cells, indicating that lactate production is 
important for both cell types (Wang et al., 2014).   
 
Other studies have also investigated the activation of the pentose phosphate pathway 
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(PPP) in AML. Based on the Cancer Genome Atlas AML dataset, in 61 % of AML 
cases, PPP genes are upregulated. Furthermore, inhibition of PPP in leukaemic cells 
suppressed growth and invasion of AML but not colony growth (Chen et al, 2016).   
Cancer metabolism is an intense area of investigation that could offer the potential of 
new therapeutic windows. Increasing evidence suggests that oxidative 
phosphorylation is an important source of energy for leukaemic cells, thus 
underscoring the importance of elucidating the exact mechanisms by which it 
contributes to leukaemogenesis and to normal haematopoiesis. With that in mind, my 
project focuses on unravelling the importance of OXPHOS in both normal 
haematopoietic cells and leukaemic cells, by deleting one of the key enzymes of the 
TCA cycle, fumarate hydratase Figure 1-5. 
 
1.11 Fumarate hydratase 
1.11.1 FH identified as a tumour suppressor in HLRCC 
Fumarate hydratase (FH in humans, Fh1 in mice) is an enzyme of the TCA cycle 
catalysing the hydration of the metabolite fumarate into malate (Figure 1-7 A).  
Although FH is generally considered a mitochondrial enzyme, it is also expressed in 
the cytoplasm where it participates in various macromolecular processes such as the 
urea, nucleotide and amino acid cycles and in the nucleus where it is thought to be 
part of the DNA damage response (Sass et al, 2001; Yogef et al, 2012). FH has been 
classified as a tumour suppressor in hereditary leiomyomas and renal cell cancer 
(HLRCC) as affected individuals inherit a germline mutation while tumours exhibit 
loss of the wild-type copy of the gene (Tomlison et al, 2002). Biallelic loss of FH 
was initially identified in patients with HLRCC and has been recently identified in 
patients with paragangliomas and pheochromocytomas (Tomlison et al, 2002; Vega 
et al, 2013). Fumarate, which is highly accumulated in FH-deficient cells, is 
considered a major pro-oncogenic factor in HLRCC. Initial studies proposed that the 
stabilisation of the hypoxia-inducible factors (HIFs), caused by the fumarate-
dependent inhibition of propyl-hydroxylases (PHDs) that negatively regulate HIFs, 
was instrumental for tumour formation (Isaacs et al, 2005; Pollard et al, 2005). 
However, it was demonstrated that neither HIF-upregulation nor PHD inactivation 
was required for renal cyst formation in Fh1-deficient cells, challenging their 
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implication in tumour formation in this context, suggesting that HIF-independent 
oncogenic pathways might be involved (Adam et al., 2013). The functions of 
fumarate identified up to date are outlined in Figure 1-7 B. 
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Figure 1-7. The catalytic reaction of fumarate hydratase and the cellular 
consequences of elevated fumarate. (A) Fumarate hydratase catalyses the hydration 
of the four carbon fumarate to the four carbon malate. (B) Loss of fumarate hydratase 
activity results in intracellular accumulation of fumarate. Dysregulated metabolism is 
linked with fumarate hydratase deletion due to a biochemical truncation of the TCA 
cycle. Fumarate has been shown to act as a competitive inhibitor of a-KG-dependent 
dioxygenases, including histone demethylases (HDMs), TET proteins and the 
negative regulator of HIF hydroxylases, propyl-hydroxylases. Succination of 
cysteine residues that could lead to the loss of protein functions has been associated 
with the elevation of intracellular fumarate. The proteins identified so far include 
Kelch-like ECH-associated protein 1(KEAP1) and aconitase 2 (ACO2) (Adapted 
from Yang et al., 2012). 
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1.11.2 Fumarate causes protein succination 
Fumarate is a natural nucleophile that can covalently (and irreversibly) bind to 
cysteine residues of proteins under physiological conditions, by a process termed 
succination (2SC; Figure 1-8) (Alderson et al., 2006). Interestingly, succination is a 
feature of FH-deficient cells, where fumarate accumulates to very high levels 
(Bardella et al., 2011). The Kelch-like ECH-associated protein 1 (KEAP1), an E3 
ubiquitin ligase and an inhibitor of the transcription factor nuclear erythroid-related 
factor 2 (NRF2), was recently identified as a target of protein succination in FH-
deficient cells (Adam et al., 2011). Its consequent inhibition led to the activation of 
NRF2 and a subsequent strong antioxidant response (Adam et al., 2011; Ooi et al., 
2011). Although KEAP1 succination could provide an explanation for the 
antioxidant phenotype observed in FH-deficient cells, other oxidation-related 
mechanisms could contribute to this response. In particular, the loss of FH has been 
previously associated with an increase in ROS (Sudarshan et al., 2009), where 
accumulation of fumarate leads to the formation of a covalent adduct between 
fumarate and glutathione (GSH), leading to oxidative stress (Sullivan et al., 2013). In 
contrast however, in a recent study Zheng et al proposed that the oxidative stress 
observed in FH-deficient cells is a result of an alternate mechanism (Zheng et al., 
2015). Specifically, the authors proposed that succination of GSH increases the 
demands of NADPH in order to sustain GSH biosynthesis. This reaction in turn 
negatively affects redox homeostasis and as a compensatory mechanism, FH-
deficient cells enhance cysteine uptake and GSH biosynthesis, causing chronic 
oxidative stress (Zheng et al., 2015). The precise mechanisms by which oxidative 
stress is caused in FH- deficient cells and how it contributes to tumorigenesis, is not 
fully understood but recent evidence suggests that oxidative stress indirectly 
activates the oncogene abelson murine leukaemia 1 (ABL1), which in turns promotes 
nuclear translocation of NRF2, potentially contributing to malignancy (Sourbier et 
al., 2014) (described in more detail in section 1.9.3- Metabolic disruption as a result 
of FH deletion). 
In an effort to identify more succinated proteins, Ternette et al searched for other 
2SC targets that could contribute to pathogenesis of FH-associated disease (Ternette 
Chapter 1 – Introduction 
Doctor of Philosophy           University of Edinburgh 2017 48 
et al., 2013). Hence, they conducted a large proteomic screen for 2SC in Fh1-
deficient mouse embryonic fibroblasts (MEFs) and in mouse kidney tissue, where 
Fh1 had been deleted from the kidney tubules. The authors identified 94 succinated 
proteins, including some that were succinated on functional cysteine residues 
(Ternette et al., 2013). In particular, they investigated the succination of three key 
cysteine residues in the TCA cycle enzyme, mitochondrial aconitase hydratase 
(ACO2). The consequences of ACO2 inhibition are described in detail in section 
1.11.3- Metabolic disruption as a result of FH deletion.   
 
Figure 1-8. Succination reaction. Fumarate is a natural electrophile and as a result 
spontaneously reacts by a Michael addition reaction with free sulfhydryl groups to 
generate a thioether linkage with cysteine residues of proteins. This results in the 
formation of S-(2-succino) cysteine (2SC), a process termed succination (Adapted 
from Alderson et al., 2006). 
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1.11.3 Metabolic disruption as a result of FH deletion 
The TCA cycle dysfunction caused by the loss of FH, poses significant challenges to 
cells in meeting their energetic demands, in the generation of macromolecular 
precursors and in their survival. Metabolic characterisation of Fh1-deficient cells 
using isotope labelling, has provided great insight about how these cells can function 
with a truncated TCA cycle. Because the TCA cycle is a major source for 
mitochondrial NADH, the truncation of the TCA cycle may have severe bioenergetic 
outcomes. Indeed, in Fh1- deficient cells, NADH levels were lower compared to 
control cells (Frezza et al., 2011). Furthermore, Fh1- deficient cells exhibit impaired 
respiration as indicated by a decrease in oxygen consumption (Frezza et al., 2011). 
However, despite the biochemical block of the TCA cycle, Fh1-deficient kidney cells 
and MEFs are still able to generate sufficient NADH for survival.  
The decrease in respiration in Fh1- deficient cells has been associated with 
upregulation of glycolysis as indicated by an increase in lactate production, as well 
as increased uptake of glucose (Sudarshan et al., 2009; O’Flaherty et al., 2010; Tong 
et al, 2011; Sourbier et al., 2014). Much effort has been put forward to better 
understand the glycolytic phenotype of Fh1-deficient cells, and how it confers a 
growth advantage to HLRCC tumours. Metabolic analysis of the human cell line 
UOK262 and HLRCC tumours has provided valuable information. Tong et al., 
showed that UOK262 and HLRCC tumours exhibit an increase in glycolysis and low 
AMPK levels, which in turn reduces p53 levels. Low AMPK activity in turn 
decreases the expression of the iron transporters, resulting in a lower iron uptake. 
Finally, the reduced cytosolic iron levels and fumarate accumulation are expected to 
inhibit PHD activity and therefore stabilize Hif-1a expression, leading to a glycolytic 
phenotype (Tong et al., 2011). As a result, the glycolytic shift coupled with low 
AMPK levels could offer a proliferative advantage in HLRCC cells. The same group 
furthered their findings regarding how glycolysis contributes to the aggressive 
phenotype of HLRCC tumours (Sourbier et al., 2014). The authors begun by 
performing an unbiased drug screen to identify drugs that would selectively kill 
HLRCC cells. Through their screen, they identified vandetanib, which was highly 
cytotoxic to UOK262 kidney cancer cells. When they looked into the mechanism by 
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which vandetanib killed UOK262 cells, they identified a reduction in the expression 
of the oncogene ABL1 known to promote glycolysis, by regulating the mTOR 
pathway. Furthermore, Fh1-deficient (and human UOK262 cells) exhibit increased 
levels of ABL1 expression, and have been previously shown to exhibit increased 
levels of mTOR concomitantly with increased glycolysis (Tong et al., 2011). The 
authors therefore concluded that vandetanib acts against FH-deficient cells by 
decreasing the glycolytic pathway (through the reduced expression of the mTOR 
regulator ABL1), necessary for survival. Finally, by using a xenograft UOK262 
mouse model, the authors showed that treatment with vandetanib reduced tumour 
burden in vivo, by decreasing the expression of ABL1-mediated glycolysis. Overall, 
this study showed that ABL1 is a key modulator in response to fumarate 
accumulation, partially providing a mechanistic explanation of FH-mediated 
tumorigenesis. 
Further insight into the metabolic reprogramming of Fh1-deficient cells has been 
provided by Frezza et al. Through isotope labelling, it has been suggested that Fh1- 
deficient renal cells exhibit increased glutaminolysis (Frezza et al., 2011). More 
importantly, through an in silico model, Frezza et al predicted that the haem- 
metabolism pathway is critical for the survival of Fh1-deficient cells (Frezza et al., 
2011). The model predicted genes for which elimination together with Fh1 would 
affect the growth ability of Fh1-deficient cells.  Haem biosynthesis is a cataplerotic 
pathway that uses TCA-derived carbon to generate haem, whereas the haem 
degradation pathway generates bilirubin that can be excreted from the cells. 
Therefore, haem biosynthesis and degradation generates a linear pathway starting 
with glutamine uptake and ending with bilirubin excretion, allowing some generation 
of mitochondrial NADH in order to support minimal mitochondrial respiration. 
Indeed, the activation of the haem pathway was validated in Fh1-deficient cells by 
identifying an increase of bilirubin excretion using mass-spectrometry (Frezza et al., 
2011). In support of these findings, knock-down of a key enzyme involved in the 
haem pathway, haem oxygenase-1 (Hmox-1), resulted in the death of Fh1-deficient 
cells (Frezza et al., 2011).  
Chapter 1 – Introduction 
Doctor of Philosophy           University of Edinburgh 2017 51 
Recently, as described in the previous section, Ternette et al identified that 
mitochondrial ACO2 function is abolished in Fh1-deficient murine MEFs and kidney 
cells (Ternette et al., 2013). Mitochondrial ACO2 functions as part of the TCA cycle, 
catalyzing the conversion of citrate to isocitrate. In their system, Ternette et al 
observed a decrease in the levels of citrate and isocitrate, supporting the observation 
that ACO2 function was decreased as a result of its cysteine residue succination. 
Furthermore, when the authors cultured the cells in deuterium-labelled glutamine, 
which labels hydrogens and thus allowed them to determine whether the oxidative 
(i.e. reversed) flux of the TCA cycle functions properly, they observed labelling 
incorporation in fumarate, malate and isocitrate but not in citrate. Some cancer cells 
display altered metabolism by utilizing glutamine-dependent reductive carboxylation 
to produce citrate, which can be used for fatty acid generation and for anaplerosis of 
the TCA cycle (Metallo et al., 2012, Mullen et al., 2012, Wise et al., 2011). This 
pathway utilizes IDH1/2 to reductively carboxylate α-KG to isocitrate and is 
considered to occur both in the mitochondria and the cytoplasm (Mullen et al., 2012).  
The results obtained by Ternette et al suggested that α-KG can be converted to 
isocitrate by reversal of the IDH-catalyzed reaction, but that isocitrate cannot be 
further metabolized to citrate, due to impaired activity of ACO2. As a result, Fh1- 
deficient MEFs may not be able to utilize reductive carboxylation. Finally, the 
absence of citrate labelling suggests that both mitochondrial and cytoplasmic 
isoforms of ACO2 are potentially inactive.  
Further insight has been provided regarding the metabolic changes that Fh1 deletion 
cause in kidney cells. A recent study found that Fh1-deficient kidney cells and 
tissues exhibit dysregulation in the urea cycle and arginine metabolism and 
accumulate high levels of argininosuccinate via the reversal of the activity of 
argininosuccinate lyase. (Adam et al., 2013; Zheng et al., 2013). Furthermore, Fh1-
deficient cells exhibit increased sensitivity to arginine deprivation, indicating that 
arginine is an important energy source for these cells (Adam et al., 2013). The 
overall metabolic alterations as a result of Fh1 deficiency, are outlined in Figure 1-9. 
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Figure 1-9. The metabolic changes occurring in Fh1- deficient cells. Enzymes are 
shown within boxes. The enzymes highlighted in red are inhibited in Fh1-deficient 
cells. The pathways which Fh1- deficient cells critically rely on or are upregulated 
are highlighted in green, whereas the pathways that are inhibited are highlighted in 
red. The red arrows next to metabolites indicate either increased levels (arrow 
pointing upwards), or decreased levels (arrow pointing downwards). Glycolysis, 
glutaminolysis and the haem pathway are upregulated in Fh1-deficient cells, whereas 
reductive carboxylation is inhibited as a result of aconitase 2 (ACO2) succination. 
Citrate and isocitrate levels are reduced as a result of decreased ACO2 function. 
Succinate and fumarate levels are increased, while malate levels are decreased as a 
result of the inactivation of fumarate hydratase (FH). Succinate dehydrogenase 
activity (SDH) is decreased possibly due to fumarate accumulation. The haem 
pathway is upregulated, generating enough NADH for minimal mitochondrial 
respiration. Arginino-succinate (and indirectly aspartate and citrulline) levels are 
increased due to reversal of the enzyme argininosuccinate lyase (ASL). Fh1- 
deficient cells are critically reliant on arginine.  
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1.11.4 Fumarate as an epigenetic modifier 
Recent studies have identified another potential mechanism of how FH (and Fh1) 
deletion and subsequent fumarate accumulation could contribute to tumorigenesis. 
Excess fumarate is known to inhibit a-KG-dependent enzymes, a large family of 
enzymes with diverse functions. Apart from PHDs, fumarate has been shown to 
inhibit epigenetic modifiers such as TET proteins (Xiao et al., 2012). TET proteins 
are DNA hydroxylases that play a central role in epigenetic control, as TET proteins 
(specifically TET1 and TET2) are responsible for the oxidation of 5mC to 5-
hydroxymethylcytosine (5hmC) (Tahiliani et al., 2009), whereas TET3 is mainly 
involved in the oxidation of 5mC to 5hmC in zygotic parental DNA after fertilization 
(Gu et al., 2011). The inhibition of TET proteins by the accumulation of fumarate has 
been supported by recent studies (Xiao et al., 2012; Hoekstra et al., 2015; Laukka et 
al., 2016;).  In human smooth-muscle tumours, inhibition of TET proteins, as a result 
of fumarate accumulation, lead to a decrease of overall 5hmC and in an increase of 
the repressive histone trimethylation H3K9me3 signatures, leading to epigenetic 
remodelling (Hoekstra et al., 2015). Similar observations were made using the 
human neuroblastoma cell line SK-N-BE cell line, and by knocking down FH in the 
human cell lines HEK293T and Hela cells, where global 5-hmC levels were reduced 
as a result of TET inhibition (Laukka et al., 2016). 
More recently, Sciacovelli et al., performed an unbiased proteomics analysis on Fh1- 
deficient kidney cells and the kidney cancer cell line UOK262 in order to identify 
oncogenic features associated with the loss of Fh1 (and FH) (Sciacovelli et al., 
2016). Gene expression profiling followed by gene enrichment analysis, confirmed 
an epithelial-to-mesenchymal transition (EMT) signature, where genes associated 
with EMT, such as vim (gene encoding for the EMT marker vimentin), snail family 
zinc finger 2 (Snai2), and the zinc-finger E-box binding homeobox proteins Zeb1 and 
Zeb2, were upregulated. The expression of these EMT-associated genes is 
suppressed by the antimetastatic micro RNA, mir-200 (De Craene and Berx, 2013), 
which was downregulated in Fh1-deficient cells and UOK262 cells. Interestingly, the 
authors found that the downregulation of mir-200 was a result of the Tet-mediated 
demethylation of its regulatory region, as a result of fumarate accumulation. Finally, 
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by re-expressing Fh1 in Fh1-deficient cells, mir-200 expression was rescued and the 
EMT phenotype was reversed, highlighting a novel means by which fumarate could 
contribute to the metastatic phenotype of HLRCC tumours (Sciacovelli et al., 2016).  
1.11.5 Fumarate hydratase in normal haematopoiesis 
Genetic evidence indicates that rare recessive mutations in the FH gene result in 
severe developmental abnormalities, including haematopoietic defects (Bourgeron et 
al., 1994; Tregoning et al., 2013). Consistent with a previous report (Bourgeron et 
al., 1994), monozygous twins with recessive FH mutations, display leukopenia and 
neutropenia, therefore suggesting a role for FH in the regulation of haematopoiesis 
(Tregoning et al., 2013). 
Previous work in our lab has demonstrated that Fh1 is critical for the haematopoietic 
system (Guitart, unpublished). Deletion of Fh1 specifically in the haematopoietic 
system using the Vav Cre deleter strain results in embryonic lethality. Fh1fl/fl; Vav-
iCre embryos at embryonic day 14.5 are pale, exhibit reduced foetal liver cellularity 
and are unable to generate colonies in vitro when plated in semi-solid media (Figure 
1-10 A, B, D). Furthermore, analysis of the haematopoietic system showed that Fh1-
null embryos exhibit significant reduction in the lineage positive compartment 
(indicating a reduction in the differentiated cells), and a significant expansion in LT-
HSC numbers (Figure 1-10 B, C). Furthermore, Fh1 loss results in the complete 
inability of foetal liver HSCs to reconstitute the haematopoietic system, in lethally 
irradiated recipient mice (Figure 1-10 E). Apart from foetal haematopoiesis, Fh1 is 
also essential for adult haematopoiesis. Lethally irradiated mice were injected with 
Fh1fl/fl; Mx1-Cre donor cells, and after efficient reconstitution was achieved, 
poly:I:poly:C administration  of the recipient mice resulted to a progressive decline 
of donor-derived cell chimerism, and a complete failure of Fh1-deficient cells to 
contribute to primitive and mature haematopoietic compartments of the recipients 
(Figure 1-10 F).  
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Finally, mass-spectrometry analysis showed that fumarate and argininosuccinate are 
significantly elevated in Fh1fl/fl; Vav-iCre stem and progenitor cells (Figure 1-11 A, 
B). 
 
Figure 1-10. Fh1 is essential in foetal and adult haematopoiesis. (A) FLs from 
14.5dpc Fh1fl/fl; Vav-iCre embryos are smaller and paler compared to Fh1+/fl;Vav-
iCre and control embryos (magnification: ×3 for upper panels, x6 for bottom panels). 
(B) Total cellularity (the sum of Lin+ and Lin−cell numbers) of nucleated cells in 
14.5dpc FLs from embryos of the indicated genotypes. (C) Total numbers of LT-
HSC (LSK CD48-CD150+) cells in FLs of day 14.5 old embryos (control n = 17, to 
Fh1+/fl; Vav-iCre n = 11 and Fh1fl/fl; Vav-iCre n = 9). (D) Colony forming cell (CFC)  
assay using 104 total FL cells. (control n = 11, Fh1+/fl; Vav-iCre n = 8 and Fh1fl/fl; 
Vav-iCre n = 4). (E) Percentage of CD45.2+ cells in PB after transplantation of 100 
FL HSCs (n = 5-8 recipients per genotype, at least 3 biological replicates were used 
per genotype). (F) Percentage of donor derived CD45.2+ cells in PB (n = 5-10 
recipient mice per biological replicate (n = 2)). Data are mean ± S.E.M., *p<0.05, 
**p<0.005, ***p<0.001, Mann-Whitney test.   
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Mechanistically, the phenotypes observed upon Fh1 deletion could result from the 
genetic block in the TCA cycle, or the accumulation of cellular fumarate. To 
differentiate between those two mechanisms, we generated mice that ubiquitously 
express the human cytosolic isoform of FH (FHCyt, which lacks the mitochondrial 
targeting sequence and therefore is excluded from the mitochondria). Expression of 
FHCyt rescued embryonic lethality and reduced the levels of fumarate and 
argininosuccinate (Figure 1-11 A, B). Furthermore, the resulting Fh1fl/fl; FHCyt; 
Vav-iCre mice exhibited normal bone marrow cellularity (Figure 1-11 C), normal 
numbers of myeloid cells (Figure 1-11 D), and depleted B cells (Figure 1-11 E). 
Finally, Fh1fl/fl; FHCyt; Vav-iCre mice exhibited an increase in the LSK and LT-
HSC compartments (Figure 1-11 F, G). 
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Figure 1-11.Cytosolic isoform of Fh1 rescues normal steady-state 
haematopoiesis in Fh1fl/fl;Vav-iCre mice. (A) Fumarate levels in FL c-Kit+ cells of 
indicated genotypes measured by liquid chromatography–mass spectrometry (LC-
MS). (control n = 6, Fh1fl/fl; Vav-iCre n = 4, control; FHCyt n = 6 and Fh1fl/fl; FHCyt; 
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Vav-iCre n = 13). (B) Argininosuccinate levels in FL c-Kit+ cells measured using 
LCMS. (control n = 6, Fh1fl/fl; Vav-iCre n = 4, control; FHCyt n = 6 and 
Fh1fl/fl;FHCyt; Vav-iCre n = 13). (C) Total number of BM nucleated cells obtained 
from two tibias and two femurs of 8-10 week old mice. (D) Total numbers of Mac-1+ 
Gr1+ myeloid cells. (E) Total CD19+ B220+ cells. (F) LSK cells (G) LT-HSC cells. 
Data are mean ± S.E.M. n = 3-4 per genotype. *p<0.05, **p<0.005, ***p<0.001, 
Mann-Whitney test.   
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The data generated from our lab in conjunction with previous reports (Bourgeron et 
al., 1994; Tregoning et al., 2013), strongly indicate that fumarate hydratase plays a 
critical role in regulating haematopoiesis, and could also play a role in leukaemic 
transformation. With that in mind, the aim of this project was to identify the roles of 
Fh1 in the generation and development of AML, as well as identify the role of the 
mitochondrial isoform of Fh1 in normal haematopoiesis. 
 
1.12 Defining the nomenclature utilised in this thesis 
Throughout this thesis, I will be referring to “genetically intact TCA cycle”, denoting 
that the TCA cycle has not been genetically manipulated and therefore it operates 
normally. Furthermore, the term “genetically truncated TCA” or “genetic truncation 
of the TCA cycle” is used to describe the fact that genetic deletion of mitochondrial 
Fh1 generates a genetic truncation in the TCA cycle. The reason I specifically refer 
to a “genetic” truncation on the TCA cycle, is because I haven’t performed any 
metabolite analyses in order to identify the biochemical consequences that 
mitochondrial Fh1 deletion has (for example a build-up or reduction in the levels of 
TCA metabolites that would have biochemical consequences). However, this has 
been previously conducted for non-transformed stem and progenitor cells (Guitart, 
unpublished) (see Figure 1-11). 
Finally, throughout my thesis, I have chosen to refer to “leukaemia-initiating cells 
(LICs)”, rather than “leukaemic stem cells (LSCs)”. The term LSC was originally 
coined to describe a very rare population of leukaemic cells, that shared a lot of 
similarities with HSCs, as described by seminal work conducted John Dick’s group 
(Lapidot et al., 1994). There are two prevailing models of leukaemogenesis. In the 
first “hierarchical” model, similarly to HSCs, LSCs are thought to reside at the top of 
the leukaemic hierarchy and produce more differentiated, heterogenic leukaemic 
blasts, that feature a high proliferative potential, a block in terminal differentiation 
and defective apoptosis, leading to the accumulation of blasts and clinical disease 
(Reya et al., 2001; Huntly and Gilliland 2005; Riether et al., 2015). The second 
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“stochastic” model proposes that every leukaemic cell has the ability to self-renew 
and recapitulate disease phenotype, given that it enters a permissive environment, an 
event which has very low probability (Huntly and Gilliland, 2005; Reya et al., 2001). 
Furthermore, it has been convincingly demonstrated that LSCs can arise from more 
differentiated progenitor cells such as CMPs and GMPs (Cozzio et al., 2003; Huntly 
et al., 2004; Somerville and Cleary; 2006; Kristov et al., 2006; 2013). There is a 
possibility that both models of leukaemogenesis occur, depending on the cell-of-
origin and the type of leukaemia (e.g. CML versus AML). I therefore believe that the 
term “LSC” might be a bit misleading as not all leukaemia-initiating cells possess the 
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2 Materials and methods 
2.1 Mouse strains 
 All mice were on the C57BL/6 genetic background. Vav1-iCre and Mx1-Cre mice 
were purchased from Jackson Laboratory. Vav1-iCre mice were originally developed 
by De Boer et al., 2003. According to Jackson Laboratory, Vav1-iCre is also known 
as Vav-iCre. As a result, for simplicity reasons throughout this thesis I will be 
referring to Vav1-iCre as Vav-iCre. Fh1fl/fl; Vav-iCre mice were generated by 
crossing Fh1fl/fl mice to Fh1+/+; Vav-iCre, and then breeding littermates that 
were Fh1+/fl; Vav-iCre. Fh1fl/fl; Mx1-Cre mice were generated in the same manner. 
Non-conditional Fh1fl/fl; FHCyt; Vav-iCre mice were generated by crossing FHCyt; 
Rosa26 mice that were generated by Adam et al., 2013, with Fh1+/+; Vav-iCre mice. 
All transgenic and knockout mice were CD45.2+. Congenic recipient mice were 
female CD45.1+/CD45.2+. All experiments on animals were performed under UK 
Home Office authorization. Irradiation protocol: Recipient mice received one dose of 
irradiation (7 gy) using a 33% attenuator. 
 
2.2 DNA extraction 
Genomic DNA from animal tissue (mouse ear notch, BM, blood) or cultured cells 
was extracted using ISOLATE II Genomic DNA Kit (BIO-52067, Bioline), 
according to the manufacturer’s instructions. A pre-lysing step was used for animal 
tissue samples where lysis buffer and proteinase K was added and the sample 
incubated at 56 oC overnight (ON). Lysis buffer and an incubation step of 10 - 15  
minutes at 70 oC were used to lyse cultured cells. After the lysis, ethanol (96 - 100 
%) was added and the samples were vortexed. DNA was bound to the silica 
membrane of the spin column (centrifuged for 1 minute at 11,000 x g) and washed 
twice (GW1, GW2 buffers). The silica membrane was dried by centrifugation (1 
minute at 11, 000 x g) and DNA was eluted using preheated (70 oC) PCR water 
(DNAse/RNAse free) (1 minute at 11,000 x g). Concentration of eluted DNA was 
measured by nanodrop spectrometer (Nanodrop ND1000 Spectrophotometer; Lab 
tech International Ltd, East Sussex, UK) by recording absorbance at wavelength 260 
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nm. The DNA purity was assessed through the ratio of absorbance at 260 nm and 
280 nm. DNA with A260/A280 ratio of 1.7 - 1.9 was considered as pure. 
2.3 Maxiprep of plasmids 
Maxiprep of all plasmids was conducted using the HiSpeed plasmid kit (Qiagen), 
according to the manufacturer instructions. Briefly, a starter culture was left 
overnight at 37 oC in 500 ml of LB media. The bacteria were harvested by 
centrifugation at 6,000 x g for 15 minutes at 4 oC. Bacterial pellet was then re-
suspended in 10 ml of buffer P1 (lysis step), followed by addition of buffer P2 and 
incubated at room temperature for 5 minutes. 10 ml of pre-chilled P3 buffer were 
added and then lysate was transferred into the QIAfilter Cartridge and incubated at 
room temperature for 10 minutes. The lysate was then poured into the HiSpeed Maxi 
tip and entered the resin by gravity flow. The Maxi tip was then washed with 60 ml 
of buffer QC and DNA was eluted with 15 ml of buffer QF. DNA was precipitated 
by adding 10.5 ml isopropanol. DNA was isolated by running the precipitated DNA 
through a QIAprecipitator Maxi module in a final volume of 0.5 ml. Concentration of 
eluted DNA was measured by nanodrop spectrometer (Nanodrop ND1000 
Spectrophotometer; Labtech International Ltd, East Sussex, UK) by recording 
absorbance at wavelength 260 nm. The DNA purity was assessed through the ratio of 
absorbance at 260 nm and 280 nm. DNA with A260/A280 ratio of 1.7 - 1.9 was 
considered as pure. 
2.4 Genotyping and PCR primers  
The PCR for Vav-iCre, Mx-Cre, and Fh1 was prepared using MangoMix™ (BIO - 
25033), a 2x Reaction Mix containing MangoTaq™ DNA Polymerase, MgCl2 and 
ultra-pure dNTPs. Water and primers were added to the MangoMix™. For FHCyt the 
Hot Start kit from Qiagen was used (Qiagen-203443) according to the 
manufacturer’s protocol.  All primers were at a concentration of 100 µM. The PCR 
programs were as follows: 5 minutes at 95 oC (double strand DNA denaturation); 30 
- 39 cycles of 95 oC for 30 seconds - 1 minute, 57 - 67 oC for 40 seconds - 60 
seconds (primer annealing, temperature dependant on the primers) and 72 oC for 30 
seconds - 60 seconds (initial extension); 72 oC for 5 minutes (final extension) and 
tubes were held at 10 oC.  The sequence of the primers, the exact PCR program and 
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the expected band size of each PCR reaction is demonstrated below (Table 3). The 
reactions were carried in the PCR cycler Biometra. 
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Table 3- PCR programs and primer sets. 
	
Vav-iCre MxCre FHCyt Fh1 
95ºC 5 min 
94ºC 40 sec 
64C 40 sec 
72ºC 30 sec 
x30 
 72ºC 5 min 
10ºC continuous 
	
95ºC 5 min 
95ºC 30 sec 
67ºC 45 sec 
72ºC 1 min 
x39 
 72ºC 5 min 
10ºC continuous 
	
95ºC 15 min 
95ºC 1 min 
60ºC 1 min 
72ºC 1 min 
x35 
 72ºC 5 min 
10ºC continuous 
	
95ºC 5 min 
95ºC 30 sec 
57ºC 45 sec 
72ºC 45 sec 
x35 




























   Reverse 2 
5’-CCTGGCACTGCA 
GACTACAA-3’ 
Expected product size 
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2.5 RNA extraction 
RNA was extracted and purified using RNeasy micro Kit (Qiagen - 74004) according 
to the manufacturer’s instructions. Briefly cells were harvested and 350 µl RLT 
buffer (Qiagen) was added to cell pellets, followed by 350 µl 70 % ethanol. The 
mixture was spun down in RNeasy MinElute spin columns (Qiagen) for 15 seconds 
at 8,000 x g 350 µl RWI buffer (Qiagen) was added and spun down for 15 seconds at 
8,000 x g 80 µl of DNase I incubation mix (Qiagen) was added and left at room 
temperature for 15 minutes. 350 µl RWI buffer (Qiagen) was added and spun down 
for 15 seconds at 8,000 x g. 500 µl RPE buffer (Qiagen) was added and spun down 
for 15 seconds at 8,000 x g. Subsequently, 500 µl 80 % ethanol was added and spun 
down for 2 minutes at 8,000 x g to wash the spin column membrane. The spin 
column was centrifuged at full speed for 5 minutes to dry the membrane. Finally, 15 
µl RNAse free water was added and spun down for 1 minute at 8,000 x g to elute 
RNA. RNA concentration was measure by NanoDrop 1000 Spectrophotometer. 
2.6 RT-PCR 
RT-PCR was performed in order to transcribe the RNA into cDNA using reverse 
transcriptase. The High-Capacity cDNA Reverse Transcription Kit was used for all 
RT-PCR reactions (Applied BiosystemsTM - 4368813). The mix consisted of 2.0 µL 
10X RT buffer, 0.8 µL dNTP mix (100 mM), 2.0 µL 10X RT random primers, 1.0 
µL reverse transcriptase, 0.5 µL RNase inhibitor, and 3.7µL distilled water (DNase 
and RNase free; gibco®, ThermoFisher Scientific - 10977-035). The samples were 
processed using TProfessional Basic Thermocycler, using the cDNA synthesis 
program that ran at 25 oC for 10 minutes, 37 oC for 120 minutes and 85 oC for 5 
minutes. 
2.7 qPCR 
Equal concentrations of RNA were reverse transcribed as indicated in 2.4.  mRNA 
levels were quantified for Meis1 and Hoxa9 of pre-LCs after the third serial re-
plating. β-actin was used as a housekeeping gene (Table 4). Technical triplicates of 
each sample were analysed and reactions were performed in a 5 µL volume.  Each 
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well was filled with 2.5 µL TaqMan® Universal PCR Master Mix (Applied 
BiosystemsTM, ThermoFisher Scientific, Cat. 4304437), 0.25 µL of the TaqMan ® 
probe/primer set for each gene (see Table 4 below), 1.25 µL distilled water, and 1 µL 
of the cDNA sample. The samples were analysed using LightCycler® 480 (Roche), 
using the following program: 50 °C for 2 minutes, 95 °C for 10 minutes, followed by 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Finally, 60 °C for 5 
minutes and 40 °C for 5 minutes. All signals were quantified using the ΔΔCt method 
using β -actin as the housekeeping gene.   
Table 4- TaqMan probes for Meis1/Hoxa9 expression. 
 
2.8  Preparation of bone marrow, spleen and thymus 
cell suspensions  
Tibias and femurs of both hind legs were taken from adult mice. These were crushed 
using a pestle and mortar until a homogeneous cell suspension was achieved. Cells 
were collected in PBS (2 % FBS) and filtered through a 70 µm nylon strainer (BD 
Falcon, 352340). Spleen and thymus were retrieved and disaggregated in PBS (2 % 
FBS). All cell counts were performed by an automatic cell counter (MEK 6500K, 
Nihon Kohden) and used in subsequent assays. 
2.9 Imunophenotypic characterisation of blood cells 
SLAM staining: 10x106 BM cells were incubated in CD16/CD32 (Fc Block) 
antibody in 50 µl of cold phosphate-buffered saline supplemented with 2 % heat-
inactivated foetal bovine serum (PBS (2 %FBS)) for 5 min on ice. 50 µL of 2X 
antibody mix containing a biotin conjugated lineage cocktail (CD3, CD5, CD4, 
CD8a, Gr-1, CD19, B220, Ter119) and Sca-1, c-Kit, CD48 and CD150 was added 
(Table 5). After 20 minutes of incubation at 4 oC (protected from light), cells were 
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washed in cold PBS (2 % FBS) and spun down at 500 x g for 5 minutes. The pellet 
was then re-suspended in 100 µL of Streptavidin - PerCP. After 15 minutes, the cells 
were washed and re-suspended in cold PBS (2 % FBS).  
Progenitor staining: 6x106 BM cells were incubated in 100 µL of an antibody mix 
containing a biotin conjugated lineage cocktail (CD3, CD5, CD4, CD8a, Gr-1, 
CD19, B220, Ter119 (Ter119 is absent in myeloid-erythroid progenitor staining)) 
and Sca-1, c-Kit, CD127, CD16/32, CD34, Flt3 (committed progenitors). After 20 
minutes of incubation at 4 oC (protected from light), cells were washed in cold PBS 
(2 % FBS) and spun down at 500 x g for 5 minutes. The pellet was then re-suspended 
in 100 µL of Streptavidin - Pacific Blue. After 15 minutes, cells were washed and re-
suspended in cold PBS (2 % FBS).  
Lineage staining: 2x105 of BM, spleen or thymus cells were incubated with antibody 
mix: myeloid (CD11b, Gr-1); B-lymphoid (CD19, B220), T-lymphoid (CD4, CD8) 
and incubated for 20 minutes at 4 oC (protected from light) (Table 5). Cells were then 
washed in cold PBS (2 % FBS) and spun down at 500 x g for 5 minutes. 
For all experiments, cells were acquired on FACSFortessaV (BD). Data were 
acquired through BD FACSDiva (BD Biosciences) and analysed by Flowjo software 
(Tree Star Inc., USA). The gating strategy for subsequent cell sorting and analysis 
was performed based on single stainings, as no isotype controls were used. 
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Table 5- List of antibodies used for flow cytometry. 
























biotin 553649 H129.19 BD Biosciences 
CD5 biotin 553019 53-7.3 BD Biosciences 
CD8a biotin 553029 53-6.7 BD Biosciences 
CD11b biotin 553309 M1/70 BD Biosciences 
45R/B220 biotin 553086 RA3-6B2 BD Biosciences 
Ter119 biotin 553672 TER-119 BD Biosciences 




















CD117/c-Kit APC 105812 2B8 Biolegend 
CD117/c-Kit BV510 135119 ACK2 Biolegend 
Sca-1/Ly-
6A/E 
APC-Cy7 122513 E13-161.7 Biolegend 
Sca-1/Ly-
6A/E 
PE-Cy7 122514 E13-161.7 Biolegend 
CD48     APC 103411 Hm48-1 Biolegend 
CD150  PE-Cy7 115914 TC15-
12F12.2 
Biolegend 
CD16/32 APC-Cy7 101328 93 Biolegend 
CD127 BV605 112324 A7R34 Biolegend 
CD135/Flt3 PE 135306 A2F10 Biolegend 
CD34 FITC 553733 RAM34 BD Biosciences 
B cells CD19 APC-Cy7 115530 6D5 Biolegend 
CD45R / 
B220 
PE 103236 RA3-6B2 Biolegend 
Myeloid 
cells 
CD11b Pacific Blue 101224 M1/70 Biolegend 
CD11b APC 101212 M1/70 Biolegend 
Gr-1/Ly-6G/C PE-Cy7 108416 RB6-8C5 Biolegend 
T cells CD4 PE 130310 H129.19 Biolegend 
CD8a PE 100708 53-6.7 Biolegend 
CD8a APC 100712 53-6.7 Biolegend 
 CD45.1 FITC 110706 A20 Biolegend 
 CD45.2 Pacific Blue 109820 104 Biolegend 
 Strepavidin Pacific Blue 405225 - Biolegend 
 Strepavidin PerCP 405213 - Biolegend 
 CD16/32 
FC block 
none 553142 2.4G2 BD Pharmagen 
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2.10 Meis1/Hoxa9 driven AML: transplantation assays 
Pre-LCs from CFC3 were harvested and counted. 100,000 c-Kit+ pre-LCs (CD45.2+) 
were injected into sub-lethally irradiated CD45.1+/CD45.2+ syngeneic recipient mice 
(7 Gy). The mice were monitored for AML development by blood sampling (via tail 
vein) every 2-4 weeks after transplantation. For secondary transplantation assays 
10,000 LICs (CD45.2+c-Kit+ cells) were sorted from primary recipients and 
transplanted into secondary CD45.1+/CD45.2+ sub-lethally irradiated (7 Gy) recipient 
mice. 
2.10.1.1 Monitoring AML development  
AML development was assessed by tracking the chimerism of CD45.2+ cells in the 
peripheral blood (Figure 2-1). Mice were bled every 2-4 weeks and white blood cells 
were stained for flow cytometry: CD45.2 (LICs), CD45.1/CD45.2 (remaining 
haematopoiesis), CD11b and Gr-1 (myeloid cells). Sick mice were harvested when 
showing signs of disease: high percentage of LICs in the blood, hunched posture, 









Figure 2-1. Syngeneic model that allows 
tracking of LIC cells in mice. 
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2.11 Blood sampling 
To assess multilineage haematopoiesis reconstitution, peripheral blood samples were 
taken from the tail vein every 4 weeks. Blood was collected using capillary blood 
collection tubes coated with EDTA (Microvette® CB 300 K2E - 16.444, Sarstedt). 
2.12 Inducible Mx1-Cre-mediated gene deletion 
After the transplanted mice reached 20-30 % of LIC chimerism in the peripheral 
blood, the mice were administered with 6 - 8 doses of polyinosinic-polycytidylic acid 
(poly (I:C); GE Healthcare; 0.3 mg per dose) every other day. Mice injected with 
PBS were used as controls. 
2.13 Isolation of haematopoietic stem and progenitor 
cells from foetal liver of E 14.5 dpc embryos 
Embryos were aseptically removed and placed in PBS (2 % FBS). The foetal liver 
was extracted and placed in a 70 µm strainer in a 35 mm petri dish (Sterilin - 121V). 
Cells were extracted in 10 mL of PBS (2 % FBS) by gently pushing them through the 
strainer using a plunger. Red blood cells were lysed by a 1 minute incubation with 
NH4Cl (Stem Cell Technologies - 07850). The reaction was stopped by adding PBS 
(2 %FCS). Cells were re-suspended in 100 µl PBS (2 % FBS) per 100x106 cells and 
incubated with immunomagnetic microbeads, conjugated to monoclonal anti-mouse 
CD117 (c-Kit) antibodies (isotype: rat IgG2b) (Mylteni Biotec - 130-091-224) for 15 
minutes at 4 °C. Cells were applied to a MACS LS column (Mylteni Biotec - 130-
042-401) placed on a QuadroMACS (Miltenyi Biotec) separator, and washed four 
times with PBS (2 % FBS). PBS (2 % FBS) was added and the column was removed 
from the magnet, and the c-kit enriched fraction was flushed out.  
2.13.1 Isolation of LSK cells via flow cytometry 
In order to isolate LSK cells, HSPCs were incubated in Fc block and then stained 
with antibodies listed on Table 5. Briefly, following Fc block, HSPCs were stained 
with the biotinylated lineage markers anti-CD4, anti-CD5, anti-CD8a, anti-B220, 
anti-Gr1 and anti-Ter119 antibodies (but excluding CD11b as it marks embryonic 
HSCs) together with APC-conjugated anti-c-Kit, APC/Cy7-conjugated anti-Sca-1, 
PE-conjugated anti-CD48 and PE-Cy7-conjugated anti-CD150 antibodies. Biotin-
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conjugated antibodies were then stained with Pacific Blue-conjugated streptavidin. 
Cell sorting was performed on a FACSAria Fusion (BD). 10,000 LSK cells were 
isolated from every foetal liver (Figure 2-2) and were retrovirally transduced using 







2.13.2 Cell lines and primary murine cells 
For virus production, two packaging cell lines were used, one for retroviral 
production (platinum E) and one for lentiviral production (HEK 293T). An overall 
schematic of lentiviral production is shown in (Figure 2-3).  
For retroviral production, no packaging plasmid was added, as Platinum E cells 
already stably express packaging proteins.  
Platinum E - cell line generated based on 293T cell line that ensures high and stable 
expression of gag, pol, env (packaging viral structural proteins) through 
EF1α promoter. This cell line was used as retrovirus packaging cell line, and allows 
for retroviral packaging with a single plasmid transfection. 
HEK 293 T- highly transfectable cell line from human embryonic kidney 293 cells 
that contains the SV40 T-antigen. 
Figure 2-2. Representative FACS plots showing gating strategy for 
LSK isolation in foetal livers from 14.5 dpc embryos. 
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NIH3T3 – mouse embryo fibroblast cells, were used for retroviral titration. All cell 
lines used were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10 % FBS, 2.0 mM L-glutamine and 1 % penicillin/streptomycin 
(100 units/mL).  
2.13.3 Retroviral constructs 
Retrovirus production was conducted using Platinum E cells expressing the structural 
proteins of the virus gag, pol, env (Figure 2-4). 
2.13.4 Transfer vectors and components 
MSCV-Meis1-puro. cDNA encoding murine Meis1 was cloned into the MSCV 
(murine stem cell virus) vector, MSCVPGK. PGK (phosphoglycerate kinase internal 
promoter) controls the expression of the puromycin resistance cassette and the long 
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MSCV-HoxA9-neo. cDNA encoding murine HoxA9 fragment was inserted at 
BamHI-XhoI site of a pMSCVneoEB (neomycin (G418) resistance) (Kroon et al., 
1998). The LTR region controls the expression of HoxA9 gene and PGK promoter 
drives the expression of the neomycin resistance cassette.  
MSCV-MLL-ENL-neo. cDNA encoding for human MLL-ENL fusion transcript was 
inserted into a MSCV vector (ECORI site) under the transcriptional control of LTR. 
The MSCV/MLL–ENL encodes a neomycin resistance gene (Lavau et al., 1997). 
MSCV-AML-ETO9a-neo cDNA encoding for human AML/ETO9a was cloned into 
MSCV-PGK-Neo vector (Xho and ECOR1 sites) (Zuber et al., 2009).  
MSCV-MLL-AF9-neo. A retroviral construct encoding MLL-AF9 was generated by 
fusion of the carboxy-terminal 91 amino acids of human AF9 (accession number 
BC036089) in-frame with the amino-terminal 1395 amino acids of human MLL in 
the retroviral vector MSCV-PGK-Neo (DiMartino et al., 2002).  
PGK – the phosphoglycerate kinase (PGK) promoter drives the expression of 
antibiotic resistance genes thus enabling selection of infected cells on the basis of 
antibiotic resistance. 
MSCV –the Murine Stem Cell Virus (MSCV) retroviral vector is optimized for 
introducing and expressing target genes in pluripotent cells, including murine 
haematopoietic cells.  
LTR – the retroviral long terminal repeat (LTR) contains promoters that drive gene 
expression in many infected cell types, including multiple haematopoietic lineages. 
Subcomponents of LTR: U3-R-U5- element. U3 and U5 are found at the end of the 
viral genomic RNA and contain sequences necessary for activation of viral genomic 
RNA transcription. 
2.13.5 Packaging vectors and components 
VSV-G- Vesicular stomatitis virus G glycoprotein is the envelope vector that 
determines the tropism of the virus (broad tropism envelope protein). 
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Gag- precursor structural protein of the retroviral/lentiviral particle containing 
matrix, capsid and nucleocapsid components. 
Pol- precursor protein containing reverse transcriptase and integrase components. 
Lentiviral constructs 
 
Figure 2-4. Components for retrovirus generation. The envelope plasmid (in this 
case VSV-G) determines the tropism of the virus. The transfer plasmid contains the 
gene of interest located in between LTR sites that will allow integration into the host 
genome, and the promoter that will allow for expression of the protein of interest. 
Taken from https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/. 
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2.13.6 Packaging vectors and components 
Lentivirus production was made using HEK 293T cells and the following constructs: 
PsPax2- expresses the HIV gag, pol, rev and tat genes that are necessary for the 
packaging of the lentivirus (Figure 2-5).  
VSV-G- Vesicular stomatitis virus G glycoprotein is the envelope vector that 
determines the tropism of the virus (broad tropism envelope protein). 
Gag- Gag is a precursor structural protein of the retroviral/lentiviral particle 
containing matrix, capsid and nucleocapsid components. 
Pol- Pol is a precursor protein containing reverse transcriptase and integrase 
components. 
Tat- Tat facilitates the activation of transcription from the LTR promoter. 
Rev- Rev binds to the Rev response element in order to facilitate nuclear export. 
2.13.7 Transfer vectors and components 
pRRL vectors contain CMV-HIFV5’ LTRs and vector backbones in which the SV40 
polyadenylation and enhancerless origin of replication sequences have been included 
downstream of the HIV 3’LTR, replacing most of the human sequence remaining 
from the HIV integration site.  These vectors are very efficient as transfer vectors 
(Dull et al., 1998). 
p-RRL-iVenus- empty transfer vector with fluorescent selection marker iVenus. This 
vector was a kind gift from Sten Eirik Jacobsen. 
p-RRL-Cre-iVenus- p-RRL-iVenus vector in which Cre is expressed under the CMV 
promoter. This vector was a kind gift from Sten Eirik Jacobsen. 
LTR- long terminal repeats flank the insert of interest and facilitate host genome 
integration. The 5’ LTR acts as an RNA pol II promoter. The 3’ LTR terminates 
transcription that started by 5’ LTR by the addition of a poly A tract.  
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RRE- Rev responsive element; sequence to which Rev binds. 
IRES- The internal ribosome entry site; Bicistronic vectors constitutively express the 
protein of interest (Cre) and a reporter protein (iVenus). Expression is driven by the 
constitutively active bidirectional human cytomegalovirus promoter. 
CMV- bidirectional human cytomegalovirus promoter. 
Subcomponents of LTR: U3-R-U5- element. U3 and U5 are found at the end of the 
viral genomic RNA and contain sequences necessary for activation of viral genomic 
RNA transcription. 
Figure 2-5. Components for lentivirus generation. The envelope plasmid 
determines the tropism of the virus. The transfer plasmid contains the gene of interest 
located in between LTR sites that will allow integration into the host genome, and 
the promoter that will allow for expression of the protein of interest. The packaging 
plasmid contains the necessary viral genes (gag, pol, tat, rev). Adapted from 
https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/. 
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2.13.8 Preparing and testing virus 
Plat-E or HEK 293T cells were transfected by Calcium Phosphate method, a method 
that involves the formation of calcium phosphate-DNA precipitates that facilitate the 
binding of condensed DNA to the cell surface, allowing the DNA to enter the cell by 
endocytosis (Kingston et al., 2003). The supernatant (containing viral particles) was 
collected at 24 and 48 hours after transfection, filtered through a 0.45 mm non-
protein binding filter and snap frozen in dry ice and stored at -80 oC. In order to test 
virus efficiency, NIH3T3 cells were plated in 6 well plates (1.8×105 cells per well) 
and incubated with the virus for 12 hours. The efficacy of infection was assessed by 
comparing the number of live cells of infected and non-infected cells after antibiotic 
selection or based on the fluorescence signal determined by flow cytometry (in the 
case of pRRL-iVenus).  
2.13.9 Retroviral/Lentiviral transduction of murine 
HSPC/LSK cells 
c-Kit+ cells were incubated overnight in Iscove’s Modified Dulbecco’s Medium 
(IMDM) with 10 % FCS, 40 ng/mL of mouse recombinant stem cell factor (SCF) 
(carrier-free) (Biolegend, Cat. 579702), 20 ng/mL of recombinant mouse IL-3 
(carrier-free) (Biolegend, Cat. 575502) and IL-6 (Biolegend, Cat. 575702) to 
promote cell cycle entry and proliferation of cells (in the case cells were infected 
with retrovirus).  
LSK cells were isolated via FACS and maintained in Iscove’s Modified Dulbecco’s 
Medium (IMDM) with 10 % FCS, 100 ng/mL of mouse recombinant stem cell factor 
(SCF) (carrier-free) (Biolegend - 579702), 100 ng/mL of recombinant mouse TPO 
(carrier-free) (Biolegend - 593306) and Flt3 ligand (Biolegend - 550704). The cells 
were transduced using the RetroNectin® (Takara, Cat. T100A/B) method.  
RetroNectin® is a recombinant human fibronectin fragment used to efficiently 
enhance retroviral mediated gene transduction through co-localization of target cells 
and virions (Figure 2-6). 48 well plates (non-tissue culture treated) were coated with 
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RetroNectin® and left overnight at 4 oC. The next day, RetroNectin® was removed 
from each well and 1 mL of retroviral supernatant was added on the coated wells. 
The plate was spun for 2 hours, 2,000 x g at 32 oC in order for the viral particles to 
bind on the plate (this method is ideal for low titre retroviruses). After centrifugation, 
the viral supernatant was removed and 200,000 c-Kit+ or 10,000 LSK cells were 
seeded on the virus-coated plates (in IMDM with 10 % FCS, and 100 ng/mL SCF, 
TPO and Flt3 ligand) and left overnight at 37 oC, 5% CO2. The next morning, a 
second plate was similarly prepared and cells were washed off the first plate and 
transferred on the second plate. The cells were left overnight at 37 oC, 5 % CO2. 48 
hours after the initiation of the infection, the cells were transferred on a plate 
containing no retronectin or virus, and were left for 24 hours to recover and also start 
expressing the antibiotic resistance genes. The next morning, the cells were seeded in 
media containing the appropriate antibiotic as well as the cytokine cocktail described 
earlier. Cells infected with both Meis1 and Hoxa9 were selected both for puromycin 
and neomycin (puromycin: 1.5 µg/mL; neomycin:1mg/mL). Cells infected with 
MLL-ENL, MLL-AF9 and AML-ETO9A were selected for neomycin resistance. 
Antibiotic selection process lasted for 3 days. Finally, cells infected with the pRRL 
vectors were selected based on iVenus expression (GFP) via flow cytometry.  
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Cell binding  




Virus receptor VLA5 – integrin 
receptor 
Lenti or retro virus 
RETRO- 
NECTIN 
Heparin H-binding  
domain 
CS-1 site; binds to 
VLA4 integrin receptor  
Figure 2-6. Retronectin reagent. Retronectin is a human fibronectin fragment that 
contains three functional domains: the cell binding domain (C-domain), the heparin 
binding domain (H-domain) and the CS-1 sequence. The viral particles bind 
retronectin via the H-domain, and the target cells bind through the interaction of the 
surface integrin receptors VLA-5 and VLA-4 with the C-domain and CS-1 sites 




Chapter 2 – Materials and Methods 
Doctor of Philosophy           University of Edinburgh 2017 81 
 
 
2.13.10 Generation of pre-leukaemic cells: colony forming 
assay 
Meis1/Hoxa9 transduced HSPCs were counted by trypan blue viability staining. Live 
cells were plated in MethoCult M3231 (Stem cell technologies, Cat. 03231) 
supplemented with 20mL IMDM; 20 ng/mL of SCF; 10 ng/mL of IL-3; 10 ng/mL of 
IL-6 and 10 ng/mL of GM-CSF (granulocyte-macrophage colony stimulating factor; 
Biolegend - 576302), 100 Units/mL penicillin and 100 mg/mL streptomycin. 
Meis1/Hoxa9 transduced HSPCs seeding concentration: 2,500 cells/mL; MLL-ENL, 
MLL-AF9-, AML-ETO9a-, pRRL-Cre-iVenus- (and control) transduced HSPCs 
seeding concentration: 25,000 cells/mL. Selection antibiotics were added according 
to the resistance of the retrovirus/retroviruses in use (puromycin (1.5 µg/mL) and/or 
neomycin (1mg/mL)). Empty wells were filled with PBS in order to avoid 
evaporation of the semi-solid medium. After 6 days in culture (CFC1), colonies were 
counted and re-plated at the same concentration and using the same culture 
conditions (CFC2, CFC3).  
2.13.10.1 Colony size assessment 
500 cells/well were seeded on a 96 well plate (5 technical replicates). After 3,4 and 5 
days after seeding the size of the colonies was measured using the Operetta high-
content automated microscope analyses (Operetta® High Content Imaging). For each 
well, six fields of view were acquired at each of the five focal planes separated by 
150 µm, ensuring no double counting of colonies. Colony size was calculated in an 
unbiased way by the Operetta microscope software at day 3,4 and 5 after plating 
using the Harmony texture-based image analysis software. All data from the Operetta 
high content automated microscope are represented as mean ± SEM. 
2.13.11 Cell cycle analyses  
For cell cycle analyses, cells were incubated with DAPI (containing 0.1 % Triton) (5 
µg/mL; Sony Biotecnhology Inc.) solution for 1 - 2 minutes at room temperature and 
acquired on FACSFortessaV (BD). Figure 2-7 shows a cell cycle profile obtained 
from CFC3 Meis1/Hoxa9 transformed cells. G1 phase reflects cell growth; S phase, 
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cell prepares for division by increasing the number of copies of its chromosomes; 
this is followed by G2/M phase where the duplicated chromosomes are checked and 
the cell divides. Cells that are not dividing leave the cell cycle and stay in G0. Gating 
was performed using the built-in Watson algorithm (Watson et al., 1987) , available 
on the FlowJo software.   
 
Figure 2-7. Gating strategy for cell cycle. Cells were gated based on 
the side and forward scatter (A) and gating was then refined in order to 
exclude doublets (B). Cell cycle analysis was performed by applying 
Watson’s algorithm on the DAPI channel histogram. 
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2.13.12 Apoptosis assay 
Cells were washed in ice-cold PBS, re-suspended in 100 µL of Annexin binding 
buffer 1X (BD, Cat.556454) containing 5 µL of Annexin V (BD, conjugated with 
FITC, Cat. 556420) and incubated for 20 minutes at room temperature. Before 
sample acquisition on FACSFortessaV (BD) DAPI was added (final concentration 10 
µg/mL) and incubated for 1 minute at room temperature. The dot plots below, 
indicate the gating strategy used as well as individually stained cells with AnnexinV-
FITC or DAPI (or unstained) (Figure 2-8). DAPI-/ AnnV-FITC- are live cells, DAPI-
/ AnnV-FITC+ are early apoptotic cells and DAPI+/ AnnV-FITC+ are late apoptotic 
cells. It is important to note that accurately measuring apoptosis using in vitro assays 
is difficult as cell debris can influence the percentage of apoptotic cells. 
Figure 2-8. Annexin V apoptosis assay. (A) Gating strategy for annexin V 
apoptosis assay. (B) unstained control, (C) cells only stained with annexinV-
FITC and (D) cells only stained with DAPI.  
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2.14 Proliferation assay 
The proliferation assays were performed with cells at a concentration of 150,000 
cells/ml. The cells were seeded on a 96 well plate in triplicate, in Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 10 % FCS, 40 ng/mL of mouse recombinant stem 
cell factor (SCF) (carrier-free) (Biolegend - 579702), 20 ng/mL of recombinant 
mouse IL-3 (carrier-free) (Biolegend - 575502) and IL-6 (Biolegend - 575702). 
Counting of cells was performed with trypan blue exclusion or via acquisition using 
BD Accuri flow cytometer. 
2.15 Seahorse assay 
Oxygen consumption rate (OCR) measurements were made using a Seahorse XF-24 
analyser (Seahorse Bioscience) and the XF Cell Mito Stress Test Kit. Briefly, LICs 
isolated from the bone marrow of sick recipient mice were plated in XF-24 
microplates pre-coated with cell-tak (BD) at 250,000 cells per well in XF Base 
Medium supplemented with 2 mM pyruvate and 10 mM glucose (pH 7.4). OCR was 
measured 2 times every 6 minutes for basal value and after each sequential addition 
of oligomycin (1µM), FCCP (4 µM) and finally concomitant rotenone and antimycin 
A(1µM). Oxygen consumption measurements were normalised to cell counts 
performed before and after each assay. Extracellular acidification rate (ECAR) was 
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3 The role of mitochondrial Fh1 and the TCA in 
aged haematopoiesis 
3.1 Introduction 
The defining characteristics of HSCs are their capacity to self-renew and provide 
life-long replenishment of the haematopoietic system. Recent studies have indicated 
that specific metabolic properties govern the fates of HSCs, such as self-renewal and 
differentiation (For detailed description, see section 1.8). Self-renewing HSCs 
suppress the flow of glycolytic metabolites into the TCA cycle and are known to rely 
on glycolysis in order to remain in a quiescent state (Takubo et al., 2013; Suda et al., 
2011; Wang et al., 2014). Furthermore, HSCs switch from glycolysis to oxidative 
phosphorylation during the differentiation process (Yu et al., 2013). Thus, it is of 
interest to clearly identify metabolic regulators of such HSC fates. 
3.1.1 Fumarate hydratase  
Fumarate hydratase (FH) is an essential part of the TCA cycle within the 
mitochondria where it catalyses the hydration of fumarate into malate. Although FH 
is considered a TCA cycle enzyme, it is also expressed in the cytoplasm and the 
nucleus (Yogef et al., 2012). Autosomal dominant mutations in FH have been 
associated with hereditary leiomyomatosis and renal cell cancer (HLRCC), 
indicating that FH functions as a tumour suppressor (Tomlinson et al., 2002).  
In order to study the role of the mitochondrial and cytoplasmic isoforms of FH in 
haematopoiesis, we generated a mouse model that lacks mitochondrial Fh1 but 
expresses the cytosolic isoform of human FH (for details, please see section 3.3). 
Consequently, haematopoietic cells are able to efficiently metabolise fumarate, while 
exhibiting a genetic truncation of the TCA cycle in their mitochondria (Figure 3-3).  
From a young age (8 weeks), preliminary analysis of mice lacking the mitochondrial 
Fh1 but expressing the cytosolic isoform, exhibited an expansion of the myeloid 
compartment in the peripheral blood (Figure 3-1), indicating a potential 
myeloproliferative disorder. In humans, myeloproliferative disorders often develop 
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into AML, with an average onset between 64 and 68 years (Heaney and Soriano, 
2013). Case reports dating back to the 1950s document patients with a history of 
myeloproliferative disorders, progressing to AML (Skversky et al., 1957; Bank et al., 
1966). The AML that arises as a consequence of myeloproliferative disorders is 
generally aggressive and resistant to conventional therapy (Heaney and Soriano, 
2013). With that in mind, we aged the mice lacking the mitochondrial isoform of 
Fh1, mice in order to observe whether they would develop AML. 
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Figure 3-1. Fh1fl/fl; FHCyt; Vav-iCre mice exhibit an expansion of the myeloid 
compartment within the peripheral blood. We generated mice lacking the 
mitochondrial Fh1 specifically within the haematopoietic system but expressing the 
cytosolic isoform (Fh1fl/fl; FHCyt; Vav-iCre mice). Mice were bled from month 5-8 
every 4wks and blood was phenotypically analysed for myeloid cells (Mac-1+Gr1+ 
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3.2 Aims 
The aim of this chapter was to age Fh1fl/fl; FHCyt; Vav-iCre mice (and age-matched 
controls) in order to observe whether these cohorts would spontaneously develop 
AML. As controls we used mice that were expressing the wild type mitochondrial 
and cytosolic isoforms of Fh1 (here after referred to as control mice) and mice that 
were expressing both isoforms of Fh1 but also expressing the human cytosolic 
isoform of FH (here after referred to as control; FHCyt). At the age between 56-60 
weeks, the mice were sacrificed and the bone marrow as well as extramedullary 
haematopoietic sites such as the spleen and the thymus were immunophenotypically 
analysed. We specifically looked at the primitive, the progenitor and the 
differentiated cell compartments. 
3.3 Experimental design 
In order to investigate the role of mitochondrial and extra mitochondrial FH we 
utilised an in vivo mouse model that specifically deletes Fh1 in the haematopoietic 
system, while simultaneously expressing the extra mitochondrial human FH. The 
transgenic mouse was generated by crossing Fh1fl/fl; Vav-iCre mice with mice 
expressing FH cDNA lacking the mitochondrial targeting sequence and therefore 
preventing its mitochondrial localisation, in the Rosa26 locus (Adam et al, 2013). 
The utilisation of the Vav promoter allows for haematopoiesis-specific deletion, 
shortly after the emergence of HSCs during embryonic development (deBoer et al, 
2003). The resulting genotypes that were used throughout this chapter are indicated 
in Figure 3-3. Control mice, (expressing wild type mitochondrial and cytosolic 
isoforms of Fh1) control; FHCyt (expressing both isoforms of Fh1 but also expressing 
the cytosolic isoform of human Fh1 (FH)), and Fh1fl/fl; FHCyt; Vav-iCre mice 
(lacking the murine mitochondrial and cytosolic isoforms of Fh1 but expressing the 
human cytosolic isoform of Fh1 (FH)). The absence of Fh1 protein in Fh1fl/fl; FHCyt; 
Vav-iCre mice has been previously validated in our team (Figure 3-2  A). Similarly, 
the exclusion of the FHCyt from the mitochondria was also validated by our team and 
other laboratories (Figure 3-2 B; Adam et al, 2013). 
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Figure 3-2. Validation of Fh1fl/fl; FHCyt; Vav-iCre mice. (A) Western blot analysis 
indicating absence of Fh1 protein in c-Kit+ cells. (B) Validation of FHCyt localisation. 
Representative immunofluorescence performed on total BM cells of control and 
control; FHCyt stained with Dapi (blue), anti-V5-FHCyt (green) and MitoTracker 
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Figure 3-3. Generation of Fh1fl/fl; FHCyt; Vav-iCre mice.  We generated mice 
lacking the mitochondrial Fh1 specifically within the haematopoietic system but 
expressing the cytosolic isoform (Fh1fl/fl; FHCyt; Vav-iCre mice). The transgenic 
mouse was generated by crossing Fh1fl/fl; Vav-iCre mice with mice expressing FH 
cDNA lacking the mitochondrial targeting sequence, in the Rosa26 locus (Adam et 
al., 2013). 
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3.4 Results 
3.4.1 Aged Fh1fl/fl; FHCyt; Vav-iCre mice exhibit an expansion 
of the myeloid compartment with a concomitant 
decrease in the B cell compartment  
A combination of both male and female mice were aged for approximately nine 
months and were bled in order to assess the myeloid compartment within the 
peripheral blood. Mice lacking mitochondrial Fh1 while simultaneously expressing 
the cytosolic isoform of FH exhibited a bias towards the myeloid compartment in the 
blood (Figure 3-4).  
Immunophenotypic analysis of the bone marrow at the point of sacrifice revealed 
lower bone marrow cellularity (WBC count) of Fh1fl/fl; FHCyt; Vav-iCre mice 
compared to control and control; FHCyt mice (Figure 3-5A). Interestingly, although 
the mice exhibited a myeloid bias in both the peripheral blood and the spleen at the 
point of sacrifice, they exhibited a comparable frequency of myeloid cells in the BM 
to that of control and control; FHCyt mice (Figure 3-5 B-G; also see representative 
FACS profile in Figure 3-6). 
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Figure 3-4. Fh1fl/fl; FHCyt; Vav-iCre mice exhibit expansion of the 
myeloid compartment in the peripheral blood. Graphs show the frequency 
of the myeloid compartment in aged mice at 30 weeks (A) and 34 weeks of 
age (B) in the peripheral blood. Myeloid cells are defined as the sum of Mac-
1+/ Gr1+ and Mac-1+ cells. n = 4-6 biological replicates per genotype. Graphs 
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Figure 3-5. Fh1fl/fl; FHCyt; Vav-iCre mice exhibit lower bone marrow cellularity 
and myeloid expansion in extramedullary haematopoietic sites. (A) The graph 
shows the total cell number of the bone marrow (WBC) of aged mice (per 1 femur 
and 1 tibia). All cell counts were performed by an automatic cell counter (MEK 
6500K, Nihon Kohden). (B, C, D) Graphs show the frequency of the myeloid cells in 
the peripheral blood (B), the spleen (C), and the bone marrow (D). (E) Graph shows 
absolute numbers of myeloid cells in the BM. Myeloid cells were defined as the sum 
of Mac-1+ Gr1+ and Mac-1+. n = 4-6 biological replicates per genotype. Mice were 
analysed at 56-60 weeks. Graphs show mean± S.E.M.  *p<0.05, **p<0.01, Mann-
Whitney test. WBC; white blood cells, BM; bone marrow, PB; peripheral blood, S; 
spleen. 
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Figure 3-6. Representative FACS plots of the myeloid compartment at the time 
of sacrifice. (A) Representative FACS plots of the myeloid compartment in the bone 
marrow, (B) spleen and (C) peripheral blood of aged mice at the point of sacrifice. 
FACS plots are for control (left panels), control; FHCyt (middle panels) and Fh1fl/fl; 
FHCyt; Vav-iCre (right panels). PB; peripheral blood, BM; bone marrow, S; spleen 
Axes are at a logarithmic scale. 
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Analysis of the lymphoid compartment revealed that aged Fh1fl/fl; FHCyt; Vav-iCre 
mice had a much lower frequency of B cells compared to control and control; FHCyt 
mice (identified based on the markers B220 and CD19). More specifically, a drastic 
decrease of B cell frequency and numbers was observed in the peripheral blood, bone 
marrow and spleen (Figure 3-7; also see representative FACS profile in Figure 3-8). 
Furthermore, the frequency of T cells (the sum of CD4+ and CD8+ cells) was 
unaffected in the peripheral blood, but was significantly decreased in the spleen 
(Figure 3-9; also see representative FACS profile in Figure 3-8). Of note, control; 
FHCyt mice also exhibited a lower frequency of T cells compared to the control mice 
(Figure 3-9). Maturation of the T cell lineage takes place in the thymus. As a result, 
we assessed the thymic T cell compartment. Fh1fl/fl; FHCyt; Vav-iCre mice exhibited 
a comparable frequency of mature T cells in the thymus to control and control; FHCyt 
mice (Figure 3-10A, C). Furthermore, the frequency of the double positive 
population of CD4+ CD8+ representing immature thymocytes (Bosselut, 2004), was 
also comparable between all three genotypes. 
Overall, these data indicate that the Fh1fl/fl; FHCyt; Vav-iCre mice exhibit a decrease 
of the B cell compartment, possibly explaining the increased frequency of the 
myeloid compartment. 
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Figure 3-7. The B cell lineage is compromised in aged Fh1fl/fl; FHCyt; Vav-iCre 
mice.  Frequency of B cells in PB (A) S (B) and BM (C). (D) Total B cell numbers in 
BM of mice at the point of sacrifice. B cells are defined as B220+ CD19+ WBC, 
representing the mature B cells. n = 4-6 biological replicates per genotype. Mice 
were analysed at 56-60 weeks. Graphs show mean ± S.E.M.  *p< 0.05, **p<0.01, 
Mann-Whitney test. PB; peripheral blood, BM; bone marrow, S; spleen. 
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Figure 3-8. Representative FACS plots of lymphoid lineages. (A) FACS plots 
showing B cells (A) and T cells (B) present in the bone marrow (BM, left panels), 
spleen (S, middle panels) and peripheral blood (PB, right panels), at the point of 
sacrifice. Plots are representative for control mice. B cells: CD19+ B220-, CD19+ 
B220+, CD19- B220+. T cells CD4+, CD8+. PB; peripheral blood, BM; bone marrow, 
S; spleen 
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Figure 3-9. The T cell lineage is compromised in the spleen of aged 
Fh1fl/fl; FHCyt; Vav-iCre mice. Frequency of T cells in PB (A), BM 
(B) and S (C) T cells are the sum of CD4+ and CD8+ cells. n = 4-6 
biological replicates per genotype. Mice were analysed at 56-60 weeks. 
Graphs show mean ± S.E.M.  *p< 0.05, Mann-Whitney test. PB; 
peripheral blood, BM; bone marrow, S; spleen. 
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Figure 3-10. Frequency of T cells in the thymus of aged Fh1fl/fl; FHCyt; Vav-iCre mice. 
(A) Frequency of mature T cells in the thymus. T cells are defined as a sum of CD4+ and 
CD8+ cells. (B) Frequency of double positive CD4+ CD8+ cells, denoting the immature 
thymocytes within the thymus. (C) Representative FACS plots of T cells and immature 
thymocytes within the thymus of control (left panel), control; FHCyt (middle panel) and 
Fh1fl/fl; FHCyt; Vav-iCre (right panel). n = 4-6 biological replicates per genotype. Mice 
were analysed at 56-60 weeks. Graphs show mean ± S.E.M.  *p< 0.05, Mann-Whitney 
test.  
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3.4.2 Fh1fl/fl; FHCyt; Vav-iCre mice exhibit increased frequency 
of the early progenitors HPC-1 and HPC-2 
We next wanted to determine the effect that mitochondrial deletion of Fh1 would 
have on the primitive haematopoietic compartment. Analysis of the most primitive 
compartment of the haematopoietic hierarchy in Fh1fl/fl; FHCyt; Vav-iCre mice 
revealed unaffected frequency and absolute cell numbers of the lineage negative 
population and the Lin-Sca-1-c-kit+ (LK) population, representing the pool of 
committed progenitor cells (Figure 3-11A-B, D-E). However, the frequency (but not 
the absolute cells numbers) of Lin-Sca-1+c-Kit+ (LSK) cells, containing the most 
primitive cell populations (stem and early progenitor cells), was significantly 
increased in Fh1fl/fl; FHCyt; Vav-iCre mice when compared to control and control; 
FHCyt mice (Figure 3-11 C, F). Further analysis of the LSK population using the 
SLAM markers CD48 and CD150, revealed that the frequency and absolute cell 
number of long-term HSCs (CD48- CD150+) was not significantly affected (Figure 
3-12 A, C). In contrast however, LT-HSCs identified based on CD34 and Flt3 (LSK 
CD34- Flt3-), appeared to be reduced both in frequency and absolute cell numbers 
(Figure 3-12 B, D; also see  Figure 3-15 for representative FACS plots).  
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Figure 3-11. Fh1fl/fl FHCyt; Vav-iCre mice exhibit an increased 
frequency of LSK cells in the BM. (A-C) Frequency of (A) lineage 
negative cells (B) Lin-Sca-1-c-Kit+ (LK) and (C) Lin-Sca-1+c-Kit+ cells 
(LSK) within the bone marrow (1 femur, 1 tibia). (D-F) Total cell 
numbers of (D) lineage negative (E) LK and (F) LSK cells within the 
BM. n = 4-6 biological replicates per genotype. Mice were analysed at 
56-60 weeks. Graphs show mean ± S.E.M. *p<0.05 Mann-Whitney test.   
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Additionally, the frequency (but not absolute numbers) of the haematopoietic 
progenitors-1 (HPC-1, LSK CD150- CD48+) and haematopoietic progenitors -2 
(HPC-2, LSK CD150+ CD48+) and HPC-2 were significantly increased (Figure 3-13 
A-B, D-E).  Furthermore, the frequency and absolute cell numbers of multipotent 
progenitors (MPP, LSK CD150- CD48-) were comparable to that of control and 
control; FHCyt mice (Figure 3-13 C, F; also see representative FACS profile in 
Figure 3-14). 
In summary, these data show that while the most primitive compartment was not 
dramatically altered, the frequency of the early progenitors HPC-1 and HPC-2, were 
significantly increased. Upon transplantation, HPC-1 an HPC-2 cells give rise to a 
mixture of cells, including both myeloid and lymphoid cells (Oguro et al., 2013). As 
a result, it is likely that the increase in these two populations result in the 
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Figure 3-12. Frequency and cumulative cell number of LT-HSCs in 
the bone marrow of aged mice. This graphs show the frequency of LT-
HSCs from the parental gate (LSK cells) (A-B) and total cell number of 
LT-HSCs. The cell number was estimated by multiplying the frequency 
of LT-HSCs in the WBC gate (not shown) by the total number of cells in 
the bone marrow (1 femur and 1 tibia). (C-D) LT-HSC characterisation 
based on expression of SLAM markers: haematopoietic stem cells (LT-
HSCs: LSK CD48-CD150+); and CD34 and Flt3 markers: long-term 
HSCs (LT-HSCs: LSK CD34-Flt3-). n = 4 biological replicates per 
genotype. Mice were analysed at 56-60 weeks. Graphs show mean ± 
S.E.M. Data are not significant, Mann-Whitney test.  
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Figure 3-13. Fh1fl/fl FHCyt; Vav-iCre mice exhibit increased numbers of HPC-1 
and HPC-2 compartments in the BM. These graphs show the frequency and total 
numbers of MPP and HPC compartments of the BM.  (A, D) Frequency and total 
numbers of HPC-1 compartment in the BM. (B, E) Frequency and total numbers of 
the HPC-2 compartment in the BM. (C, F) Frequency and total numbers of the MPP 
compartment in the BM. n = 4-6 biological replicates per genotype. Mice were 
analysed at 56-60 weeks. Graphs show mean ± S.E.M. *p<0.05, **p<0.01, Mann-
Whitney test. MPPs, LSKCD150-CD48-; HPC-1, LSKCD150-CD48+ and HPC-2, 
LSK CD150+CD48+. HPC-1; haematopoietic progenitor cell-1, HPC-2; 
haematopoietic progenitor cell-2, MPP; multipotent progenitor. 
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Figure 3-14. Representative FACS plots for stem and early 
progenitor cells. (A) FACS plots show the lineage negative population 
from which LK (Lin−c-Kit+Sca-1−) and LSK (Lin−c-Kit+Sca-1+) 
populations are isolated. (B) FACS plots show the LK and LSK 
populations. (C) FACS plots show the isolation of LT-HSCs and early 
progenitor cells using the SLAM markers. HPC-1 (LSK CD150- 
CD48+), HPC-2 (LSK CD150+ CD48+), LT-HSC (LSK CD150+ CD48-), 
MPP (LSK CD150- CD48-). Cells were isolated from the bone marrow 
of mice analysed at 56-60 weeks (1 femur and 1 tibia). n = 4-6 
biological replicates per genotype. FACS plots show control (left 
panels), control; FHCyt (middle panels) and Fh1fl/fl; FHCyt; Vav-iCre 
(right panels). LT-HSC; long-term haematopoietic stem cells. HPC-1; 
haematopoietic progenitor cell-1, HPC-2; haematopoietic progenitor 
cell-2, MPP; multipotent progenitor. 
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3.4.3 Fh1fl/fl; FHCyt; Vav-iCre mice do not exhibit significant 
changes in the committed progenitor compartment  
We next wanted to analyse the committed progenitor compartment that gives rise to 
the differentiated cells of the haematopoietic system. HSCs and immediate progeny 
are characterised as multipotent cells that in turn give rise to oligopotent progenitor 
cells of restricted lineage. These oligopotent progenitors will in turn give rise to the 
terminally differentiated cells of the haematopoietic system (Figure 3-16A).  
Via immunophenotypic characterisation, committed progenitor cells that arise from 
the LK population, can be discriminated based on their expression of CD34 and 
CD16/32 (receptor-II/III (FcgR)) (Akashi et al., 2000). CD16/32 is an important 
marker for myelomonocytic cells and CD34 marks the fraction of haematopoietic 
stem and progenitor cells (Osawa et al., 1996; Lacaud et al., 1998). The resultant 
populations are the common myeloid progenitors (CMP, CD16/32- CD34+), 
granulocyte-monocyte progenitors (GMP, CD16/32+ CD34+) and megakaryocyte-
erythrocyte progenitors (MkEP, CD16/32- CD34-). Furthermore, via the use of CD34 
and Flt3 a population of progenitors that possess B-cell, T-cell and GM (granulocytic 
monocytic) potential but lack significant MegE (megakaryocyte erythrocyte) 
potential can be isolated. This population is double positive for CD34 and Flt3 (LSK 
CD34+ Flt3+) and is referred to as lymphoid-primed multipotent progenitors (LMPP) 
(Adolfsson et al., 2005). 
Immunophenotypic analysis of the bone marrow, showed that Fh1fl/fl; FHCyt; Vav-
iCre mice exhibited a trend in the increase of the LMPP, CMP and GMP frequencies 
when compared to control and control; FHCyt mice (Figure 3-16 B, C; also see  
Figure 3-15 and Figure 3-17). Additionally, MkEP and CLP progenitors in Fh1fl/fl; 
FHCyt; Vav-iCre mice were comparable to control and control; FHCyt mice (Figure 
3-16 B, C; also for representative FACS plots see Figure 3-17). 
Overall, given the fact that we observed a drastic decrease in the B cell compartment 
with a concomitant bias towards the myeloid compartment, it is surprizing that we 
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did not observe any dramatic changes in the committed progenitor compartment. To 
that end, it is possible that the metabolic changes that may have occurred due to the 
deletion of mitochondrial Fh1, affect mainly the differentiated cells rather than the 
more primitive compartments. 
 
 Figure 3-15. Representative FACS plots of the LMPP and LT-HSC 
compartments based on the CD34 and Flt3 markers. The graphs depict control 
(left panel), control; FHCyt (middle panel) and Fh1fl/fl; FHCyt; Vav-iCre (right panel). 
LMPP: lymphoid-myeloid multipotent progenitor cells (LSK CD34+Flt3+), LT-HSC: 
long-term haematopoietic stem cells (LSK CD34- Flt3-). 
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Figure 3-16. The distribution and absolute numbers of committed 
progenitor cells are not affected in Fh1fl/fl; FHCyt; Vav-iCre mice. (A) 
Schematic representation of the haematopoietic hierarchy. LT-HSC; long-
term haematopoietic stem cell, MPP; multipotent progenitor, LMPP; 
lymphoid-primed multipotent progenitor; CLP, common lymphoid 
progenitor, CMP; common myeloid progenitor, MkEP; megakaryocyte- 
erythrocyte progenitor, GMP; granulocyte-monocyte progenitor (Adapted 
from Adolfson et al., 2005). (B) Frequency and total cell numbers (C) of 
committed progenitor cells within the bone marrow of aged mice (per 1 
femur and 1 tibia). LMPP (LSK CD34+ Flt3+), CMP (Lin−c-Kit+Sca-1− 
(LK) CD34+CD16/32−), GMP (LK, CD34+CD16/32+), MkEP (LK, CD34-
CD16/32-), CLP (Lin−c-KitlowSca-1lowCD127+Flt3+). The cell number was 
estimated by multiplying the frequency of each cell population by the total 
number of cells in the bone marrow. n = 4-5 biological replicates per 
genotype. Mice were analysed at 56-60 weeks. Graphs show mean ± 
S.E.M. ns, Mann-Whitney test. 
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Figure 3-17. Representative FACS dot plots of committed progenitors. 
(A) This figure shows representative FACS plots for the isolation of LK 
(Lin−c-Kit+Sca-1− ) and pre-CLP (Lin−c-KitlowSca-1low) cells. (B) Shows 
representative FACS plots for the committed progenitor cells (GMP, 
CMP, MEP) arising from the LK gate. CMP (Lin−c-Kit+Sca-1− (LK) 
CD34+CD16/32−), GMP (LK, CD34+CD16/32+), MkEP (LK, CD34-
CD16/32-). (C) Shows representative FACS plots for CLP progenitor cells 
(Lin−c-KitlowSca-1lowCD127+Flt3+). FACS plots show control (left panels), 
control; FHCyt (middle panels) and Fh1fl/fl; FHCyt; Vav-iCre (right panels). 
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3.5 Discussion 
3.5.1 Primitive compartment of the haematopoietic system 
In Fh1fl/fl; FHCyt; Vav-iCre mice, the frequency of LSK cells, containing the most 
primitive compartment and the early haematopoietic progenitors, was increased. 
Within the LSK compartment, via the use of the SLAM markers CD48 and CD150 
we observed a significant increase in the early progenitors HPC-1 and HPC-2. Based 
on transplantation studies, HPC-1 and HPC-2 cells contain a mixture of progenitor 
cells that can collectively give rise to all lineages (Oguro et al, 2013). More 
specifically, HPC-1 cells are able to transiently produce myeloid, B and T cells and 
to a lesser extent platelet cells. HPC-2 cells have a limited reconstitution capacity in 
vivo but are able to transiently produce erythrocytes and platelets and to a lesser 
extent myeloid and B cells (Oguro et al, 2013). However, even though their 
differentiation potential is somewhat understood, their relationship with oligopotent 
progenitor cells such as GMP, CMP or CLPs is not clear. As a result, we cannot infer 
whether the expansion of HPC-1 and HPC-2   cells has to correlate with a 
downstream expansion in one of the oligopotent compartments. It would have been 
of interest to investigate further the haematopoietic hierarchy in order to identify a 
potential deregulation in progenitor cells downstream of HPC-1 and HPC-2, which at 
the time of analysis was not considered. Specifically, it would be of interest to 
characterize the early erythroid-myeloid progenitors using the staining panel 
developed by Pronk et al (Pronk et al., 2007), in order to identify whether the 
expansion of HPC-1 and HPC-2 translates into an expansion of the erythroid-
myeloid progenitors, therefore explaining the myeloid bias we observe.  Finally, 
although I did not observe any significant changes in the frequency or the cell 
number of progenitor populations downstream of HPC-1 and HPC-2, there is a trend 
towards an increase in CMPs and a decrease in CLPs. Therefore, it is likely that if I 
utilised more biological replicates I would have observed a significant change, as 
there would be less variability within the biological replicates.   
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3.5.2 Lymphoid lineage 
We showed that mice lacking mitochondrial Fh1 exhibited a bias towards the 
myeloid compartment in expense of the B-cell lineage.  
Recent studies have shown that lineage specification is dictated by distinct metabolic 
pathways. A recent study demonstrated that lineage commitment of human and 
murine HSCs is dependent on glutamine metabolism. Specifically, when the authors 
blocked the glutamine transporter ASCT2, erythropoietin-stimulated HSCs diverted 
to myelomonocytic differentiation, highlighting the importance of metabolic 
pathways in lineage commitments (Oburgoglu et al., 2014). In a similar manner, it is 
possible that, due to a genetic perturbation of the TCA cycle (as a result of Fh1 
deletion) HSCs are skewed towards a specific lineage. 
In Fh1fl/fl; FHCyt; Vav-iCre mice B cell (B220+ CD19+) frequency and absolute cell 
numbers were decreased in the bone marrow, spleen and peripheral blood. However, 
the CLP and LMPP progenitors appeared normal in both frequency and absolute cell 
numbers in the Fh1fl/fl; FHCyt; Vav-iCre mice, indicating that there might be a 
possible blockade downstream in the lymphoid differentiation.  
B-cell development occurs in both the bone marrow and peripheral lymphoid organs 
such as the spleen. The initial stages of B cell differentiation occur within the bone 
marrow. In the bone marrow B cells that successfully go through the self-reactive 
checkpoint (checkpoint that eliminates autoreactive B cells), exit the bone marrow 
where they mature in peripheral organs. It would be interesting to decipher the exact 
stage at which B cell differentiation has been compromised in Fh1fl/fl; FHCyt; Vav-
iCre mice by using a larger panel of surface markers. However, it is clear that B cell 
differentiation or survival is compromised.  
T cell maturation occurs in the thymus after CLP progenitors exit the bone marrow 
(Petrie et al., 2002). T cells then undergo differentiation steps typically defined by 
the expression of CD4 and CD8. To begin with, thymocytes start as double negative 
for CD4 and CD8 expression, then they become double positive and lastly maturing 
into single positive CD4+ or CD8+ (Anderson et al., 2001). Interestingly, the 
frequency of mature T cells (sum of single positive CD4 and CD8 cells) was not 
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altered in the thymus but was significantly decreased in the spleen. The spleen is an 
important site for lymphocyte traffic (Cesta et al, 2006). It is therefore possible that 
adhesion molecules involved in T cell homing to the spleen are absent in Fh1fl/fl; 
FHCyt; Vav-iCre mice. For instance, lymphocytes lacking the lymphocyte- function 
associated antigen-1 (LFA-1) and alpha 4 beta 1 integrin, are unable to migrate to the 
white pulp of the spleen (Nolte et al., 2002; Lo et al., 2003). 	  
Furthermore, it is interesting that we observed a significant dysregulation in B cell 
but not T lineage (with the exception of the decrease in the spleen that could be 
explained by the inability of cells to migrate to that site) in the organs that were 
analyzed. The difference we observed could be attributed to the differential 
metabolic requirements of these two lineages. B cells have been shown to utilise 
glycolysis and oxidative phosphorylation at equal rates. Conversely, in order for B 
cells to produce antibodies, they upregulate glycolysis to specifically convert 
pyruvate to lactate and inhibition of glycolysis leads to suppression of antibody 
production (Caro-Maldonado et al., 2014; Doughty et al., 2006). However, the 
importance of oxidative phosphorylation is not well understood, but literature 
highlights that a fine balance between glycolysis and oxidative phosphorylation is 
required for their maintenance. Given the fact that we deleted a key enzyme of the 
TCA cycle, it is possible that the fine-tuning of these pathways might be disrupted 
and as a result, B cell maturation is limited.  
Conversely, relatively quiescent T cells primarily utilise oxidative phosphorylation 
and lipid oxidation (MacIver et al., 2013). However, activated T cells robustly 
proliferate and utilise glycolysis in order to meet their energetic demands (Chen et 
al., 2013; Pearce et al.,2013; MacIver et al., 2013; Caro-Maldonado et al., 2014). 
Overall, it is plausible that since T cells do not heavily rely on oxidative 
phosphorylation, they are not affected by deletion of mitochondrial Fh1 (and thus the 
potential genetic perturbation of the TCA cycle). On the other hand, since B cells 
appear to require a fine-tuned ratio of oxidative phosphorylation and glycolysis it is 
possible that mitochondrial Fh1 deletion would lead to deleterious effects on the B 
cell lineage.  
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3.5.3 Myeloid lineage  
The disruption of the lymphoid lineage could result in a bias towards the myeloid 
lineage as a compensatory mechanism, rather than Fh1 deletion having a direct effect 
on the myeloid lineage. Interestingly, recent findings indicate that myeloid cells 
exhibit a glycolytic rather than oxidative phosphorylation phenotype. Specifically, a 
recent study showed that neutrophils (and to a lesser extent monocytes), have little to 
no dependency on oxidative phosphorylation (Chacko et al., 2013). These 
conclusions were drawn based on the seahorse assay, that measures the oxygen 
consumption rate of cells, directly translating to what extent cells use oxidative 
phosphorylation.  
Furthermore, is also worth noting that we only observed an expansion of the 
differentiated myeloid lineage in the peripheral blood and spleen of the mice and not 
in the bone marrow. Overall, these data suggest that since myeloid cells do not 
appear to critically rely on oxidative phosphorylation, mitochondrial Fh1 deletion 
(and the resultant genetic perturbation of the TCA cycle), would not negatively 
impact the myeloid lineage. Most importantly, the most likely explanation regarding 
the increased frequency of the myeloid lineage, is the depletion of the B cell lineage.  
3.6 Summary 
In summary, even though we observed a persistent myeloid expansion in the 
peripheral blood of the Fh1fl/fl; FHCyt; Vav-iCre mice, the mice did not spontaneously 
develop AML, potentially indicating that if mitochondrial Fh1 deletion is involved in 
leukaemogenesis, it may be only one of the co-operative events required for AML 
development. Furthermore, while we observed only a minimal dysregulation in the 
most primitive haematopoietic compartment of these mice, we observed a drastic 
decrease in the B cell lineage but not the T cells lineage (Figure 3-18). Given the fact 
that mitochondrial Fh1 deletion resulted in a genetic truncation of the TCA, these 
data could potentially highlight the distinct metabolic requirements of B, T and 
myeloid cells. 
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Figure 3-18. Summary of changes in the different haematopoietic compartments 
of Fh1fl/fl; FHCyt; Vav-iCre mice. The table indicates changes between Fh1fl/fl; 
FHCyt; Vav-iCre and control mice. ND: no difference observed, arrow pointing 
downwards indicates a decrease in the cell population while the arrow pointing 
upwards indicates an increase in the cell population, - indicates that analysis was not 
performed. LT-HSC: long-term haematopoietic stem cell, HPC-1: haematopoietic 
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4 The role of mitochondrial Fh1 and the TCA in 
leukaemic transformation 
4.1 Introduction 
Alterations in cellular metabolism represent a hallmark of cancer (Hanahan and 
Weinberg, 2011). Until recently, it was widely accepted that most cancer cells rely 
more on glycolysis rather than oxidative phosphorylation in order to meet their 
energy demands (Warburg, 1956), (Gatenby and Gillies, 2004).  
However, recent studies have demonstrated that some cancer cells rely on oxidative 
phosphorylation rather than on glycolysis.  For example, Sugamuma et al., showed 
that while some AML cell lines such as NB4 rely more on glycolysis, other cells 
such as THP1 rely more on oxidative phosphorylation, as demonstrated by the 
induction of cell death of THP1 cells through inhibition of ATP synthase (by 
treatment with oligomycin) (Suganuma et al., 2010). Similarly, a recent study 
showed that cells isolated from CLL patients primarily utilise oxidative 
phosphorylation and inhibition of such (using a benzodiazepine derivative that 
blocks ATP synthase), led to cell death (Jitschin et al., 2014). In another study, 
quiescent leukaemic stem cells (LSCs) exhibited low ROS, relied more on oxidative 
phosphorylation and underwent cell death when oxidative phosphorylation was 
inhibited (Lagadinou et al., 2013). Furthermore, in another study, to address whether 
loss of mitochondrial function in vivo impacts tumorigenesis, the authors crossed the 
Kras-driven lung cancer model with mice harbouring floxed alleles of the 
mitochondrial transcription factor Tfam (Weinberg et al., 2010s). TFAM is required 
for mitochondrial DNA replication and Tfam-null cells are deficient in electron 
transport and OXPHOS. Cre-treated Kras-G12D-Tfam-null mice exhibited smaller 
tumours, indicating that functional mitochondrial electron transport chain is required 
for tumorigenesis (Weinberg et al., 2010). Additionally, knock-down of p32, a 
mitochondrial membrane protein, in the breast carcinoma cell line MDA-MB-435 
shifted their metabolism from OXPHOS, as indicated a decrease in the activity of 
complexes III and IV of the electron transport chain, to glycolysis, as indicated by 
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increased glucose consumption and lactate production, and reduced their viability in 
vitro. Furthermore, knock-down of p32 in the highly aggressive MDA-MB-231 
D3H2LN breast cancer cell line, reduced tumour development in nude mice (Fogal et 
al., 2010). More recently, it was shown that when compared to normal 
haematopoietic cells, AML cell lines and patient samples exhibited low maximal 
respiration capacity and increased mitochondrial mass with no corroborative increase 
in the activity of the electron transport chain. As a result, the cells were more 
susceptible to oxidative stress and preferentially underwent cell death  
(Sriskanthadevan et al., 2015). 
Collectively, the studies available suggest that there is a lot more to be understood 
about cancer metabolism and that there is wide heterogeneity when considering the 
metabolic properties of cancer cells.  With that in mind, this chapter aims to uncover 
the importance of mitochondrial respiration through the genetic deletion of the key 
TCA enzyme Fh1 in malignant haematopoiesis, utilizing the retroviral Meis1/Hoxa9 
AML model.   
4.1.1 Meis1/Hoxa9 retroviral model 
For the purpose of this chapter, I utilised the Meis1/ Hoxa9 retroviral model. Meis1 
and Hoxa9 are oncogenes frequently deregulated in AML patients. Furthermore, 
their over-expression leads to immortalisation of haematopoietic stem and progenitor 
cells (Zeisig and Wai Eric So, 2009). Out of 6817 genes, Hoxa9 is the single most 
highly correlated gene with poor prognosis (Golub et al., 1999). The Meis1/Hoxa9 
retroviral AML mouse model is well characterised and is widely used in leukaemic 
studies (Kroon et al., 1998b) (Thorsteinsdottir et al., 2001) (Pineault et al., 2002) 
(Thorsteinsdottir et al., 2002). The use of this model has the advantage to study the 
requirement of Fh1 in a step-wise manner. Below, I describe the implication of 
Hoxa9 and Meis1 genes in normal haematopoiesis and leukaemogenesis. 
4.1.2 Hoxa9 
The clustered Hox family of homeobox genes (class I homeobox genes) is an 
evolutionarily highly conserved set of genes encoding DNA-binding transcription 
factors that were first identified as key regulators in positional identification of cells 
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during development (Krumlaf et al, 1994). In mammals, there are 39 Hox genes 
organised into 4 distinct genomic clusters (A-D) located on four different 
chromosomes. Gene expression analyses showed that the majority of Hox genes are 
highly expressed in the most primitive compartment of the haematopoietic system 
while down regulated in more differentiated cells, suggesting that the Hox genes play 
key roles in primitive haematopoietic cells, and that dysregulation of such genes may 
impact leukaemic transformation (Sauvengeau et al., 1994; Pineault et al., 2002; 
Giampaolo et al., 1994; Kawagoe et al., 1999). Like most Hox genes Hoxa9 is highly 
expressed in foetal liver (FL) and bone marrow (BM) primitive haematopoietic cells 
and is downregulated during differentiation (Sauvengeau et al., 1994; Pineault et al., 
2002). Indeed, Hoxa9-deficient mice exhibited multilineage defects (Lawrence et al., 
1997). Competitive repopulation assays revealed that the major defect of Hoxa9-/- 
animals was the inability of HSCs to repopulate haematopoiesis in recipient mice 
(Lawrence et al., 1997), suggesting that Hoxa9 is crucial for HSC self-renewal. This 
was reinforced by the fact that overexpression of Hoxa9 can enhance HSC 
regeneration in vivo, with additional defects in differentiation that eventually led to 
leukaemia (Thorsteinsdottir et al., 2002). HOX proteins, bind target DNA with little 
obvious selectivity (Argiropoulos et al., 2007). HOX cofactors have been shown to 
directly interact with HOX proteins to increase their DNA-binding affinity and to 
modify their transregulatory properties (Argiropoulos et al, 2007). HOX proteins 
from paralog groups 1-10 have been shown to interact with PBX1 while those from 
paralog groups 9-13 interact with Meis1a (Shen et al., 1997).  
4.1.3 Meis1 
Meis1 also belongs to the Hox family of homeobox genes and is expressed in foetal 
HSC compartments (Krumlaf et al, 1994; Azcoitia et al., 2005). Similarly to Hoxa9, 
Meis1 is expressed in the most primitive haematopoietic subpopulations and is 
downregulated during differentiation (Argiropoulos et al., 2007; Pineault et al., 
2002). Deletion of Meis1 causes embryonic lethality by embryonic day 14.5, causing 
multiple vascular and haematopoietic effects. Meis1 was first identified as a common 
viral integration site in myeloid leukaemic cells of BXH-2 mice (Moskow et al., 
1995). The importance of MEIS1 in human leukaemogenesis was highlighted by the 
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finding that it was frequently up-regulated in primary AML and acute lymphoblastic 
leukaemia samples (Kawagoe et al., 1999; Imamura et al., 2002; Rozovskaia et al., 
2001). Interestingly, Meis1 has no transforming capacity alone (Kroon et al., 1998b). 
Co-activation of HOXA9 with MEIS1 is a frequent occurrence in leukaemias 
associated with MLL rearrangements (Yeoh et al., 2002; Kohlmann et al.,2003; Fine 
et al., 2004; Tsutsumi et al., 2003). Indeed, co-overexpression of Hoxa9 and Meis1 in 
murine bone marrow cells recapitulates MLL-ENL-mediated immortalisation of 
myeloid progenitor cells (Zeisig et al., 2004).  Furthermore, in another study the 
authors showed that the ability of MLL fusion proteins to induce and maintain 
leukaemic transformation in progenitor cells, was dependent and rate-limited by 
Meis1 (Wong et al., 2007). 
 
4.2 Aims  
As described in chapter 3 Fh1fl/fl; FHCyt; Vav-iCre cells lack the expression of the 
mitochondrial isoform of Fh1 but express the human cytosolic isoform (FHCyt). This 
modification results in a genetic truncation of the TCA cycle while fumarate is 
metabolized efficiently in the cytoplasm. We have previously demonstrated in the lab 
that Fh1fl/fl; Vav-iCre mice are not viable but the expression of the cytosolic isoform 
rescues lethality, indicating that the cytosolic expression of Fh1 is essential.  The 
aims of this chapter were to assess the importance of intact TCA cycle in:   
• The generation of pre-LCs 
• The generation of LICs 
• Maintenance of LICs 
4.3 Experimental design 
4.3.1 Generation of pre-LCs and LICs 
In order to address the points above I utilised the retroviral model Meis1/Hoxa9, as 
described in the previous chapter. Briefly, LSK cells were isolated from the foetal 
liver of control (Fh1fl/f1, Vav-iCre negative), control; FHCyt (Fh1fl/f1, Vav-iCre 
negative, expressing the cytosolic isoform of human FH) and Fh1fl/fl; FHCyt; Vav-
Chapter 4 – The role of mitochondrial Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  122 
iCre (Fh1fl/f1; Vav-iCre positive cells that lack mitochondrial Fh1 but express the 
cytosolic isoform of human FH; thereafter referred to as cells lacking mitochondrial 
Fh1) 14.5 dpc embryos and were infected with retroviruses over-expressing 
Meis1/Hoxa9. Cells over-expressing Meis1 and Hoxa9 were then selected based on 
their antibiotic resistance to puromycin and neomycin, respectively. Selected cells 
subsequently underwent three rounds of serial re-plating in semi solid media. The 
established pre-LCs were then injected into primary recipient mice (for the outline of 
the experimental design, see Figure 4-1 A).  
4.3.2 Maintenance of LICs 
In order to assess the role of mitochondrial Fh1 in the maintenance of self-renewal 
capacity of LICs, I utilised the Meis1/Hoxa9 model in an Mx1-Cre background, 
therefore allowing for the conditional deletion of Fh1. LSK cells (CD45.2+) were 
isolated from the foetal liver of embryos at 14.5 dpc. The cells were isolated from 
embryos of the following genotypes: control (Fh1fl/fl; Mx1-Cre negative), control; 
FHCyt (Fh1fl/fl; Mx1-Cre negative cells that over-express the cytosolic isoform of FH) 
and Fh1fl/fl; FHCyt; Mx1-Cre (Fh1fl/fl; Mx1-Cre positive cells that over-express the 
cytosolic isoform of FH). After isolation, the cells were subsequently infected with 
retroviruses over-expressing Meis1 and Hoxa9. The cells over-expressing Meis1 and 
Hoxa9 were then selected based on their antibiotic resistance to puromycin and 
neomycin, respectively. The cells were then serially re-plated in semi-solid media. 
100,000 of the resultant pre-LCs were injected in sub-lethally irradiated recipient 
mice (CD45.1+/CD45.2+). Once the chimerism of leukaemic CD45.2+ cells reached 
20-30 % in the peripheral blood of the recipient mice, the mice were intra-
peritoneally injected 6-8 times every alternate day with 300µg poly (I:C), in order to 
induce the deletion of Fh1. This experiment allows for the study of the generation of 
LICs. In order to assess the maintenance of the self-renewal capacity of LICs, 10,000 
LICs (CD45.2+c-Kit+) were transplanted into secondary sub-lethally irradiated 
recipient mice (for the outline of the experimental design, see Figure 4-1 B). 
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Figure 4-1. Experimental design. (A) LSK cells were isolated from the foetal liver of 
control (Fh1fl/f1, Vav-iCre negative), control; FHCyt (Fh1fl/f1, Vav-iCre negative, expressing 
the cytosolic isoform of human FH) and Fh1fl/fl; FHCyt; Vav-iCre (Fh1fl/f1; Vav-iCre positive 
cells that lack mitochondrial Fh1 but express the cytosolic isoform of human FH; thereafter 
referred to as cells lacking mitochondrial Fh1) 14.5 dpc embryos and were infected with 
retroviruses over-expressing Meis1/Hoxa9. Cells over-expressing Meis1 and Hoxa9 were 
then selected based on their antibiotic resistance to puromycin and neomycin, respectively. 
Selected cells subsequently underwent three rounds of serial re-plating in semi solid media. 
The established pre-LCs were then injected into primary recipient mice. (B) LSK cells 
(CD45.2+) were isolated from the foetal liver of embryos at 14.5 dpc. The cells were isolated 
from embryos of the following genotypes: control (Fh1fl/fl; Mx1-Cre negative), control; 
FHCyt (Fh1fl/fl; Mx1-Cre negative that over-express the cytosolic isoform of FH) and Fh1fl/fl; 
FHCyt; Mx1-Cre (Fh1fl/fl; Mx1-Cre positive cells that over-express the cytosolic isoform of 
FH). After isolation, the cells were subsequently infected with retroviruses over-expressing 
Meis1 and Hoxa9. The cells over-expressing Meis1 and Hoxa9 were then selected based on 
their antibiotic resistance to puromycin and neomycin, respectively. The cells were then 
serially re-plated in semi-solid media. 100,000 of the resultant pre-LCs were injected in sub-
lethally irradiated recipient mice (CD45.1+/CD45.2+). Once the chimerism of leukaemic 
CD45.2+ cells reached 20-30 % in the peripheral blood of the recipient mice, the mice were 
intra-peritoneally injected 6-8 times every alternate day with 300µg poly (I:C), in order to 
induce the deletion of Fh1. 
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4.4 Results 
4.4.1 Mitochondrial Fh1 deletion does not affect the 
transforming capacity of cells 
We wanted to assess the importance of mitochondrial Fh1 deletion in leukaemic 
transformation. To address this aim, I isolated LSK cells from the foetal liver of 
control, control; FHCyt and Fh1fl/fl; FHCyt; Vav-iCre 14.5 dpc embryos and infected 
them with retroviruses over-expressing Meis1 and Hoxa9, in order to assess the 
transforming and clonogenic capacity of cells lacking mitochondrial Fh1. The cells 
were able to efficiently generate colonies in vitro, indicating that a genetically intact 
TCA is not necessary for leukaemic transformation, at least using the Meis1/Hoxa9 
retroviral model (Figure 4-2A). Pre-LCs lacking mitochondrial Fh1 (but expressing 
FHCyt), had a smaller average colony size compared to control cells, potentially 
indicating a slower proliferation rate (Figure 4-2 B-E).  
 
Chapter 4 – The role of mitochondrial Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  125 
 
Figure 4-2. Assessing colony number and colony size of pre-LCs lacking 
mitochondrial Fh1. (A) CFC counts at each re-plating (plating round 1, 2 
and 3) are shown. Data are mean ± S.E.M., n = 6-8 biological replicates per 
genotype. Cells were seeded at a density of 2,500 cells per well. Colonies 
were counted 6 days post seeding. (B) Graph shows average colony size in 
um2. Data are mean ± S.E.M., n = 3 biological replicates per genotype. 500 
cells per 96-well plate well were seeded. 5 technical replicates were seeded 
for each biological replicate. Counting of colonies was performed using the 
Perkin Elmer Operetta high content imaging system at day 3, 4 and 5 post 
seeding. (C-E) Representative colony images of control (C), control; FHCyt, 
(D) and Fh1fl/fl; FHCyt; Vav-iCre.  Images were at 4X magnification. Unpaired 
t test, * p< 0.05, ***p< 0.001 
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4.4.1.1 In vitro characterisation of pre-LCs lacking mitochondrial 
Fh1 
In order to address the possibility of a slower proliferation rate in pre-LCs lacking 
mitochondrial Fh1, I performed a proliferation assay, counting the cumulative cell 
number over the span of 48 hours. Fh1fl/fl; FHCyt; Vav-iCre cells had a proliferation 
rate comparative to that of control and control; FHCyt cells (Figure 4-3 A). 
Furthermore, in the span of 48 hours Fh1fl/fl; FHCyt; Vav-iCre cells exhibited 
differences in the percentage of apoptotic cells compared to control and control; 
FHCyt cells (Figure 4-3 B). Specifically, Fh1fl/fl; FHCyt; Vav-iCre cells had an average 
percentage of apoptotic and late apoptotic cells of 2.8 % and 6.3 % respectively, 
while control cells and control; FHCyt cells exhibited a percentage of 4.5 %, 18.8 % 
and 6.26 %, 19.1 % respectively. Of note, there was no difference in the cell cycle 
status of the pre-LCs lacking mitochondrial Fh1 (Figure 4-4). Furthermore, the 
fraction of cells in the sub-G0 phase can be indicative of the fraction of apoptotic 
cells. Pre-LCs lacking mitochondrial Fh1 had a significantly lower percentage of 
sub-G0 cells after 48 hours, corroborating well with the data obtained from the 
annexin V assay (Figure 4-5). Collectively, these data indicate that there is no 
difference in the proliferation rate or cell cycle status, but that a higher percentage of 
cells are alive within the Fh1fl/fl; FHCyt; Vav-iCre population. 
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Figure 4-3. Pre-leukaemic cells lacking mitochondrial Fh1 exhibit normal 
proliferation rate but lower cell death rate. (A) Proliferation curves of pre-
leukaemic cells in liquid culture. Cell were seeded at a concentration of 150,000 
cells/ml. ns, Unpaired t test performed between each time point (B) Apoptosis 
assay using annexin V-FITC and DAPI staining analysed using flow cytometry 0 
(left), 24 (middle) and 48 hours (right) after seeding. Data are mean ± S.E.M, n = 3 
biological replicates. unpaired t test, *p<0.05, ** p<0.001 
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Figure 4-4. pre-LC cells lacking mitochondrial Fh1 exhibit normal cell cycle 
status. Cell-cycle analysis of pre-leukaemic cells. Graph indicates percentage of cells 
(from the single cell gate) at each stage of the cell cycle at 24hours (left) and 48hours 
(right). Data are mean ± S.E.M., n = 3 biological replicates per genotype, 3 technical 
replicates. This is a representative experiment carried out twice. Analysis was 
performed using DAPI (containing 0.1% Triton) staining and cells were analysed via 
flow cytometry. ns, Unpaired t test. (For gating strategy see section 2.13.11). 
 
Chapter 4 – The role of mitochondrial Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  129 
 
Figure 4-5. Sub-G0 phase of pre-LCs indicative of cell death rate. (A-B) Graphs 
indicate percentage of cells (from the single cell gate used to exclude doublets) in the 
sub-G0 phase of cell cycle.   Sub-G0 fraction was determined based on the DNA 
content of cells, using DAPI and analysing cells via flow cytometry. (B-C) 
Representative histograms indicating how the sub-G0 phase was determined at 24 
hours (B) and at 48 hours (C) for control (left), control; FHCyt (middle) and Fh1fl/fl; 
FHCyt; Vav-iCre (right). Representative of two experiments. n = 3 biological 
replicates per genotype, Data are mean ± S.E.M, ** p<0.01, Unpaired t test. 
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4.4.2 Mitochondrial Fh1 and genetically intact TCA are 
required for AML generation in vivo 
After characterising the pre-LCs lacking mitochondrial Fh1 in vitro, I wanted to 
assess whether mitochondrial Fh1 (and effectively intact TCA) is required for AML 
propagation. To this end, 100,000 pre-LCs (myeloid cells that are CD45.2+/ c-Kit+) 
were injected into sub-lethally irradiated recipient mice (CD45.1+/CD45.2+) (Figure 
4-6 A, B). Equal expression of Meis1 and Hoxa9 was confirmed via qRT-PCR 
(Figure 4-7 A, B).  Interestingly, the percentage of surviving recipient mice that were 
injected with pre-LCs lacking mitochondrial Fh1 was much higher than the mice 
injected with control or control; FHCyt pre-LCs (Figure 4-7  C). Specifically, while 
only 25 % and 30 % of control and control; FHCyt respectively recipient mice 
survived, 76 % of mice injected with pre-LCs lacking Fh1 survived (Figure 4-7 D). 
At the point of sacrifice, the bone marrow and spleen of recipient mice were 
infiltrated with LICs expressing myeloid markers, confirming that the mice 
succumbed to AML (Figure 4-8 A-B). Furthermore, mice also exhibited 
splenomegaly at the time of sacrifice (Figure 4-8 C). These data indicate that 
mitochondrial Fh1 and genetically intact TCA are required for efficient generation of 
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Figure 4-6. Flow cytometry profile of pre-LCs lacking mitochondrial Fh1. (A) Graph 
shows percentage of myeloid cells of pre-LCs of the indicated genotypes. Cells were 
analysed via flow cytometry after harvesting from the third serial re-plating. Myeloid cells 
are the sum of Mac-1+/Gr1+ and Mac-1+. (B) Representative flow cytometry profiles of 
control (left panel), control; FHCyt, (middle panel) and Fh1fl/fl; FHCyt; Vav-iCre (right 
panel). n = 3 biological replicates per genotype. Graphs show mean ± S.E.M, ns, Mann-
Whitney test. 
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Figure 4-7. Mitochondrial Fh1 is required for efficient LIC generation. 
(A-B) Relative mRNA expression of Meis1 (A) and Hoxa9 (B) in pre-LCs 
after CFC3, before transplantation into recipient mice. The analysis was 
performed using control as a reference point, and β -actin as a housekeeping 
gene (CT method).  n = 3-6 biological replicates per genotype.   (C) Kaplan-
Meier survival curve of sub-lethally irradiated primary recipient mice 
transplanted with 100,000 c-Kit+ pre-leukaemic cells obtained from serial 
re-plating assays. (D) Table indicating recipient mice injected with LICs of 
the indicated genotypes, that succumbed to leukaemia or remained disease-
free up to 20 weeks. n = 8-10 recipients per biological replicate, n = 4-6 
biological replicates per genotype. **** p< 0.0001, Log-rank (Mantel-Cox) 
and Gehan-Breslow-Wicoxon tests. 
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Figure 4-8. Infiltration of LICs in the bone marrow and spleen of 
recipient mice. (A) Percentage of CD45.2+ LICs in the bone marrow (left) 
and spleen (right) of sick recipient mice at the point of sacrifice. (B) 
Percentage of myeloid cells in the bone marrow (left) and spleen (right) 
within the LIC compartment (myeloid cells were defined as the sum of Mac-
1+/Gr1+ and Mac-1+). (C) Representative image of spleens isolated from sick 
recipient mice at the point of sacrifice (lane 1 = control, lanes 2-4 = control; 
FHCyt mice, lanes 5-7 = Fh1fl/fl; FHCyt; Vav-iCre mice). Graphs show mean ± 
S.E.M, n = 6-7 recipient mice per genotype, *p< 0.05, ** p<0.001, Mann-
Whitney test. 
 
Chapter 4 – The role of mitochondrial Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  134 
 
 
4.4.3 LICs lacking mitochondrial Fh1 exhibit low spare 
respiratory capacity 
Given the fact that mitochondrial Fh1 is part of the TCA, and the TCA in an integral 
component of the electron transport chain, I wanted to assess whether deletion of 
such would result in dysfunction of mitochondrial respiration. To this end, I utilised 
seahorse technology (for a detailed explanation of how the Seahorse assay functions, 
see Figure 4-9). Briefly, the assay measures key parameters of mitochondrial 
function by directly measuring the oxygen consumption rate (OCR) of cells after the 
sequential addition of inhibitors of the electron transport chain. After the addition of 
each inhibitor, several values can be extracted and thus assess mitochondrial 
function. LICs were isolated from the bone marrow of sick recipient mice and their 
mitochondrial fitness was assessed using the Seahorse assay. Interestingly, although 
the basal respiration appeared to be at comparable levels to that of control and 
control; FHCyt cells, the spare respiratory capacity (SRC), was significantly lower in 
LICs lacking mitochondrial Fh1 (Figure 4-10 A, B). SRC is the extra mitochondrial 
capacity available in a cell in order to produce energy under stress conditions, and is 
thought to be important for long-term survival and function (van der Windt et al., 
2012) (Choi et al., 2009) (Ferrick et al., 2008) (Nicholls, 2009). The SRC reflects the 
difference between basal and maximal respiration, which is determined by measuring 
OCR before the treatment with oligomycin and after treatment with FCCP. Of note, 
in LICs lacking mitochondrial Fh1 SRC had a negative value indicating that cells 
were not only incapable of displaying normal SRC but were also unable to reach the 
basal levels of their oxygen consumption rate (Figure 4-10 B).    
Given the fact that cells lacking mitochondrial Fh1 do not appear to be able to utilise 
mitochondrial respiration efficiently (reflected by the low SRC after FCCP addition 
that mimics physiological high stress conditions), we hypothesized that the cells 
must use a different metabolic pathway to do so. Since glycolysis is a pathway that 
many cancer cells utilise in order to meet their energy demands, we assessed the 
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glycolysis rates of LICs exhibiting low SRC. In order to do that, I measured the 
extracellular acidification rate (ECAR) of the cells, by utilising seahorse technology. 
ECAR can be measured in the surrounding media of the cells, which predominantly 
arises from the excretion of the lactic acid and is indicative of glycolysis taking place 
(TeSlaa and Teitell, 2014). 
In order to measure changes in ECAR, 2-deoxy-glucose (2-DG) was injected into the 
media. 2-DG is a glucose analogue that cannot be metabolised therefore resulting to 
the inhibition of the glycolytic pathway (Zhong et al., 2009). As a result, a decrease 
in ECAR after the addition of 2-DG will be specifically due to glycolysis shutdown. 
LICs lacking mitochondrial Fh1 exhibited a greater drop in ECAR after 2-DG 
addition. Furthermore, LICs lacking mitochondrial Fh1 exhibit higher basal levels of 
ECAR (Figure 4-11 A, B). These data suggest that cells could indeed rely more on 
the glycolytic pathway in order to meet their energetic demands.  
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Figure 4-9. Outline of SeaHorse technology to assess mitochondrial 
fitness of LICs lacking mitochondrial Fh1. (A) The SeaHorse assay 
measures key parameters of mitochondrial function and directly 
measures oxygen consumption rate (OCR), after the sequential addition 
of compounds that inhibit different components of the electron transport 
chain. Initially, addition of oligomycin will inhibit ATP synthase, 
resulting in a drop of OCR. Then addition of FCCP, a mitochondrial 
membrane potential uncoupler, mimicks a pysiological high energy 
demand by stimulating the chain to operate at a maximum capacity, and 
therefore OCR will increase. The addition of FCCP allows for extraction 
of information about how well the cells can respond to high energy 
demand situations, or by measuring the spare respiratory capacity of the 
system (SRC). The third and final injection is a mix of rotenone and 
antimycin alpha that will inhibit complex I and III of the electron 
transport chain respectively. This combination shuts down mitochondrial 
respiration and as a result, OCR decreases. (B) Graph indicating how the 
trace of OCR is plotted after the sequential addition of electron transport 
chain inhibitors. 
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Figure 4-10. LICs lacking mitochondrial Fh1 exhibit low spare respiratory 
capacity. (A) Oxygen consumption rate in LICs of the indicated genotypes under 
basal conditions and following the sequential addition of the ATP synthase 
inhibitor oligomycin, the uncoupler FCCP, and the electron transport chain 
inhibitors antimycin alpha and rotenone. 250,000 cells/well were used. Values 
were normalised against the number of cells per well using either trypan blue 
discrimination or propidium ionide exclusion by flow cytometry (B) Graph shows 
spare respiratory capacity (SRC) of indicated genotypes. SRC was calculated by 
substracting the value obtained right before the addition of oligomycin (i.e second 
measurement of basal respiration) from the value obtained after  the addition of 
FCCP. OCR was measured using the Seahorse XF24 analyser. Data are mean ± 
S.E.M. n = 4-9 technical replicates per genotype. This is a representative graph of 
an experiment repeated 3 times using n = 3-4 biological replicates per genotype.  
** p<0.01, Mann-Whitney test. 
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Figure 4-11. ECAR rate of LICs with low SRC. (A-B) The graphs show the same 
experiment performed twice using n = 1 biological replicate per genotype for (A) and 
n = 2 biological replicates per genotype for (B) with n = 4-9 technical replicates. 
ECAR is the extracellular acidification rate and is indicative of the glycolysis rate.  
2-DG is a non-specific inhibitor of glycolysis. 250,000 cells/well were used and 
normalisation was done using the cell number/well. Cell numbers were determined 
using either trypan blue discrimination or propidium ionide exclusion by flow 
cytometry. ECAR was measured using the Seahorse XF24 analyser. LICs were 
isolated from the bone marrow of primary sick recipient mice. Graphs show mean ± 
S.E.M, Data are non-significant at time-point of 2-DG addition, Mann-Whitney test. 
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4.4.4 In vitro characterisation of LICs exhibiting low SRC  
LICs isolated from the bone marrow of sick recipient mice were also assessed for 
their proliferation and apoptosis rates as well as cell cycle status. The proliferation 
rate of LICs with low SRC was comparable to that of control and control; FHCyt 
LICs (Figure 4-12). Furthermore, LICs with low SRC exhibited a trend of a lower 
percentage of late apoptotic (or early apoptotic) cells when assessed using the 
annexin V apoptotic assay (Figure 4-13 A-B change of axes on figure). Additionally, 
the fraction of sub-G0 cells of LICs exhibiting low SCR was significantly lower 
compared to control LICs, indicative of a lower apoptosis rate (Figure 4-14). Of 
note, when the experiment was repeated using two additional biological replicates, 
although the difference was not statistically significant, it was nevertheless of a 
similar trend. These data indicate that similarly to pre-LCs, LICs with low SRC 
exhibit a lower percentage of apoptotic cells. Additionally, based on the data of two 
independent experiments, LICs with low SRC exhibited more cells in G0/1 phase 
and fewer cells at the S and G2/M phases at the 24-hour time-point. At the 48-hour 
time-point, in one of the experiments cells exhibited a trend similar to that of 24-hour 
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Figure 4-12. Proliferation rate of LICs lacking 
mitochondrial Fh1. Proliferation curves of LICs in 
liquid culture. Cell were seeded at a concentration of 
150,000 cells/ml. Data are mean ± S.E.M. n = 3 
biological replicates per genotype with 3 technical 
replicates ns, Unpaired t test. 
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Figure 4-13. Apoptosis rate of LICs lacking mitochondrial Fh1. (A-B) Show 
experiment carried out twice using n = 1 biological replicate for (A) and n = 2 
biological replicates for (B). Apoptosis assay using annexin V-FITC and DAPI 
staining and analysed using flow cytometry 0 (left), 24 (middle) and 48 hours (right) 
after seeding. Data are mean ± S.E.M, n = 3 technical replicates. LICs were isolated 
from the bone marrow of sick recipient mice at the point of sacrifice. LICs were 
sorted based on the CD45.2 and c-Kit markers (CD45.2+/c-Kit+).  * p<0.05, 
**p<0.01, ***p<0.001 Unpaired t test. 
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Figure 4-14. Sub-G0 phase of LICs with low SRC indicative of cell death rate. 
(A) Graphs indicate percentage of cells (from the single cell gate used to exclude 
doublets) in sub-G0 phase at 24 hours (left) and at 48 hours (right). The sub-G0 
fraction was determined based on the DNA content of cells, using DAPI and 
analysing cells via flow cytometry. (B-C) Representative histograms indicating how 
the sub-G0 phase was determined at 24 hours (B) and at 48 hours (C) for control 
(left), control; FHCyt (middle) and Fh1fl/fl; FHCyt; Vav-iCre (right). The graphs are 
representative of two independent experiments. n = 3 biological replicates per 
genotype. Data are mean ± S.E.M, **** p<0.0001, Unpaired t test. 
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Figure 4-15. Cell cycle status of LICs with low SRC. Graph 
indicates percentage of cells at each stage of the cell cycle at 24 
hours (left) and 48 hours (right). n = 1 biological replicate for (A) 
and n = 2 biological replicates for (B). Analysis was performed 
using DAPI staining (containing 0.1% Triton) and cells were 
analysed via flow cytometry. Data are mean ± S.E.M., n = 3 
technical replicates per genotype. LICs were isolated from the 
bone marrow of sick recipient mice at the point of sacrifice. LICs 
were sorted based on the expression of CD45.2 and c-Kit markers 
(CD45.2+/C-Kit+). *p< 0.05, **p< 0.01, ***p<0.001, 
****p<0.0001, Unpaired t test. 
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4.4.5 Mitochondrial Fh1 is not required for the long term self-
renewal capacity of LICs 
As described in the experimental design section (section 4.3), 100,000 pre-LCs of the 
Mx1-Cre background that were c-Kit+ and expressing Mac-1 and Gr1 (Figure 4-16), 
were transplanted into sub-lethally irradiated primary recipient mice. After the 
chimerism of LICs reached 20-30 % in the peripheral blood of the recipient mice, the 
mice were administered with 6 injections of poly (I:C) in order to induce the deletion 
of Fh1. Interestingly, the chimerism of LICs significantly decreased after the first 
three injections of poly (I:C) when compared to the LIC chimerism before poly (I:C) 
administration (Figure 4-17A-B). Deletion of mitochondrial Fh1 was assessed before 
and after poly (I:C) administration (Figure 4-18 B). Of note, the chimerism of LICs 
in the control mice was not decreased, indicating that the decrease in chimerism was 
specifically due to deletion of mitochondrial Fh1. Fh1Δ/Δ; FHCyt; Mx1-Cre mice 
developed disease at a similar rate to control mice indicating that after LICs are 
established and generate AML in mice, the lack of mitochondrial Fh1 does not affect 
their self-renewal capacity (Figure 4-18 A). On that note, the recipient mice that 
succumbed to leukaemia exhibited infiltration of LICs in their bone marrow and 
spleen (Figure 4-19A-D). LICs isolated from the bone marrow of sick recipient mice 
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Figure 4-16. Flow cytometry profile of pre-LCs prior to transplantation in 
recipient mice. (A) Percentage of pre-LCs expressing myeloid markers (Mac-
1+/Gr1+). Myeloid cells are defined as the sum of Mac-1+/Gr1+ and Mac-1+. (B) 
Percentage of pre-LCs that are positive for c-Kit, within the myeloid 
compartment. Graphs show mean ± S.E.M. (C-E) Representative FACS dot 
plots of pre-LCs showing the expression of myeloid markers Mac-1 and Gr1. 
(C) control, (D) control; FHCyt and (E) Fh1fl/fl; FHCyt; Mx1-Cre pre-LCs. (F-H) 
Representative FACS histogram showing the expression of c-Kit in control pre-
LCs (F) control; FHCyt (G) and (H) Fh1fl/fl; FHCyt; Mx1-Cre pre-LCs. No 
statistical analysis was performed as n = 2 for control, n = 1 for control; FHCyt 
and n = 2 for Fh1fl/fl; FHCyt; Mx1-Cre. This is a representation of an experiment 
performed twice independently. 
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Figure 4-17.  LIC chimerism during poly (I:C) administration in 
primary recipient mice. (A-B) Chimerism of leukaemic cells in the 
peripheral blood of recipient mice. Data are presented as summary 
(A) and for each individual recipient (B). Statistics were performed 
for Fh1fl/fl; FHCyt; Mx1-Cre between pre-poly (I:C) and each time 
point onwards, and between genotypes at each time-point. No 
statistics were performed for control; FHCyt as there was only 1 
recipient available after the initiation of poly (I:C). Graphs show 
mean ± S.E.M. This is a representation of an experiment performed 
independently twice. n = 2 biological replicates for control, n = 1 
biological replicate for control; FHCyt and n = 2 biological replicates 
for Fh1fl/fl; FHCyt; Mx1-Cre, n = 3-8 recipient mice per genotype. 
PIPC = poly (I:C). Mann-Whitney test, * p< 0.05. 
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Figure 4-18. Mitochondrial Fh1 is not required for self-renewal of LICs 
in vivo. (A) Kaplan-Meier survival curve of sub-lethally irradiated primary 
recipient mice transplanted with 100,000 c-Kit+ pre-leukaemic cells obtained 
from serial re-plating assays. (B) Representative genomic PCR assessing 
deletion of Fh1 before poly (I:C) (top) and after poly (I:C) (bottom) 
administration. Lane 1 = control, lane 2 = control; FHCyt, lane 3 = Fh1fl/fl; 
FHCyt; Mx1-Cre. n = 2 biological replicates for control, n = 2 biological 
replicate for control; FHCyt and n = 2 biological replicates for Fh1Δ/Δ; FHCyt; 
Mx1-Cre, n = 5-8 recipient mice per genotype. Log-rank (Mantel-Cox) and 
Gehan-Breslow-Wicoxon tests were performed where data were statistically 
non-significant. fl- undeleted conditional allele, Δ- excised allele. This is a 
representation of an experiment carried out twice independently. 
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Figure 4-19. LIC infiltration in the bone marrow and spleen of 
primary recipient mice. Percentage of LICs (CD45.2+) in bone 
marrow (A) and spleen (B) that express myeloid markers (myeloid 
cells are defined as the sum of Mac-1+/Gr1+ and Mac-1+) in bone 
marrow (C) and spleen (D). Graphs show mean ± S.E.M. (E) Image 
of genomic PCR of Fh1 in LICs isolated from the bone marrow of 
sick recipient mice. lanes 1-2 = control, lanes 3-4 = control; FHCyt, 
lanes 5-8 = Fh1Δ/Δ; FHCyt; Mx1-Cre. n = 4-7 recipient mice analysed 
per genotype. Mann-Whitney test, * p< 0.05. fl- undeleted 
conditional allele, Δ- excised allele. This is a representation of an 
experiment carried out twice independently. 
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In order to assess whether mitochondrial Fh1 is required for the long-term self-
renewal capacity of LICs, I performed a secondary transplantation using LICs 
isolated from the bone marrow of sick primary recipient mice. Specifically, 10,000 
LICs (CD45.2+/ c-Kit+) were transplanted into sub-lethally irradiated secondary 
recipient mice, after ensuring efficient deletion of mitochondrial Fh1 (Figure 4-20B). 
Mice transplanted with control and Fh1Δ/Δ; FHCyt; Mx1-Cre LICs developed disease at 
the same rate, demonstrating that mitochondrial Fh1 is not required for the long-term 
self-renewal capacity of LICs (Figure 4-20A). Of note, the cohort of the control; 
FHCyt mice succumbed to AML 21 days after transplantation compared to the other 
two cohorts that succumbed to AML at approximately 50 days post transplantation 
(Figure 4-20A). Similarly, to the previous experiment, fewer recipient mice for the 
control; FHCyt cohort were used and as a result, the survival curve could have been 
skewed. Recipient mice that succumbed to AML exhibited LIC infiltration in their 
bone marrow and spleen (Figure 4-21A-B). Finally, LICs isolated from the bone 
marrow of sick recipient mice were assessed for deletion of mitochondrial Fh1 
(Figure 4-21 C). 
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Figure 4-20. LICs lacking mitochondrial Fh1 propagate AML in 
secondary recipient mice. (A) Kaplan- Meier survival curve of sub-lethally 
irradiated secondary recipient mice. 10,000 LICs (CD45.2+/c-Kit+) were isolated 
from primary recipient mice and transplanted into secondary recipient mice. (B) 
Gel images from genomic PCR performed to ensure deletion of Fh1 (top) and 
presence of cytosolic isoform of FH (bottom) in LICs before the injection into 
secondary recipient mice. fl- undeleted conditional allele, Δ- excised allele, 
FHCyt - presence of mitochondial isoform of FH. Lane 1-2 = control,  lane 3 = 
control; FHCyt, lane 4-5 = Fh1Δ/Δ; FHCyt; Mx1-Cre, lane 6 =   positive control of 
FHCyt. n = 2 biological replicates for control and Fh1Δ/Δ; FHCyt; Mx1-Cre, n = 1 
for control; FHCyt. n = 7-17 recipient mice per genotype. *** p< 0.001, ****p< 
0.0001, Log-rank (Mantel-Cox) and Gehan-Breslow-Wicoxon tests.  
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Figure 4-21. Infiltration of LICs in the bone marrow and spleen of 
secondary recipient mice. (A) Percentage of LICs (CD45.2+) (left) 
that express myeloid markers (right) (myeloid cells are defined as the 
sum of Mac-1+/Gr1+ and Mac-1+) in the bone marrow (A) and in the 
spleen (B). Graphs are mean ± S.E.M. (C) Image of genomic PCR of 
Fh1 in LICs isolated from the bone marrow of sick recipient mice. 
lanes 1-2 = control, lane 3 = control; FHCyt, lanes 4-6 = Fh1Δ/Δ; FHCyt; 
Mx1-Cre.     n = 3-11 recipient mice analysed per genotype. Unpaired t 
test, * p<0.05, ** p<0.01, ***p< 0.001 
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4.4.6 Fh1Δ/Δ; FHCyt; Mx1-Cre LICs exhibit low spare respiratory 
capacity 
 
Mitochondrial Fh1 causes a genetic truncation in the TCA cycle, and as a result 
could cause defects in mitochondrial respiration. One of the characteristics of such a 
defect is a low spare respiratory capacity (SRC). SRC was assessed by the Seahorse 
assay. 
As expected, LICs lacking mitochondrial Fh1 exhibited a very low SRC compared to 
control and control; FHCyt LICs (Figure 4-22A-B). Interestingly, when ECAR 
(which is indicative of the glycolysis rate of cells) was assessed, LICs lacking 
mitochondrial Fh1 exhibited comparable ECAR rates to control and control; FHCyt 
LICs after the addition of 2-DG (Figure 4-23). These data indicate that LICs with the 
low SRC might be utilising another source other than glycolysis (such as fatty acid 
oxidation), in order to meet their energy demands under stressful conditions.   
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Figure 4-22. Fh1Δ/Δ; FHCyt; Mx1-Cre LICs exhibit low SRC. (A) Oxygen 
consumption rate in LICs of the indicated genotypes under basal conditions 
and following sequential addition of the ATP synthase inhibitor 
oligomycin, the uncoupler FCCP, and the electron transport chain 
inhibitors antimycin alpha and rotenone. 250,000 cells/well were used. 
Values were normalised against the number of cells per well using either 
trypan blue discrimination or propidium ionide exclusion by flow 
cytometry. Stars indicate statistical significance between control and Fh1Δ/Δ; 
FHCyt; Mx1-Cre or control; FHCyt and Fh1Δ/Δ; FHCyt; Mx1-Cre.  (B) Graph 
shows spare respiratory capacity (SRC) of indicated genotypes. SRC was 
calculated by substracting the value obtained right before the addition of 
oligomycin (i.e second measurement of basal respiration) from the value 
obtained after  the addition of FCCP. OCR was measured using the 
Seahorse XF24 analyser. Data are mean ± S.E.M. n = 3-5 technical 
replicates per genotype. This is a representative graph of an experiment 
repeated 2 times using n = 1-2 biological replicates per genotype. *p< 0.05, 
** p<0.01, Mann-Whitney test. 
 
Chapter 4 – The role of mitochondrial Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  154 
 
Figure 4-23. ECAR rate of Fh1Δ/Δ; FHCyt; Mx1-Cre LICs. 
ECAR is the extracellular acidification rate and is indicative of 
the glycolysis rate.  2-DG is a non-specific inhibitor of glycolysis. 
250,000 cells/well were used and normalisation was done using 
the cell number/well. Cell numbers were determined using either 
trypan blue discrimination or propidium ionide exclusion by flow 
cytometry. ECAR was measured using the Seahorse XF24 
analyser. LICs were isolated from the bone marrow of primary 
sick recipient mice. Data are mean ± S.E.M. n = 3-5 technical 
replicates per genotype. This is a representative graph of an 
experiment repeated 2 times using n = 1-2 biological replicates 
per genotype. Statistics were performed for the values obtained 
after the addition of 2-DG. Data are non-significant, Mann-
Whitney test. 
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4.4.7 Fh1Δ/Δ; FHCyt; Mx1-Cre LICs exhibit normal apoptosis and 
cell cycle status 
LICs that were isolated from the bone marrow of primary recipient mice were 
assessed for the cell cycle status as well as their apoptosis rates. In terms of 
apoptosis, LICs lacking mitochondrial Fh1 exhibited a higher but non-significant 
percentage of apoptotic cells at the 24 hour time-point (Figure 4-24 figure axes 
changed). 
On a similar note, LICs lacking mitochondrial Fh1 only exhibited a higher 
percentage of cells in the G0/1 phase of the cell cycle and a lower percentage of cells 
in the G2/M phase (Figure 4-25). 
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Figure 4-24. Apoptosis rate of Fh1Δ/Δ; FHCyt; Mx1-Cre LICs. Graphs 
show percentage of cells. The apoptosis assay was performed using 
annexin V-FITC and DAPI staining, via flow cytometry at 0 hours (A), 24 
hours (B) and at 48 hours (C). Data are mean ± S.E.M., n = 2 biological 
replicates for control and Fh1Δ/Δ; FHCyt; Mx1-Cre and n = 1 for control; 
FHCyt with n = 4-6 technical replicates. LICs were isolated from the bone 
marrow of sick primary recipient mice at the point of sacrifice. LICs were 
sorted based on the expression of CD45.2 and c-Kit markers (CD45.2+/c-
Kit+).  * p<0.05, **p<0.01, Unpaired t test. 
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Figure 4-25. Cell cycle status of Fh1Δ/Δ; FHCyt; Mx1-Cre LICs. Graphs 
indicate percentage of cells at each stage of the cell cycle at 0 hours (A), 
24 hours (B) and 48 hours (C). Data are mean ± S.E.M., n = 2 biological 
replicates for control and Fh1Δ/Δ; FHCyt; Mx1-Cre and n = 1 for control; 
FHCyt with n = 4-6 technical replicates. LICs were isolated from the bone 
marrow of sick primary recipient mice at the point of sacrifice. LICs were 
sorted based on the expression of CD45.2 and c-Kit markers (CD45.2+/C-
Kit+).  * p<0.05, **p<0.01, ****p< 0.0001, Unpaired t test. 
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4.5 Discussion 
4.5.1 Mitochondrial Fh1 and genetically intact TCA are 
important for LIC generation in vivo 
In this chapter I demonstrated that pre-LCs lacking mitochondrial Fh1 generate AML 
at a much lower rate compared to control and control; FHCyt pre-LCs. Specifically, 
while 76 % of mice injected with LICs lacking mitochondrial Fh1 survived, only 25 
% and 30 % of control and control; FHCyt mice respectively survived. In that 
context, from the 6 biological replicates of Fh1fl/fl; FHCyt; Vav-iCre only 3 replicates 
generated disease in recipient mice. 
Deletion of the mitochondrial isoform of Fh1, resulted in a genetic truncation in the 
TCA cycle. In order to assess the impact of the mitochondrial Fh1 deletion on 
mitochondrial respiration, I utilised the seahorse assay. Interestingly, LICs lacking 
mitochondrial Fh1 exhibited very low SRC compared to control and control; FHCyt 
LICs. This mitochondrial respiration deficit could potentially explain the inability of 
the pre-LCs to generate disease. In fact, recent studies have shown that oxidative 
phosphorylation (and mitochondrial respiration) are important for the survival of 
cancer cells. By using agents that blocked mitochondrial protein translation, 
specifically complexes of the electron transport chain, it was possible to decrease 
oxygen consumption and preferentially induce cell death in AML cell lines (Škrtić et 
al., 2011). In another study, knockdown of the mitochondrial proteasome member 
CIcP led to cell death of AML cell lines, as CIcP knockdown led to inhibition of 
oxidative phosphorylation and mitochondrial metabolism (Cole et al., 2015). The 
emerging studies have therefore indicated that mitochondrial respiration can be 
critical for the survival of leukaemic cells, thus offering new insight into the 
metabolic adaptation of cancer cells.   
4.5.2 Mitochondrial Fh1 and a genetically intact TCA are not 
required for LIC maintenance in vivo 
Furthering this study, I wanted to assess whether a genetically intact TCA is also 
important for the maintenance of LICs in vivo. To that end, I isolated control, 
control; FHCyt and Fh1fl/fl; FHCyt; Mx1-Cre LSK cells and generated pre-LCs using 
the Meis1/ Hoxa9 model. I then injected 100,000 c-Kit+ pre-LCs into sub-lethally 
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irradiated primary recipient mice. Once the LIC chimerism reached 20-30 % in the 
peripheral blood of recipient mice, I treated the mice with poly (I:C) in order to 
induce deletion of Fh1. Of note, in Fh1fl/fl; FHCyt; Mx1-Cre cells, poly (I:C) 
treatment resulted in the deletion of mitochondrial Fh1. Deletion of mitochondrial 
Fh1 did not affect the self-renewal capacity of LICs as mice succumbed to AML at a 
similar latency to mice injected with control or control; FHCyt LICs. Furthermore, 
upon transplantation into secondary recipient mice, Fh1Δ/Δ; FHCyt; Mx1-Cre LICs 
generated AML at a similar rate to control LICs. These data indicate that 
mitochondrial Fh1 (and effectively a genetically intact TCA) are not required for 
long term self-renewal capacity of LICs. Of note, the recipient mice injected with 
control; FHCyt LICs succumbed to AML faster compared to the other two cohorts. It 
is unlikely that the additional expression of fumarate hydratase (endogenous 
expression and the cytosolic transgene expression), exert a positive effect on LICs, as 
this was only observed in this particular experiment but was not observed in the 
transplantations using the Vav Cre model.    
In summary, the data indicate that Fh1 (and effectively genetically intact TCA) are 
important for the generation of LICs but are dispensable for the long-term self-
renewal capacity of LICs and maintenance of AML. Indeed, there are 
genes/pathways that have been shown to be differentially required for the initial (pre-
leukaemic) and later (fully leukaemic) stages of the disease. We have previously 
demonstrated in our lab that, Hif-2a deletion accelerated the development of LICs 
but had no impact on LIC maintenance in a knock-in model of MLL-AF9 and the 
retroviral model of Meis1/Hoxa9 (Vukovic et al., 2015). Furthermore, in another 
study, mTORC1 inactivation abolished the tumour-initiating capacity of LIC cells 
but did not affect their self-renewal capacity (Hoshii et al., 2012). Another study 
looked at the role of the polycomb repressive complex 2 (PRC2) component EZH2 in 
the generation and maintenance of AML. Using the retroviral model of MLL-AF9 the 
authors showed that Ezh2-null cells were unable to re-plate in vitro indicating that 
Ezh2 impaired leukaemic colony formation (Neff et al., 2012). Interestingly, by using 
Ezh2- MLL-AF9 cells of the Mx1-Cre background (thus allowing for inducible 
deletion of Ezh2), the cells generated disease in vivo at an equal rate as their wild 
type counterparts, but exhibited prolonged disease latency when transplanted in 
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secondary recipient mice. These data therefore indicated that Ezh2 is required for the 
initiation of the disease but is dispensable once LICs are established.  
The studies described above demonstrate that while some pathways/genes are critical 
for the initiation of AML, they are dispensable for the maintenance of AML and self-
renewal capacity of LSCs. In a similar manner, mitochondrial Fh1 and genetically 
intact TCA appear to be important for the initial stages of the disease but not 
thereafter. 
4.5.3 LICs lacking mitochondrial Fh1 exhibit higher ECAR 
rates 
Given the fact that cells lacking mitochondrial Fh1 exhibited low SRC, which is 
through to reflect how well a cell can respond to high energy demands we wanted to 
assess whether these cells utilise more glycolysis in order to compensate for their 
inability to efficiently utilise mitochondrial respiration. For that we used the seahorse 
assay that offers simultaneous measurements of OCR and ECAR, reflecting 
mitochondrial respiration and glycolysis rates respectively. Based on 2 independent 
experiments, we observed that LICs with low SRC, appeared to have a sharper drop 
in ECAR after the addition of the glycolytic inhibitor 2-DG, and also exhibited 
higher basal ECAR rate. This could potentially indicate that LICs rely more on 
glycolysis compared to control and control; FHCyt LICs. However, it is important to 
consider that ECAR (which measures protons) arises from both lactate secretion 
(indicative of glycolysis) and respiratory acidification (in the form of CO2) 
(Mookerjee et al., 2015). Therefore, ECAR is only indicative of glycolytic rates and 
validation experiments such as lactate measurements may be additionally 
informative.  
4.5.4 Pre-LCs lacking mitochondrial Fh1 exhibit lower 
apoptosis rates 
Pre-LCs lacking mitochondrial Fh1 exhibited similar proliferation rates to control 
and control; FHCyt pre-LCs as well as similar cell cycle status. Interestingly, the cells 
lacking mitochondrial Fh1 exhibited a lower percentage of apoptotic and late 
apoptotic cells in the span of 48 hours. Furthermore, the sub-G0 content of cells can 
provide information regarding the apoptotic/late apoptotic fraction of cells. That is 
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because cells in the late stage of apoptosis lose DNA content due to their membrane 
breaking down. With that in mind, it was interesting to see that pre-LCs lacking 
mitochondrial Fh1 exhibited a significantly lower percentage of cells at sub-G0 at 
the 48-hour time-point, corroborating with the data from the annexin V assay. 
Similarly, LICs lacking mitochondrial Fh1 exhibited a trend of fewer apoptotic/late 
apoptotic cells as well as a significantly lower percentage of cells in the sub-G0 
phase. Furthermore, LICs exhibited a higher percentage of G0/1 cells at the 24-hour 
time-point, potentially indicating that there is a larger fraction of the cells at a resting 
phase, compared to control and control; FHCyt LICs. However, if that were the case it 
would be expected that cells would have a lower proliferation rate, which was not 
observed.  
It has been suggested that complete or partial OXPHOS defects may induce 
apoptosis resistance. Specifically, inhibition of the respiratory chain can suppress the 
activation of the pro-apoptotic BCL-2 proteins Bax and Bak (Tomiyama et al., 2006). 
Thus, the decreased apoptosis rate observed in Fh1fl/fl; FHCyt; Vav-iCre cells could be 
attributed to the disruption of OXPHOS due to deletion of mitochondrial Fh1. 
Interestingly, evasion of apoptosis has been observed in FH-null renal cancer cells 
(Bardella et al., 2012). The authors found that AMPK activation, as a result of 
fumarate accumulation, led to an increase of the inhibitory phosphorylation of the 
pro-apoptotic protein BAD (Bardella et al., 2012). Based on those observations, the 
authors proposed that increased fumarate could activate G-protein coupled receptors, 
which may lead to activation of AMPK. It has been shown previously by others and 
by our lab that FHCyt expression metabolises the accumulated fumarate, as a result of 
mitochondrial Fh1 deletion, thus bringing fumarate concentration to almost 
physiological levels. However, we have observed that fumarate is still significantly 
increased in Fh1fl/fl; FHCyt; Vav-iCre compared to control cells. As a result, it is 
possible that elevated fumarate concentration is enough to activate AMPK and 
effectively inhibit BAD.  
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4.6 Summary 
In summary, in this chapter the data indicate that Fh1 (and effectively genetically 
intact TCA) are important for the generation of LICs but are dispensable for the 
long-term self-renewal capacity of LICs and maintenance of AML. Furthermore, 
LICs isolated from the bone marrow of sick recipient mice exhibited low SRC.  
Based on other studies, low SRC could be the reason why cells were unable to 
efficiently generate AML in mice, as SRC is thought to reflect how well cells can 
respond to high energy demands and also support long-term function. Additionally, 
LICs with low SRC could potentially utilise more glycolysis in order to compensate 
for their inability to efficiently utilise mitochondrial respiration. Finally, pre-LCs and 
LICs lacking mitochondrial Fh1, exhibited lower rates of apoptosis, that could be 
attributed to inhibition of pro-apoptotic proteins as a result of either OXPHOS 
disruption or AMPK activation. This chapter has provided insight about the role of 
oxidative respiration in AML cells in the Meis1/Hoxa9 background. However, it will 
be informative to assess the role of Fh1 and mitochondrial respiration using 
additional AML models. 
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5 The role of Fh1 in leukaemic transformation 
5.1 Introduction  
5.1.1 FH in AML 
AML is a clonal disease that is initiated from a small number of pre-leukaemic cells 
(pre-LCs) that have acquired initiating mutational events. Additional genetic hits lead 
to the generation of leukaemia-initiating cells (LICs). Pre-LCs consist of self-
renewing haematopoietic stem and progenitor cells that can give rise to leukaemia in 
vivo with variable latency, and upon gradual accumulation of co-operative hits, LICs 
are functionally defined by their capacity to generate fully penetrant AML, with a 
short latency in murine models (Pandolfi et al., 2013). 
Mutations of the metabolic enzyme IDH1/2 genes represent a novel class of 
mutations in AML, present in approximately 20 % of all AML cases (Mardis et al., 
2009). IDH1 and IDH2 enzymes catalyse the oxidative decarboxylation of isocitrate 
to a-kegotlutarate in the cytoplasm and mitochondria respectively. Mechanistically, 
IDH1/2 mutations result in the accumulation of the metabolite 2-hydroxyglutarate. 
This metabolite accumulates at high concentrations in the cell at the expense of the 
metabolite a-ketoglutarate, thus leading to the inhibition of dioxygenase enzymes 
(that utilise a-ketoglutarate as a co-factor). Such enzymes include TET proteins and 
histone demethylases. The activity of the mutant IDH1/2 enzymes affect the 
energetic landscape of the cells, and the resultant generation of the 2-
hydroxyglutarate (referred to as an “oncometabolite”), leads to epigenetic 
reprogramming, disruption of normal differentiation and contributes to a malignant 
phenotype (Rakheja et al., 2012). The identification of IDH mutations as a novel 
class of contributors to AML, opened the avenue to study metabolic enzymes and 
their role in malignant transformation.  
Fh1 (FH in humans) is a bona fide tumour suppressor in kidney cancer and is an 
essential component of the TCA cycle (see section 1.11). However, its role in 
haematological malignancies has not been established. A study published in 1960 
found that FH activity was significantly elevated in acute monocytic leukaemia as 
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well as moderately increased in acute granulocytic leukaemia. Interestingly, such 
increase was not observed in acute lymphocytic leukaemia cells (Tanaka et al., 
1961). Similarly, a recent proteomics study identified that 7 out of 12 human AML 
patient samples that were studied had elevated FH protein levels. The study 
compared peripheral myeloid blast cells isolated from AML patients to CD34+ cells 
isolated from healthy individuals (Elo et al., 2014).  
Additionally, a search on Oncomine, a cancer genomics database, indicates that FH 
is both up- and down- regulated in different sub-types of AML with no apparent 
association with cytogenetics (oncomine.com). For instance, in a study looking at 43 
AML patient samples, FH mRNA expression was deregulated in a fashion that was 
not consistent with FAB subtype, FLT3 mutation status or MLL re-arrangement 
status (Gutierrez et al., 2005). 
The data obtained from different studies up to this point do not provide evidence to 
support whether the deregulation of the enzymatic activity of FH has a causal role in 
the generation of myeloid leukaemia or whether it is a consequence of the disease. 
Therefore, the aim of this chapter was to uncover the role of Fh1 in AML using in 
vivo and in vitro murine models. The specific aims of the chapter are outlined below 
(See section 5.2). 
5.2 Aims  
The purpose of the following experiments was to determine the role of Fh1 at 
different stages of leukaemic transformation. In particular, this chapter aims to 
determine the role of Fh1: In the generation of pre-leukaemic cells (pre-LCs) 
 In the maintenance of pre-LCs  
 In the maintenance of leukaemia-initiating cells (LICs): 
 By acute deletion of Fh1 in vitro utilising lentivirally 
expressed Cre 
 By acute inducible deletion of Fh1 in vivo utilizing the Mx1-
Cre model 
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5.3 Experimental design 
In order to address the aims of this chapter, the retroviral model of Meis1/Hoxa9 was 
utilised, thus allowing for the assessment of the requirement of Fh1 at different 
stages of leukaemic transformation. In this model primitive cells of the 
haematopoietic compartment are isolated and subsequently infected with retroviruses 
over-expressing Meis1 and Hoxa9. The cells over-expressing Meis1 and Hoxa9 are 
then selected based on their antibiotic resistance to puromycin and neomycin, 
respectively. The experimental design was modified in order to address the above 
points individually, and are described via schematic representations below. Figure 
5-1 describes the experimental design used to address whether Fh1 plays a role in the 
generation of pre-LCs. Figure 5-2 describes the experimental design used to address 
whether Fh1 plays a role in the maintenance of pre-LCs and LICs in vitro. 
Finally, in order to address whether Fh1 plays a role in the maintenance of LICs in 
vivo, the Mx1-Cre mouse model was used. Mx1 (myxovirus resistance-1) is a vital 
part of the viral defence mechanism and its expression can be induced in response to 
interferon. Cre recombinase under the Mx1 promoter can be activated by mimicking 
viral infection by the administration of the synthetic double-stranded RNA analogue 
poly:I:polyC (Kühn et al., 1995). A background activation of approximately 2-3 % is 
typically observed in the Mx1-Cre model as a result of endogenous interferon (Kühn 
et al., 1995). Mx1-Cre has been shown to be active in several tissues including heart, 







Chapter 5 – The role of Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  167 
Figure 5-1. Experimental design. C-Kit+ cells isolated from 14.5dpc foetal 
livers were transduced with Meis1/Hoxa9, MLL-AF9, MLL-ENL and AML-
ETO9a retroviruses and plated into methylcellulose, in order to assess their 
clonogenic potential. Specifically, 250,000 c-Kit+ cells underwent two rounds of 
infection with the respective viruses using retronectin-coated plates. After 48 
hours, the cells were incubated with media containing antibiotics in order to 
select for the cells expressing the retroviruses (for Meis1/Hoxa9 selection 
puromycin/neomycin was used. Neomycin was used for the rest of the plasmid-
containing viruses). Following 48 hours of antibiotic selection, cells were 
seeded on semi-solid media (25,000 cells for control, and all surviving cells for 
Fh1fl/fl; Vav-iCre cells). Colonies were counted 6 days after plating.  This 
protocol was used to generate samples for figures 5-4 –5- 6.   
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Figure 5-2. Experimental design. Fh1+/+ and Fh1fl/fl (without Vav-iCre) LSK (lineage- 
Sca-1 + c-Kit+) cells sorted from 14.5dpc foetal livers were co-transduced with Meis1 and 
Hoxa9 retroviruses and serially re-plated 3 times. The cells were subsequently infected 
with a bicistronic lentivirus expressing Cre and iVenus (or with lentivirus expressing the 
empty vector). iVenus+ cells were sorted and plated into methylcellulose. In parallel, 
Fh1+/+ and Fh1fl/fl pre-LCs were transplanted into recipient mice. LICs (CD45.2+c-Kit+ 
cells) were sorted from leukaemic recipients, transduced with Cre lentivirus (or with 
lentivirus expressing the empty vector) and after sorting, 25,000 cells were plated into 
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Figure 5-3. Experimental design. Control and Fh1fl/fl; Mx1-Cre LSK (lineage- 
Sca-1 + c-Kit+) cells sorted from 14.5dpc foetal livers were co-transduced with 
Meis1 and Hoxa9 retroviruses and were serially re-plated. The resultant pre-LCs 
were transplanted into sub-lethally irradiated CD45.1+/CD45.2+ recipients 
(100,000 cells per recipient). Once chimerism of leukaemic CD45.2+ cells 
reached 20 % in the peripheral blood of recipient mice, mice were injected 
intra-peritoneally 6-8 times every alternate day with 300µg poly (I:C). Then 
10,000 LICs (CD45.2+c-Kit+) from primary recipients were transplanted to 
secondary recipients. This protocol was used to generate figures 5-9 to 5-12.   
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5.4.1 Fh1 is essential for the generation of pre-LCs 
As described in Figure 5-1 stem and progenitor cells (c-Kit+ cells) were isolated from 
the foetal liver of 14.5 dpc of control or Fh1fl/fl; Vav-iCre embryos and were then 
infected with retroviruses expressing oncogenes or chromosomal translocations 
known to be involved in leukaemogenesis (described in section 1.9.3). When stem 
and progenitor cells lacking Fh1 were transduced with Meis1/Hoxa9, MLL-ENL, 
MLL-AF9 and AML-ETO9a retroviruses, they failed to generate colonies in vitro, 
indicating that cells require Fh1 in order to undergo leukaemic transformation 
(Figure 5-4). Furthermore 48 hours post infection (and before the addition of 
antibiotics), there were fewer Fh1fl/fl; Vav-iCre surviving cells compared to control 
cells indicating that expression of oncogenes/chromosomal translocations is not able 
to rescue the poor survival capacity of cells lacking Fh1(Figure 5-5; Figure 5-6).  
Chapter 5 – The role of Fh1 in leukaemic transformation 
Doctor of Philosophy          University of Edinburgh 2017  171 
 
Figure 5-4. Fh1-deficient c-Kit+ cells fail to undergo transformation in vitro. (A-D) 
Shows colony counts 6 days after plating for retroviruses (A) Meis1/Hoxa9, (B) AML-
ETO9a, (C) MLL-ENL, (D) MLL-AF9. (E-H) Shows representative colony images (10X 
magnification) (E) Meis1/Hoxa9, (F) AML-ETO9a, (G) MLL-ENL, (H) MLL-AF9. Data 
are mean ± S.E.M.  n = 4-6 biological replicates per genotype. 
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Figure 5-5. A higher percentage of Fh1fl/fll; Vav-iCre cells undergo apotosis 
compared to control cells during leukaemic transformation. The percentage of 
cells that are annexinV-DAPI- (live), annexinV+DAPI- (apoptotic) and 
annexinV+DAPI+ (late apoptotic) using the retroviruses (A) Meis1/Hoxa9, (B) 
AML1-ETO9a, (C) MLL-ENL, (D) MLL-AF9. The percentage indicates the fraction 
of cells from the parental gate (lymphocytes) during leukaemic transformation but 
before antibiotic selection. n = 2 biological replicates, Graphs show mean ± S.E.M. 
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Figure 5-6. Representative FACS plots of annexinV staining during leukaemic 
transformation. (A-B) AML1-ETO9a, (C-D) MLL-AF9, (E-F) MLL-ENL, (G-H) 
Meis1/Hoxa9. In the left-hand panels apoptosis prolife of control cells 48 hours after 
retroviral infection. The apoptosis profile of Fh1fl/fll; Vav-iCre cells is shown in the 
right-hand panels. The percentage of cells that are annexinV-DAPI- (live), 
annexinV+DAPI- (apoptotic) and annexinV+DAPI+ (late apoptotic) using the 
retroviruses AML1-ETO9a, MLL-AF9, MLL-ENL, and Meis1/Hoxa9. 
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5.4.2 Fh1 is essential for the maintenance of pre-LCs 
I next wanted to determine the impact of Fh1 deletion on the colony formation 
capacity of pre-LCs. I transduced Fh1+/+ (Vav-iCre negative) and Fh1fl/fl (Vav-iCre 
negative) foetal liver LSK (lineage- Sca-1 + c-Kit+) cells with Meis1 and Hoxa9 
retroviruses. Following three rounds of serial re-plating, the cells were infected with 
Cre –iVenus lentivirus (or lentivirus containing the empty vector pRRL–iVenus), to 
acutely induce deletion of Fh1 (for experimental design see Figure 5-2). Contrary to 
Fh1+/+ cells expressing Cre, Fh1fl/fl cells failed to generate colonies but occasionally 
generated microscopic clusters that consisted of approximately 50-100 cells (Figure 
5-7 B, C-D). Deletion of Fh1 was assessed via genomic PCR of pre-LCs sorted 
based on iVenus positivity, 48 hours post-infection (Figure 5-7 E). Notably, Fh1fl/fl 
cells expressing the empty vector (pRRL-iVenus) generated significantly fewer 
colonies compared to Fh1+/+ cells, potentially indicating lentiviral-related toxicity 
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Figure 5-7. Acute deletion of Fh1 in pre-LCs abolishes their clonogenic capacity. 
(A) Shows number of colonies generated by cells expressing the empty vector pRRL-
iVenus at CFC3 (B) Shows number of colonies generated by Cre-expressing cells 
(pRRL-Cre-iVenus). Data are ± S.E.M., n = 3 biological replicates per genotype. (C-
D) Representative images of colonies generated by Fh1+/+ (C), or Fh1fl/fl cells (10x 
magnification) (D). (E) Representative gel showing PCR amplification of genomic 
DNA sorted from cells expressing either pRRL-iVenus emty vector or with pRRL-
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Cre-iVenus (Lanes 1-3 = Fh1+/+ infected with pRRL-Cre-iVenus, lanes 4-6 = Fh1fl/fl 
infected with pRRL-iVenus, lanes 7-9 = Fh1fl/fl infected pRRL-Cre-iVenus). fl- 
undeleted conditinal allele, Δ- excised allele, +-wild type allele. **p value< 0.005, 
Unpaired t test. 
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5.4.3 Fh1 is essential for the self-renewal capacity of LICs in 
vitro 
In order to determine the requirement of Fh1 for the maintenance of LICs, foetal 
liver LSK cells from Fh1+/+ (Vav-iCre negative) and Fh1fl/fl (Vav-iCre negative) 
embryos were infected with Meis1 and Hoxa9 retroviruses. After three rounds of 
serial re-plating in semi-solid media the pre-LCs were transplanted into sub-lethally 
irradiated recipients. At the point where the primary recipient mice developed AML 
(i.e over 30 % of LIC chimerism in the peripheral blood of recipient mice), LICs 
were isolated and were then infected with lentiviruses expressing either Cre or the 
empty vector and were plated in semi-solid media to assess their clonogenic capacity 
(for experimental design see Figure 5-2). 
Fh1-deficient LICs failed to generate colonies indicating that Fh1 is required for LIC 
self-renewal (Figure 5-8 A, B). Similarly to pre-LCs, LICs lacking Fh1 occasionally 
generated relatively small colonies compared to the large colonies generated by 
Fh1+/+ cells expressing Cre (Figure 5-8 C, D). Deletion of Fh1 was confirmed by 
genomic PCR of LICs isolated based on iVenus positivity, 48 hours post-infection 
(Figure 5-8 E). 
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Figure 5-8. Acute deletion of Fh1 in LICs abolishes their clonogenic capacity. 
(A) Shows number of colonies generated by cells expressing the empty vector. (B) 
Shows number of colonies generated by Cre-expressing cells. LICs were isolated 
from the bone marrow of mice that succumbed to AML and were then infected with 
lentivirally expressed Cre, to induce deletion of Fh1. Data are ± S.E.M. n = 3 
biological replicates per genotype. (C-D) Representative images of colonies 
generated by Fh1+/+ (C), or Fh1fl/fl cells (10x magnification). (E) Representative gel 
showing PCR amplification of genomic DNA sorted from cells expressing either 
empty vector (pRRL-iVenus) or Cre (pRRL-Cre-iVenus). Lane 1 = Fh1+/+ infected 
with pRRL-Cre iVenus, lanes 2-4 = Fh1fl/fl infected with pRRL-iVenus, lanes 5-7 = 
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Fh1fl/fl infected with pRRL-Cre-iVenus. fl- undeleted conditional allele, Δ- excised 
allele, + wild type allele. Unpaired t test. 
 
 
5.4.4 Fh1 deletion can result in a decrease of LICs in vivo 
To assess whether Fh1 is required for the maintenance of LICs in vivo, LSK cells 
from 14.5 foetal liver embryos of the Mx1-Cre background were infected with 
retroviruses expressing Meis1 and Hoxa9 (For experimental design and description 
of the Mx1-Cre model, see section 5.3). After three rounds of serial re-plating 
100,000 pre-LCs (c-Kit+; double positive for Mac-1+, Gr1+) (see profile in Figure 
5-9) were transplanted into primary recipient mice. The mice were monitored for 
clinical signs of AML, including hunched posture, slow movement, anaemia (white 
paws) and difficulty breathing. Once the chimerism of leukaemic cells (CD45.2+) 
reached 20-30 % in the peripheral blood of recipient mice (CD45.1+/CD45.2+), mice 
were administered 6-8 intraperitoneal injections of poly (I:C) in order to induce 
deletion of Fh1 within the leukaemic cell compartment (Figure 5-10; for more details 
on experimental design, see Figure 5-3). The primary recipient mice were monitored 
in order to assess the chimerism of the leukaemic cells in the peripheral blood. 
10,000 LICs (CD45.2+/c-Kit+) LICs were then isolated from the bone marrow of 
primary recipient mice that succumbed to AML and were transplanted into sub-
lethally irradiated secondary recipients. LICs are functionally defined by their 
capacity to generate fully penetrant AML, with a short latency in murine models 
(Pandolfi et al., 2013). 
We found that upon administration of poly (I:C), the chimerism of Fh1Δ/Δ; Mx1-Cre 
leukaemic cells (cells with deletion of Fh1 after they were treated with poly (I:C)) 
decreased significantly after the third injection of poly (I:C) compared to chimerism 
of the control cells (Figure 5-10;  A). Specifically, while control recipient mice 
exhibited increasingly high chimerism in their peripheral blood (20-30% before poly 
(I:C) compared to 50-60 % after 8 injections of poly (I:C)), Fh1Δ/Δ; Mx1-Cre 
recipient mice exhibited decreased chimerism (40-60 % before poly (I:C) compared 
to 1-2 % after 8 injections of poly (I:C)). Notably, after the third injection of poly 
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(I:C), there was a decrease in the chimerism of the leukaemic cells in the control 
mice, indicative of the effect of poly (I:C) on leukaemic cells irrespective of the 
status of Fh1 deletion (Figure 5-10;  A). 
Interestingly, two weeks after the last poly (I:C) injection the chimerism of Fh1Δ/Δ; 
Mx1-Cre cells increased between 20-80 % (Figure 5-10; A). Recipient mice 
succumbed to AML as indicated by infiltration of LICs in the bone marrow and 
spleen (Figure 5-10; C, D). Genomic PCR performed on LICs isolated from the bone 
marrow of sick recipient mice at the point of sacrifice, indicated that Fh1 deletion in 
the bone marrow was incomplete, suggesting that there might be two populations co-
existing, one with undeleted Fh1 and one with a complete deletion of Fh1(Figure 
5-10; B). In order to assess whether the leukaemic cells with Fh1 deletion could 
outcompete the other population and propagate leukaemia, we isolated CD45.2+ c-
Kit+ LICs from the bone marrow of primary recipient mice and transplanted them 
into sub-lethally secondary recipient mice (n = 1 control, n = 2 Fh1Δ/Δ; Mx1-Cre). 
Recipients from both cohorts developed leukaemia at a similar same rate and bone 
marrow was largely populated by LICs (Figure 5-11 B). Genomic PCR analysis of 
LICs isolated from the peripheral blood of recipient mice, showed that some of the 
recipients injected with Fh1Δ/Δ; Mx1-Cre LICs exhibited full deletion of Fh1 (Figure 
5-11A).  
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Figure 5-9. Flow cytometry profile of control and Fh1fl/fl; Mx1-Cre pre-LCs 
prior to transplantation in recipient mice. (A) Percentage of pre-LCs expressing 
myeloid markers (Mac1+/Gr1+). (B) Percentage of pre-LCs that are positive for c-Kit, 
within the Mac1+/Gr1+ compartment. (C-D) Representative FACS plots of control 
pre-LCs (C) and Fh1fl/fl; Mx1-Cre pre-LCs (D) expressing the myeloid markers Mac1 
and Gr1. (E-F) Representative FACS histogram showing the expression of c-Kit in 
control pre-LCs (E) and Fh1fl/fl; Mx1-Cre pre-LCs (F). Data are ± S.E.M. with n = 2 
biological replicates for control and n = 3 biological replicates for Fh1fl/fl; Mx1-Cre. 
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Figure 5-10. Acute deletion of Fh1 in LICs reduces their self-renewal capacity in 
vivo. (A) Chimerism of leukaemic cells in the peripheral blood of recipient mice. 
Chimerism was assessed two days after each poly (I:C) administration and two 
weeks after the last injection. (B) Representative gel of genomic PCR assessing the 
deletion of Fh1 before poly (I:C) treatment (top gel: lane 1= Control, lanes 2-3 = 
Fh1fl/fl; Mx1-Cre) and after 6 doses of poly (I:C) treatment (bottom gel: lanes 1-2 = 
Control, lanes 3-4= Fh1Δ/Δ; Mx1-Cre.) PCR was performed on leukaemic cells 
isolated from the peripheral blood of recipient mice that were sorted for CD45.2+. 
(C) Chimerism of leukaemic cells in the bone marrow (left) and spleen (right) of 
recipient mice at the point of sacrifice. (D) Percentage of myeloid cells within the 
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CD45.2 compartment, in the bone marrow (left) and spleen (right) of recipient mice 
at point of sacrifice (myeloid cells are defined as the sum of Mac1+/Gr1+ and 
Mac1+). n = 2-3 biological replicates per genotype, 6-10 recipient mice per genotype. 
PB – Peripheral Blood; BM – Bone Marrow; S – Spleen. PIPC – poly (I:C). Data are 




Figure 5-11. Assessing the role of Fh1 in the maintenance of LICs. (A) Genomic 
PCR assessing the status of Fh1 deletion from LICs isolated from the peripheral 
blood of secondary receipients. Bands represent individual recipients. Lanes 1-4 = 
LICs isolated from one biological sample (injected into 4 recipient mice), exhibiting 
full deletion of Fh1. Lanes 5-7 = LICs isolated from a second biological sample and 
exhibit incomplete deletion of Fh1. (B) Graph shows chimerism of leukaemic cells 
within the bone marrow of sick recipient mice at the point of sacrifice (n = 3 
recipient mice for control, n= 9 recipient mice for Fh1Δ/Δ; Mx1-Cre mice. Data are ± 
S.E.M. p = 0.075, Wilcoxon paired test. fl- undeleted conditional allele, Δ- excised 
allele.  
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Notably, all recipients were injected with LICs originating from the same biological 
sample. These data indicate that it is possible for LICs to survive without Fh1 and 
generate AML in recipient mice. Given the fact that out of the three biological LIC 
samples, one was able to survive without Fh1 I repeated the primary transplantation 
with two additional biological samples. Similarly to the first experiment, Fh1Δ/Δ; 
Mx1-Cre LIC chimerism decreased after poly (I:C) administration (Figure 5-12 A) 
and Fh1 deletion was confirmed via genomic PCR (Figure 5-12  B top before poly 
(I:C), bottom after poly (I:C)). Two weeks after the last poly (I:C) administration, 
mice succumbed to AML as indicated by infiltration of LICs (CD45.2+; Mac1+/Gr1+) 
in the bone marrow and spleen (Figure 5-12  D, E). At the point of sacrifice LICs 
were isolated from the bone marrow of recipient mice in order to assess the deletion 
status of Fh1. Genomic PCR showed that Fh1 was fully deleted in LICs (Figure 5-12  
C). Collectively, it appears that lack of Fh1 is not always detrimental to the long-
term survival of LICs. 
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Figure 5-12. Acute deletion of Fh1 in LICs results in reduction of their self-
renewal capacity. (A) Chimerism of leukaemic cells in the peripheral blood of 
recipient mice. Chimerism was assessed two days after each poly (I:C) 
administration and two weeks after the last injection of poly (I:C). Of note, 2 weeks 
after poly (I:C) there were no remaining control mice. (B) Representative gel of 
genomic PCR assessing the deletion of Fh1 before poly (I:C) treatment (top) and 
after 6 injections of poly (I:C) treatment (bottom). Top gel: lane 1 = control, lanes 
2,3 = Fh1 fl/fl; Mx1-Cre mice. Bottom gel: lane 1= control, lanes 2,3 = Fh1 Δ/Δ; Mx1-
Cre mice. (C) Genomic PCR assessing the deletion of Fh1 in the bone marrow of 
recipient mice at the point of sacrifice. Lanes 1-3 = Control, lanes 4-5 = Fh1Δ/Δ; 
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Mx1-Cre mice. (D) Chimerism of leukaemic cells in the bone marrow (left) and 
spleen (right) of recipient mice at the point of sacrifice. (E) Percentage of myeloid 
cells within the CD45.2+ compartment, in the bone marrow (left) and spleen (right) 
of recipient mice at point of sacrifice (myeloid cells are defined as the sum of 
Mac1+/Gr1+ and Mac1+). n = 2 biological replicates per genotype, 4 recipient mice 
per genotype. Data are ± S.E.M. Mann- Whitney, * p< 0.05.  
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5.5.1 Fh1 is essential for the generation and maintenance of 
pre-LCs 
In this chapter I assessed the requirement of Fh1 in the generation of pre-LCs by 
infecting control or Fh1fl/fl; Vav-iCre stem and progenitor cells with retroviruses 
expressing oncogenes or chromosomal translocation fragments known to be involved 
in AML development. In all cases, Fh1fl/fl; Vav-iCre cells were unable to generate 
colonies indicating that Fh1 is critical for the generation of pre-LCs.  
However, given the fact the chromosomal translocations utilised above are frequently 
identified with other driver or secondary mutations in AML patients, it is possible 
that their expression alone would not be sufficient to rescue the effects that Fh1 
deletion would have. Therefore, it would be informative to express the oncogenes or 
chromosomal translocation fragments in combination in Fh1fl/fl; Vav-iCre cells.  
It is notable that Fh1fl/fl; Vav-iCre cells exhibited decreased survival rates compared 
to control cells during the infection process before the addition of antibiotics 
indicating that cells lacking Fh1 would eventually die, regardless of the oncogene 
they were expressing thus indicating that Fh1 is essential for the survival of 
haematopoietic cells. 
The requirement of Fh1 in the maintenance of pre-LCs was assessed as well. For that 
pre-LCs were generated by isolating LSK cells from Fh1fl/fl (Vav-iCre negative) and 
Fh1+/+ (Vav-iCre negative) embryos and infecting them with retroviruses expressing 
Meis1 and Hoxa9. Established pre-LCs were then infected with lentivirus expressing 
Cre in order to induce deletion of Fh1. Following deletion of Fh1, pre-LCs were 
unable to generate colonies when plated in semi-solid media indicating that Fh1 is 
required for pre-LCs to efficiently self-renew. It is notable that Fh1fl/fl (Vav-iCre 
negative) cells infected with pRRL-empty vector exhibited a lower colony count 
compared to Fh1+/+ (Vav-iCre negative) (mean count of approximately 200 versus 
800 colonies). This potentially indicates that the infection process itself had a 
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negative impact on the Fh1fl/fl (Vav-iCre negative) cells, as no background deletion 
was observed.  
 
5.5.2 Fh1 deletion can result in drastic decrease of LICs in 
vivo 
 
In order to assess the requirement of Fh1 in the maintenance of LICs in vivo, I 
generated pre-LCs (as described above) of the Mx1-Cre background. Once the 
recipient mice exhibited LIC chimerism of 20-30 %, I initiated poly (I:C) injections. 
It is notable that after the third injection I observed a decrease in the chimerism of 
the leukaemic cells regardless of the status of Fh1 deletion, indicating that poly (I:C) 
might have an effect on the survival of leukaemic cells. Indeed, when I performed a 
literature search, I found a scientific paper stating that poly (I:C) has a negative 
impact on the survival of leukaemic cells (Zeleznick and Bhuyan, 1969). The 
proposed mechanism is that poly (I:C) induces the host interferon response which 
slows the multiplication of the leukaemic cells, rather than exerting a cytotoxic effect 
on them(Zeleznick and Bhuyan, 1969). Furthermore, poly (I:C) elicits an interferon 
alpha response, and interferon alpha was used extensively to treat CML indicating 
that poly (I:C) would have an effect on leukaemic cells (Talpaz et al., 1983; 1986). 
Although the decrease in chimerism that I observed during the first three injections 
cannot be solely attributed to Fh1 deletion, it is probable that the decrease observed 
beyond that point, was in fact attributed to Fh1 deletion (as chimerism of control 
mice increased while it decreased in the Fh1Δ/Δ; Mx1-Cre mice).  
Moreover, when deleting Fh1 acutely in vitro in LICs (using lentivirally expressed 
Cre), I observed very small clusters (approximately 50 - 100 cells) indicating that 
LICs lacking Fh1 can support minimal levels of their self-renewal capacity. In 
corroboration with this finding, following deletion of Fh1 in LICs in vivo, I observed 
residual (1-2 %) and eventually full chimerism (60-80 %) of a mixed population of 
LICs, indicating that LICs lacking Fh1 can survive for a period of time and fully 
expand and generate disease. We questioned whether the population of LICs with the 
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full deletion of Fh1 would be able to propagate disease. In order to assess this point, 
we isolated LICs from the bone marrow of sick primary recipient mice and injected 
them into secondary recipients. At the point of sacrifice, we assessed the deletion of 
Fh1 in LICs isolated from the bone marrow of sick recipient mice. Surprisingly, we 
found that some of the recipients (that were injected with LICs originating from the 
same biological sample), exhibited a full deletion of Fh1.  
Given the fact that one biological sample out of the three was able to eventually 
expand and generate disease, we repeated the experiment using two additional 
biological samples. Similarly, once the LIC chimerism in primary recipient mice 
reached 20-30 %, we initiated poly (I:C) treatment. A few weeks after the last poly 
(I:C) treatment, Fh1Δ/Δ; Mx1-Cre mice exhibited expanded LIC chimerism. At the 
point of sacrifice, the bone marrow cells of these mice were genotyped in order to 
assess the deletion of Fh1. To our surprise, all of the mice that were sacrificed 
exhibited a full deletion of Fh1 in LICs.   
Fh1 deletion, in combination with other mutations that could be occurring in vivo, 
offered a competitive survival advantage to the remaining LICs (as most LICs were 
eradicated after Fh1 deletion), thus by-passing the potential metabolic defects as a 
result of Fh1 deletion. Furthermore, although we have hypothesised that fumarate 
accumulation, as a result of Fh1 deletion, has detrimental effects to haematopoietic 
cells (possibly due to inactivation of various proteins as a result of succination, or 
due to allosteric regulation of various enzymes by fumarate), it is nevertheless 
plausible that just like in the case of kidney cancer cells, fumarate acts as an 
oncometabolite in our retroviral Meis1/ Hoxa9 model (Yang et al., 2012). It appears 
that in certain cases Fh1 deletion selects for aggressive AML clones that are able to 
bypass the effects that Fh1 deletion would have. Furthermore, this study potentially 
highlights the difference in metabolic requirements of pre-LCs and LICs as Fh1 
appears to be essential for the survival of pre-LCs but not for LICs. 
In summary, Fh1 is essential for the generation and maintenance of pre-LCs. The 
requirement of Fh1 for LIC maintenance appears to be initially critical as the bulk 
population of AML cells were eradicated. However, in half of the cases observed the 
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remaining 1-2 % of LICs appeared to be able to repopulate the bone marrow of 
recipient mice, despite the deletion of Fh1. A certain percentage of AML patients 
after chemotherapy, exhibit relapse of AML due to “chemotherapy resistant” LICs. 
These LICs are often more aggressive than the initial AML clone, as chemotherapy 
is thought to select for these aggressive AML clones. In a similar manner, Fh1 
deletion could provide a selective advantage for certain AML clones within our 
murine model. 
Furthermore, Fh1 does not appear to be a tumour suppressor in AML, as opposed to 
in HLRCC. Finally, it is important to keep in mind that our findings were observed 
using one in vivo model and therefore conclusions about AML subtypes with varying 
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6 Discussion and final conclusions 
Previous work has focused on understanding how cell metabolism regulates HSC fates. 
During homeostasis, while HSCs utilize glycolysis to maintain their pool (Simsek et al., 
2010), mitochondrial respiration plays a central role in the regulation of HSC quiescence and 
differentiation (Mantel et al., 2010; Gan et al., 2010; Nakada et al., 2010; Gurumurthy et al., 
2010; Yu et al., 2012; Maryanovich et al., 2015). Furthermore, constitutively active 
OXPHOS, has been associated with HSC exhaustion (Maryanovich et al., 2015), and a recent 
study identified that deregulated mitochondrial activity is associated with HSC ageing 
(Mohrin et al., 2015).  
Similarly, in an effort to better define the metabolic properties of malignant haematopoiesis, 
studies utilising primary AML samples, AML cell lines and transgenic mouse models, have 
identified several pathways that appear to be critical. Those pathways include glycolysis 
(Herst et al., 2011; Chen et al., 2014; Wang et al., 2014; Qin et al., 2016), fatty acid oxidation 
(Polet et al., 2016; Lee et al., 2015; Ricciardi et al., 2014; Samudio et al., 2010), and 
mitochondrial respiration (Skrtic et al., 2011; Sriskanthadevan et al., 2015; Cole et al., 2015).  
This study, focused on uncovering the importance of mitochondrial respiration by genetically 
truncating the TCA cycle, through the deletion of the mitochondrial isoform of Fh1. FH is a 
bone fide tumour suppressor in HLRCC and previous work conducted in our lab has indicated 
that Fh1 is essential for foetal and adult murine haematopoiesis. My project focused on two 
things; First to identify the importance of genetically intact TCA in non-malignant, aged 
haematopoiesis and in malignant haematopoiesis, by deleting the mitochondrial isoform of 
Fh1. Secondly, to understand whether, similarly to HLRCC, Fh1 plays a tumour-suppressive 
role in malignant haematopoiesis. 
6.1 Lack of mitochondrial Fh1 affects the early progenitor 
compartment and the differentiated cell compartment 
in aged mice 
Circulating white blood cells are programmed for distinct roles in normal physiology. As a 
result, each cell type requires different metabolic machineries in order to meet its energetic 
demands (MacIver et al., 2013; Caro-Maldonado et al., 2014; Doughty et al., 2006; Chacko et 
al., 2013).  By genetically deleting the mitochondrial isoform of Fh1 we generated a genetic 
perturbation of the TCA cycle and wanted to assess the impact it would have on the 
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haematopoietic system, after ageing mice for approximately 60 weeks. The key changes we 
observed in the primitive haematopoietic compartment were limited to an increase in the 
frequency of LSK cells and within the LSK population, we observed an increase in the 
frequency of the early progenitors HPC-1 and HPC-2. HPC-1 and HPC-2 cells are thought to 
contain a mixture of progenitor cells. Upon transplantation, HPC-1 cells are to transiently 
give rise to myeloid, B cells and T cells, and to a lesser extent platelets (Oguro et al., 2013). 
HPC-2 cells have limited reconstitution capacity and can give rise to erythrocytes and 
platelets, and to a lesser extent myeloid and B cells (Oguro et al., 2013). Interestingly, the 
expansion in these compartments did not translate to a deregulation in the downstream 
oligopotent progenitors, that would explain the drastic decrease in B cells and the myeloid 
bias B-cell depletion could result from the genetic truncation of the TCA cycle. 
Both naïve and activated B cells (i.e. before and after the exposure to antigen) are known to 
rely on the TCA cycle but to different extents (Caro-Maldonado et al., 2014; Doughty et al., 
2006). Naïve B cells heavily rely on the TCA cycle in order to meet their energetic demands 
as based on metabolite analysis, naïve B cells exhibit higher concentrations of the TCA 
metabolites fumarate and malate (Kunisawa et al., 2015).  Furthermore, inhibition of 
mitochondrial respiration via the use of rotenone (that inhibits complex I of the electron 
transport chain), led to increased apoptosis of naïve B cells (Kunisawa et al., 2015). In 
addition, another study showed that naïve B cells use glucose-independent glutamine 
metabolism via the TCA cycle that is essential for their survival (Le et al., 2012). Activated B 
cells have been shown to utilise glycolysis and the TCA cycle at equal rates in order to meet 
their energetic demands, highlighting the importance of a fine balance between these two 
pathways (Kunisawa et al., 2015; Caro-Maldonado et al., 2014; Doughty et al., 2006).  
In the aged mice, we observed a drastic depletion in the frequency of mature B cells in the 
bone marrow, peripheral blood and spleen. The B cell compartment was also depleted in 
terms of absolute numbers in the bone marrow. Collectively, my study is in agreement with 
previous reports, demonstrating that the TCA cycle is important for the development of B 
cells.  
On the other hand, naïve T cells (i.e. T cells that have not encountered an antigen) utilise lipid 
oxidation and mitochondrial respiration in order to meet their energy demands, while T cell 
activation (i.e. engagement of the T cell receptor by the antigen-major histocompatibility 
complex) is generally associated with increased glucose uptake and glycolysis (Fox et al., 
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2005; Frauwirth et al., 2002; MacIver et al., 2013; DeBernadinis et al., 2008; Michalek et al., 
2011). We did not observe a drastic change in the frequency of T cells, especially in the 
thymus (which is the site for T cell development). As a result, our observations appear to be 
in line with other reports, in which T cells do not heavily rely on mitochondrial respiration 
and subsequently, mitochondrial Fh1 deletion, does not impact on T cell survival. 
 
6.2 The expansion of the myeloid compartment could be a 
result of a compensatory mechanism due to B-cell 
depletion in aged mice 
The expansion of the myeloid compartment could either be a result of to the genetic block of 
the TCA or due to a compensatory mechanism of the haematopoietic, in response to B-cell 
depletion. In terms of metabolic properties, myeloid cells are known to exhibit a glycolytic 
rather than OXPHOS phenotype (Chacko et al., 2013). Therefore, a genetic truncation of the 
TCA cycle should not have a negative impact on the myeloid lineage. However, it is possible 
that other metabolic pathways such as glycolysis, could be upregulated due to the genetic 
truncation of the TCA cycle or fatty acid oxidation, thus providing a continuous energy 
source for myeloid cells. Consequently, the myeloid bias we observed is most likely 
attributed to the depletion of the B-cell lineage.   
6.3 Aged mice lacking mitochondrial Fh1 do not 
spontaneously develop AML 
We observed that mice lacking mitochondrial Fh1 displayed a bias towards the myeloid 
lineage in the peripheral blood from a young age (approximately 8 weeks). That prompted us 
to hypothesize that these mice could develop AML as they aged, and for that reason we left 
the mice to age up to approximately 60 weeks. Although the mice exhibited a persistently 
higher frequency of myeloid cells in their peripheral blood as they aged, they nevertheless did 
not spontaneously develop AML. AML is considered a “two-hit” disease, in which (at least) 
two lesions, each belonging to a different class, collaborate to generate AML, when neither is 
sufficient to do so in isolation (Gilliland and Griffin, 2002). The initiating lesions in AML are 
thought to be mutations that cause a block in normal differentiation, whereas secondary 
mutations are thought to provide a proliferative advantage. Given the fact that deletion of 
mitochondrial Fh1 results in the expansion of the myeloid compartment with a parallel 
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depletion of B cells, it is possible that secondary “hits” are required to result to the 
development in AML.  
6.4 Genetically intact TCA is differentially required for the 
generation and long-term self-renewal capacity of LICs 
in a retroviral Meis1/Hoxa9 model 
6.4.1 A genetically intact TCA is required for the efficient 
generation of LICs 
Using the retroviral model of Meis1/Hoxa9 we generated pre-LCs that were lacking the 
mitochondrial isoform of Fh1, resulting in a genetic truncation of the TCA cycle. The 
established pre-LCs were subsequently injected into sub-lethally irradiated primary recipient 
mice, in order to assess the importance of genetically intact TCA in the generation of LICs in 
vivo. Interestingly, we found that the survival rate of mice injected with pre-LCs with the 
genetic truncation of the TCA cycle, was significantly higher compared to the control cohorts 
of mice. More specifically, while only 25-30 % of the control mice cohorts survived, 76 % of 
the mice injected with pre-LCs with the genetic truncation of the TCA cycle, did not develop 
AML. This observation suggests that a genetically intact TCA is required for the efficient 
generation of LICs.  
In an effort to understand the consequences that a genetic truncation of the TCA would have 
on overall mitochondrial respiration, we measured the oxygen consumption rate of LICs 
lacking mitochondrial Fh1. We found that LICs with the genetic truncation of the TCA 
exhibited a significant decrease in SRC, which based on the literature, is thought to reflect 
how well a cell can respond to high energy demand conditions (van der Windt et al., 2012; 
Choi et al., 2009; Ferrick et al., 2008; Nicholls, 2009). As a result, it is possible that the 
defect in SRC could play a causal role in the ability of the pre-LCs to generate disease as 
efficiently as pre-LCs with normal SRC and overall intact mitochondrial respiration. Indeed, 
as described earlier, recent studies have provided convincing evidence that mitochondrial 
respiration is important for the survival of several leukaemic cell lines as well as primary 
AML patient samples (Suganuma et al., 2010; Škrtić et al., 2011; Lagadinou et al., 2013; 
Cole et al., 2015). Furthermore, the importance of OXPHOS for cancer stem cells has been 
convincingly demonstrated in lung cancer, glioblastoma, pancreatic ductal adenocarcinoma 
and epithelial cancer stem cells (Ye et al., 2011; Janiszewska et al., 2012; Sancho et al., 2015; 
Pasto et al., 2014). Our data therefore provide additional evidence for the importance of 
mitochondrial respiration for cancer cells during disease initiation. 
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6.4.2 A genetically intact TCA is dispensable for the long-term self-
renewal capacity of LICs 
Interestingly, although the presence of genetically intact TCA played a role in the efficient 
generation of LICs from pre-LCs in vivo, it was dispensable for the long-term self-renewal 
capacity of LICs. We demonstrated this by using pre-LCs of the Mx1-Cre background, 
allowing inducible deletion of mitochondrial Fh1. Interestingly, once LICs were established, 
the genetic truncation of the TCA did not have an impact on LICs, as they generated AML in 
secondary recipient mice with similar latency to LICs of the control cohorts. Furthermore, 
LICs with the genetic truncation of the TCA exhibited a persistent defect in the SRC that did 
not appear to negatively impact their ability to generate AML in secondary recipient mice. 
These data demonstrate that LICs with the genetic truncation of the TCA cycle might be 
utilising alternate pathways in order to meet their energetic demands. It is plausible that those 
cells would rely more on glycolysis or fatty acid oxidation, since both pathways have been 
shown to be important for the survival of leukaemic cells. For instance, the self-renewal of 
both HSCs and LICs appears to be dependent on fatty acid oxidation (Samudio et al., 2010; 
Ito et al., 2012). Furthermore, glycolysis, appears to be the preferred energy source for many 
cancer (stem) cells as for example breast cancer stem cells. Specifically, it was demonstrated 
that the metabolic switch from OXPHOS to glycolysis was essential for the functionality of 
breast cancer stem cells (Dong et al., 2013). Similarly, glycolysis appears to be the preferred 
metabolic programme in cases of nasopharyngeal carcinoma stem cells (Shen et al, 2015), 
hepatocellular carcinoma (Chen et al., 2015), as well as leukaemic stem cells (Wang et al., 
2014). Specifically, in a recent study, by deleting enzymes that affect aerobic glycolysis with 
different potencies (PKM2 or LDHA), the authors found that leukaemia initiation was 
impaired, highlighting the importance of glycolysis in an MLL-AF9 mouse model and a CML 
model (Wang et al., 2014).  
My data collectively demonstrate that a genetically intact TCA appears to be important for 
the initial stages of the disease (LIC generation), but is dispensable for later stages of the 
disease (LIC long-term self-renewal), indicating that during different stages of leukaemic 
transformation, the cells can undergo metabolic rewiring in order to meet their energetic 
demands, as for example observed in normal haematopoiesis during HSC differentiation 
(HSCs utilise primarily glycolysis but then switch to OXPHOS as the differentiation process 
takes place). A recent study carried from our lab showed that Hif-2a deletion accelerated the 
development of LICs but had no impact on LIC maintenance (Vukovic et al., 2015). 
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Similarly, in another study, the requirement of mTORC1 was critical for the tumour-initiating 
capacity of LICs but not for their self-renewal capacity (Hoshii et al., 2012). The PRC2 
component, EZH2 was similarly required for the initiation of LICs but was dispensable for 
their long-term self-renewal capacity (Neff et al., 2012). Therefore, my data is in agreement 
with other reports demonstrating that genes/pathways can be critical for initial stages of AML 
but dispensable for the later stages. 
6.4.3 Fh1 is not a tumour suppressor in a retroviral Meis1/Hoxa9 
model of AML 
Germline loss-of-function mutations in the TCA cycle enzyme FH predispose affected 
individuals to benign cutaneous and uterine leiomyomata, renal cysts and hereditary 
leiomyomatosis and renal cell cancer, suggesting that, in this context, FH is a tumour 
suppressor (Tomlinson et al, 2002).  FH-deficient cells and tumours have been shown to 
accumulate fumarate to very high levels with multiple consequences including the activation 
of multiple oncogenic pathways (Isaacs et al., 2005; Pollard et al., 2005). It has been 
previously postulated that tumorigenesis associated with FH deletion, might be driven by the 
upregulation of a number of oncogenic pathways driven by HIF (Gottlieb and Tomlinson, 
2005). Indeed, it has been shown that fumarate competitively inhibits 2-oxoglutarate-
dependent oxygenases, in particular PHDs, thus mimicking hypoxia and leading to the 
activation of oncogenic target genes (Isaacs et al., 2005). Furthermore, it has been shown that 
fumarate inhibits the activity and function of other members of the 2-oxoglutarate-dependent 
oxygenases including histone demethylase enzymes and TET proteins which are crucial in 
epigenetic regulation (Xiao et al., 2012), thus leading to epigenetic remodelling.  In addition 
to its role as an allosteric regulator of 2-oxoglutarate-dependent oxygenases, fumarate is also 
an electrophile, spontaneously reacting with cysteine residues and forming S-2-succinyl-
cysteine. This process is termed succination (Alderson et al., 2006).  Accumulation of 
fumarate has been shown to directly correlate with an increase of succinated proteins, that 
could in part account for the oncogenic phenotype (Adam et al., 2011; Trnette et al., 2013). 
Studies have shown that fumarate accumulation leads to the succination (and therefore 
inactivation) of the Kelch-like ECH associated protein 1 (KEAP1), the negative regulator of 
the antioxidant nuclear factor-like 2 (NRF2) (Adam et al., 2011). As a result of all the effects 
that fumarate exerts, fumarate is considered an “oncometabolite” (Yang et al., 2012). An 
oncometabolite is a small molecule of normal metabolism whose accumulation causes 
metabolic dysregulation and effectively primes cells, allowing future progression to cancer 
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(Yan et al., 2012). The term oncometabolite was first coined to describe R-2-
hydroxyglutarate (R-2HG). R-2HG is a by-product produced by the gain of function mutation 
of IDH1/2 (Leonardi et al., 2012).   
The discovery of mutated metabolic enzymes (as for example FH and IDH) that lead to the 
accumulation of oncometabolites, has provided significant evidence that dysfunctional 
metabolism plays a direct role in oncogenesis. Given the fact that FH is considered a bona 
fide tumour suppressor in kidney cancer, we sought to determine whether Fh1, plays a similar 
role in leukaemogenesis. 
To that end, we began by assessing its importance at the generation and maintenance of pre-
LCs. We isolated Fh1-null stem and progenitor cells and infected them with retroviruses 
expressing oncogenes and chromosomal translocations known to be involved in AML 
development. The cells were then plated in semi-solid media in order to assess their 
clonogenic potential. Interestingly, cells lacking Fh1 were unable to generate colonies. We 
then wanted to assess the importance of Fh1 in the maintenance of pre-LCs. For that I 
generated pre-LCs, that had intact Fh1, using the Meis1/Hoxa9 retroviruses. Acute deletion 
of Fh1 in established pre-LCs led to the inability of the cells to generate any colonies. Overall 
these data indicate that Fh1 is essential for the pre-leukaemic stage of the disease. 
In order to assess the importance of Fh1 in the later stages of the disease, I injected pre-LCs 
(in which Fh1 was intact) into sub-lethally irradiated recipient mice. Once the mice 
succumbed to AML, I isolated the LICs and acutely deleted Fh1 using lentivirally expressed 
Cre. Interestingly, following deletion of Fh1, LICs were unable to generate colonies in vitro, 
indicating that Fh1 is essential for the maintenance of LICs in vitro. 
Finally, I wanted to assess whether Fh1 is important for the maintenance of LICs in vivo, by 
using the Mx1-Cre mouse model, that allows inducible deletion of Fh1.  In this model, pre-
LCs with intact Fh1 were injected in sub-lethally irradiated recipient mice. Once the mice 
exhibited 20-30 % of LIC chimerism in the peripheral blood, I administered poly (I:C) in 
order to induce deletion of Fh1 in LICs. As we were expecting, the chimerism of LICs was 
drastically decreased and recipient mice exhibited a very low percentage of LICs in their 
peripheral blood (0.5-2 %). To our surprise, approximately 2 weeks later, some of the 
recipient mice exhibited a very high LIC chimerism and succumbed to AML. Furthermore, 
when we assessed the deletion of Fh1 in LICs, we found that LICs exhibited a complete 
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deletion of Fh1. This observation was very surprising as up to that point we observed that 
Fh1 is essential for the initial stages of the disease as well as essential for the survival of 
LICs, at least in vitro. Furthermore, the drastic decrease in LIC chimerism as a result of Fh1 
deletion, resulted in half of the recipient mice to be “leukaemia-free”, indicating that Fh1 
deletion can have a deleterious effect on the survival of LICs in vivo.  
Based on these data, parallels can be drawn between the classical stages of AML in patients 
and in our mouse model. Typically, after patients are diagnosed with AML, they are treated 
with conventional chemotherapy drugs that eradicate the bulk population of AML cells, thus 
leading to clinical remission. However, in approximately 60 % of cases, the patients fall into 
relapse (Burnett et al., 2011). The patient relapse is thought to be a result of the insensitivity 
of leukaemic stem cells (LSCs) to the conventional chemotherapy drugs. Similarly, it is 
possible that via deletion of Fh1, we eradicated the bulk population of leukaemic cells but are 
simultaneously provided a selective advantage to the LIC clones that are able to survive and 
generate disease, despite the deletion of Fh1.  
Overall, this study indicates that in the haematopoietic system, Fh1 does not appear to play a 
tumour suppressive role, since in the pre-leukaemic stage and in half the cases at the 
leukaemic stage, deletion of both isoforms of Fh1 halted the progression of the disease. 
Finally, this study highlights the differences that exist between kidney cancer and 
haematopoietic malignancy, supporting the notion that genes can play a tumour suppressive 
or tumour initiating role, depending on the biological system.  
6.5 Future directions of the study 
The overall conclusion of this project is that mitochondrial respiration has varying degrees of 
importance in aged, non-malignant haematopoiesis and in malignant haematopoiesis.  
With respect to the truncation of the TCA cycle, it would be informative to biochemically 
validate that the deletion of mitochondrial Fh1 causes a biochemical truncation of the TCA 
cycle, that could be verified by mass-spectrometry analysis. Additionally, despite the deletion 
of mitochondrial Fh1, the basal oxygen consumption rate of the cells is comparable to cells 
with intact TCA indicating that there are compensatory mechanisms rectifying for the genetic 
truncation of the TCA. Global metabolomic analyses could provide some insight for that. It 
would also be of considerable interest to study the role of genetically intact TCA using 
another in vivo model of AML, in order to identify whether my findings can be applicable to 
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different subtypes of AML. Furthermore, it would be important to understand why a 
genetically intact TCA appears to be required for the initial stages of the disease but not for 
the later stages. Flux metabolomics could help identify the metabolic rewiring that LICs have 
undergone in order to compensate for the genetic truncation of the TCA cycle, thus revealing 
their potential metabolic vulnerabilities.  
With respect to the full deletion of Fh1 (i.e. both the mitochondrial and cytosolic isoforms of 
Fh1 using the Vav-iCre model), it would be informative to understand why it is detrimental to 
the survival of pre-LCs and LICs in vitro. The phenotype I observed could be attributed to 
different mechanisms, such as the fumarate-associated inhibition of a-KG-dependent 
dioxygenases such as TETs and KDMs. Similarly, identifying the key differences between 
Fh1-/- LICs that generated disease in vivo and the ones that did not, could offer a new insight 
about the tumour suppressive or oncogenic context associated with Fh1 deletion.
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